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Abstract 
Background 
Severe asthmatics have increased numbers of airway neutrophils compared to 
mild asthmatics, and blood neutrophils may be activated in asthmatics. Activated 
neutrophils may contribute to airway inflammation and tissue damage. 
Hypothesis 
Activation of both eosinophils and neutrophils is important in severe 
asthmatics, through enhancement of mediator release. The effect of corticosteroids on 
inhibition of neutrophils from severe asthma may be attenuated. Patients with severe 
allergic asthma may respond to anti-IgE monoclonal antibody treatment. 
Methods 
The level of expression of baseline and stimulated blood neutrophil surface 
markers was investigated in severe corticosteroid-dependent asthmatics and compared 
to normal subjects and milder asthmatics. The effect of adding or increasing 
maintenance oral prednisolone (30mg/day for one week), on surface molecules, IL-8 
and myeloperoxidase levels, neutrophil elastase and oxidative burst in blood was also 
studied. 
The level of expression and effect of corticosteroids on histone deacetylase 
(HDAQ activity from asthmatics was studied. The immediate effect of inhaled 
fluticasone propionate was also investigated, along with the efficacy of subcutaneous 
anti-IgE therapy. 
Results 
CD35 and CD11b expression was increased in neutrophils from severe 
asthmatics compared to normal subjects. Prednisolone inhibited surface marker 
expression, oxidative burst and IL-8 release from mild but not severe asthmatics. 
HDAC activity was reduced in alveolar macrophages compared to PBMCs in 
asthmatics. Prednisolone increased HDAC activity in PBMCs from mild, but not severe 
3 
asthmatics. HDAC activity was generally reduced in granulocytes compared with 
PBMCs. 
Inhaled fluticasone reduced exhaled nitric oxide levels in moderate asthmatics at 
four hours. Subcutaneous administration of anti-IgE therapy was well tolerated and 
decreased high affinity IgE receptor levels on basophils and monocytes during 
treatment. 
Conclusion 
Peripheral blood neutrophils from severe asthmatics show a higher state of 
activation than normal subjects, and show loss of inhibitory corticosteroid response. 
Potential alternative treatments for severe asthma include anti-IgE antibody therapy. 
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Chapter I 
1. Introduction 
1.1 Inflammatory basis of asthma 
Bronchial asthma is a common clinical condition which can affect individuals of 
almost any age, and is an important cause of respiratory morbidity and mortality. It is 
characterised by variable dyspnoea, wheeze, cough and chest tightness due to 
widespread narrowing of the peripheral airways in the lungs, which varies in severity 
over short periods of time either spontaneously or as a result of medication. Usually, 
asthma develops during childhood in atopic individuals (1). The prevalence of asthma is 
highest in the second decade of life where this disease affects 10- 15% of the population. 
There is also geographical variation with asthma being common in, for example, New 
Zealand, but rarer in Far Eastern countries. Studies of occupational asthma suggest that 
a high percentage of the workforce, perhaps up to 20% may become asthmatic if 
exposed to potent sensitizers (2). 
There is substantial evidence for the role of inflammation in asthma and bronchial 
hyperreactivity. Early autopsy studies of patients who died following attacks of fatal 
asthma showed epithelial denudation, mucosal oedema, glandular hypertrophy, and 
dense eosinophilic infiltration (3). More recently, techniques including bronchoalveolar 
lavage (BAL) and bronchial biopsy have been used to investigate airway inflammation 
in mild asthmatics. Elevated numbers of eosinophils, both in the bronchial mucosa and 
in BAL fluid were shown to be a constant feature of patients with mild asthma (4,5). 
Similarly, increased numbers of activated lymphocytes were also seen. These were 
identified as either irregular, atypical lymphocytes by transmission electron microscopy 
(6) or as CD25+ cells as shown by immunocytochemistry, most of which were shown to 
be T-lymphocytes (7). 
Studies in asthmatic patients challenged with aeroallergens have shown increased 
numbers of BAL fluid eosinoPhils, mast cell mediators, and products of other 
inflammatory cells (8,9). In addition, transbronchial biopsies in patients with mild well 
controlled asthma, showed significant inflammatory changes. Asthma is thus associated 
with chronic inflammation of the airways, characterised by infiltration of the airway 
mucosa by eosinophils, mast cells, and T-lymphocytes, by subepithelial fibrosis, and 
almost always by intraluminal eosinophilia. The inflammation is mediated by the 
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release of an array of cytokines and inflammatory mediators (10,11). Furthermore, 
studies have shown an association between the degree of inflammatory changes on 
bronchial biopsies, and measurements of non-specific bronchial hyperresponsiveness 
(12,13). 
Role of Neutrophils in Asthma 
The majority of asthmatics can be managed with intermittent short-acting beta- 
2-agonists and low dose inhaled corticosteroids or combination therapy consisting of 
inhaled corticosteroids and long-acting bronchodilators, but a small minority of patients 
require high doses of inhaled corticosteroids as well as oral corticosteroids 
(corticosteroid-dependent asthmatics) in order to maintain control. These patients often 
have severe and difficult to control asthma and develop side-effects due to their 
medication. They also account for a large proportion of total asthma costs in terms of 
medication and resource utilization. The pathogenesis and mechanism(s) involved in the 
development of this severe asthmatic state have not been fully elucidated. Although the 
role of eosinophils in the pathogenesis of asthma is well established, the role of 
neutrophils in asthma is more controversial, but there is increasing evidence to suggest 
the importance of neutrophils in more severe asthma and the allergic process. 
1.2.1 Evidencefor the Involvement of Neutrophils in Asthma Exacerbations 
Airway hyperresponsiveness is an exaggerated bronchoconstrictive response to 
physical, chemical, or pharmacological stimuli (14) and is a common and important 
feature of bronchial asthma. Evidence suggests that in asthma, airway 
hyperresponsiveness is associated with the presence of airway inflammation (15,16), 
but the relative role of each inflammatory cell remains unclear. In stable mild 
asthmatics, long-lasting airway hyperresponsiveness significantly correlates with 
bronchoalveolar eosinophils, metachromatic cells, and epithelial cells (15), but not with 
neutrophils, suggesting that neutrophils may not be involved in long-lasting 
hyperresponsiveness and ongoing asthma. 
The importance of neutrophils for asthma exacerbations has been examined in 
experimentally induced airway hyperresponsiveness in normal and asthmatic subjects. 
Exposure to ozone (17,18), nitrogen dioxide (19) and inhalation of inflammatory 
mediators such as platelet activating factor (PAF) (20), increase the airway 
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responsiveness of normal subjects and cause transient airway neutrophilia. BAL studies 
in asthmatics exposed to ozone, show evidence of significant neutrophilia and increased 
levels of the cytokines interleukin-8, (IL-8) and IL-6, even at levels of ozone exposure 
that do not reduce pulmonary function (18). Similarly, aerosolized tumour necrosis 
factor-alpha, (TNF-cc) causes a transient increase of airway responsiveness associated 
with sustained sputum neutrophilia but not eosinophilia in normal subjects (21), further 
suggesting that they may be involved in the transient increase of airway responsiveness 
induced by different inflammatory stimuli. Whether the increase in neutrophils is 
merely associated with such transient increases of airway responsiveness or whether 
neutrophils are involved in the development of such transient increase of airway 
responsiveness is unclear. 
Studies in asthmatics of spontaneous moderate to severe asthma exacerbations 
by Fahy et al (22) and Sur et al (23), have shown increased numbers of neutrophils and 
eosinophils in sputum and BAL samples respectively. In contrast, mild asthma 
exacerbations that occur during tapering of inhaled glucocorticoid treatment (24) and 
exacerbation induced by natural allergen exposure (25) are associated with a more 
prominent airway eosinophilia rather than neutrophilia, suggesting that the triggers of 
exacerbations may be important in determining the type of cellular response. 
1.2.2 Evidencefor the Involvement of Neutrophils in Stable Severe Asthma 
Although several studies have shown no difference in the numbers of 
neutrophils in bronchial biopsy, BAL and sputum specimens in stable asthmatic 
patients compared to healthy control subjects (15,16,25), other studies have reported 
an increase of sputum and BAL neutrophils in more severe asthmatics (26,27). Boulet 
et al showed that subjects with occupational asthma induced by different sensitizing 
agents have a significant increase of neutrophil number in bronchial biopsy specimens 
even after removal of the causal agent (28). Frangova et al found a slight but 
significant increase of BAL neutrophils and eosinophils in both atopic and non-atopic 
moderate asthmatics (27). Similarly, Kelly et al showed a significant increase in the 
number of BAL neutrophils and also showed a correlation between the number of 
neutrophils and the degree of airway hyper-responsiveness in stable asthmatic subjects 
(25), but this correlation was not found in other studies (15,16). 
The lack of increase of neutrophils in the airways of asthmatics does not 
necessarily rule out their involvement in the inflammatory process, as airway 
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neutrophils may be activated despite a lack of increase in their number. Studies have 
shown increased expression of cyclooxygenases, 15-lipooxygenase, neutrophil 
myeloperoxidase (MPO), and lipocalin in neutrophils in the blood and sputum of 
patients with atopic asthma (29,30). Also, in corticosteroid-resistant asthmatics, there 
is an increased production of leucotriene B4 (LTB4) by neutrophils in response to 
cytokines produced by peripheral blood mononuclear cells (PBMCs), (3 1). 
Jatakanon et al showed increased numbers of neutrophils and IL-8 levels in the 
sputum of patients with stable severe asthma (32), and increased levels of neutrophils 
have been demonstrated in bronchial biopsies from severe asthmatics on high doses of 
maintenance oral corticosteroids (33). Thus, although neutrophils do not seem to play a 
significant role in mild to moderate stable asthma, they might be involved in ongoing 
severe asthma. 
1.2.3 Nocturnal Asthma 
The involvement of neutrophils in nocturnal asthma is controversial. Whereas 
Wenzel et al showed a significant increase of BAL neutrophils and eosinophils at night 
in patients with nocturnal asthma (34), this has not been confirmed in other studies. 
Transbronchial biopsy specimens (but not endobronchial biopsies) of nocturnal 
asthmatics showed an increase of eosinophils only when compared to those of non- 
nocturnal asthmatics (35). It is possible that only severe nocturnal asthma is associated 
with a significant increase of inflammatory cells in the BAL (36). Treatment with 
systemic corticosteroids and theophylline reduces nocturnal symptoms, airflow 
limitation, and the associated BAL neutrophilia and eosinophilia, suggesting the 
importance of bronchoalveolar inflammation, and possibly of neutrophils, in nocturnal 
asthma 
1.2.4 Neutrophils in severe asthma exacerbations 
Mild asthma exacerbations are typically associated with sputum eosinophilia, or 
sputum eosinophilia and neutrophilia (24), whilst. severe asthma exacerbations have 
been shown to be associated with a predominant sputum neutrophilia (22). In addition, 
high levels of IL-8 and neutrophil elastase activity have been shown in the sputum of 
patients with severe exacerbations. Slindo et al showed that the arterial blood 
concentrations of the neutrophil chernotaxin LTB4, correlated with the severity of 
asthma exacerbations and levels were reduced by glucocorticoids, further suggesting 
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the importance of neutrophils in severe asthma exacerbations (37). Previous studies by 
Buchanan et al (38) also showed that severe asthma exacerbations were associated with 
an increase of serum neutrophil chemotactic activity (NCA). Further, Lamblin et al 
showed massive BAL neutrophilia in mechanically ventilated patients with 
noninfectious severe asthma exacerbations (39). 
1.2.5 Neutrophils andfatal asthma 
Death from asthma may occur either from slow progression of the disease, or by 
sudden death (40). Asthma death associated with a slow progression of the disease is 
characterized by plugging of the airways with mucus, inflammatory cells, smooth 
muscle hyperplasia, oedema, and massive infiltration of the airway walls with 
inflammatory cells (41). In particular, a dramatic increase of eosinophils in the 
submucosa has been demonstrated. In contrast, sudden-onset fatal asthma is 
characterized by more neutrophils in the airway submucosa (42) and less mucus in the 
airway lumen. These observations suggest that the mechanism of airway inflammation 
and airway narrowing in sudden-onset fatal asthma may be different from that in slow- 
onset fatal asthma. Thus the time course of the asthma exacerbation and possibly the 
nature of the trigger may be important in determining the type of cellular response (42). 
1.2.6 Neutrophils and bronchoprovocation with allergens and sensitizing agents 
BAL studies have shown that neutrophilia is present before the onset and during 
the first few hours of the late asthmatic reactions induced by allergens (43), and 
sensitizers such as toluene diisocyanate (44). Further, bronchial biopsy specimens 
showed a significant increase in neutrophil numbers following local allergen challenge 
in the airways of sensitized asthmatics (45). The increase in neutrophils has been shown 
to usually precede, but sometimes parallel or follow, the increase of eosinophils, 
metachromatic cells, and lymphocytes (43). 
It has been suggested that the allergen-induced BAL neutrophilia might be due 
to either a nonspecific effect of the procedures involved in local bronchoprovocation 
or to endotoxin contamination of the allergen extracts. However, previous studies have 
shown BAL neutrophilia during late asthmatic reactions to allergens or isocyanates 
even in sites not previously lavaged (44). This suggests that the neutrophilia may be 
specific, and that the nonspecific increase observed after saline solution infusion is 
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linked to the specific maneuver of lavaging the same segment twice after a short 
interval. The specificity of airway neutrophilia that occurs during the first few hours 
after allergen challenge is also suggested by biopsy studies, which show increased 
neutrophil numbers in allergen-challenged airways only and not in control airways 
(45). In addition to neutrophil numbers, the serum heat-stable NCA has been shown to 
be elevated during early and late asthmatic reactions induced by allergens and toluene 
diisocyanate (46). Further, the percentage increase in plasma NCA induced by 
inhalation of toluene diisocyanate has been shown to correlate with the percentage 
decrease of FEV I of the early asthmatic reaction. 
1.2.7 Animal Experimental Studies Investigating the Role of Neutrophils in 
Asthma 
In dogs, the transient increase in airway responsiveness induced by allergen 
inhalation, or by exposure to ozone and PAF, is associated with airway neutrophilia in 
BAL and/or biopsy specimens. The increased airway responsiveness and neutrophilia 
can be prevented by depletion of circulating neutrophils induced by the cytotoxic 
agent hydroxyurea (47). Similarly, in rabbits actively sensitized to Alternaria, an 
increased number of neutrophils in the airway mucosa are present during the late 
asthmatic reactions and during the transient increase of airway responsiveness induced 
by inhalation of Alternaria extracts. These effects of the inhalation challenge were 
prevented by neutrophil depletion and reproduced following neutrophil repletion of 
the animals with concentrated neutrophils (48). Other experiments in rabbits showed a 
neutrophilia in the airway mucosa during the transient increase of airway 
responsiveness induced by aerosolized complement factor 5a (C5a) des arg, (a 
complement fragment with marked neutrophil chernotactic activity), and this effect 
was prevented by neutrophil depletion (49). In a murine model of atopic asthma, 
infiltration of lung tissue and airways with eosinophils was associated with increased 
numbers of other leukocytes including neutrophils (50). Further, transgenic mice 
expressing IL-4 in the lung showed airway inflammation with infiltration of lung 
tissue and airways with both eosinophils and neutrophils (5 1). In general, animal 
studies have suggested a significant pathogenic role of neutrophils in late asthmatic 
reactions, and for the transient increase of airway responsiveness induced by allergen 
challenge. 
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Both human and animal studies suggest that the long-lasting 
hyperresponsiveness which is present between asthmatic exacerbtions is associated 
with mild airway inflammation due to activation of eosinophils, T-lymphocytes and 
mast cells but not neutrophils. Further, neutrophils do not appear to be involved in the 
chronic airway inflammation associated with mild and moderate stable asthma, but 
may have a role in severe stable asthma. There is evidence, particularly in humans, 
that neutrophils may be involved in exacerbations of asthma, and particularly in the 
early stages of sudden and severe asthma exacerbations. Also, the predominant 
involvement of neutrophils in some types of asthma exacerbations, such as those 
induced by occupational sensitizers and following severe asthma exacerbations, 
suggests that different triggers of asthma may induce airway inflammation through 
different mechanisms. 
1.3 Neutrophil biology 
1.3.1 Neutrophil development 
The neutrophil is derived from a pluripotent stem cell which gives rise to the 
lymphoid and myeloid stem cells. From the latter, under the influence of stem cell 
factor (SCF), IL-3, and granulocyte/macrophage colony stimulating factor (GM-CSF), 
the colony forming unit-granulocyte/erythrocyte/macrophage/megakaryocyte (CFU- 
GEMM) is formed. This multipotent cell gives rise to the colony forming unit- 
granulocyte/macrophage (CFU-GM) under the continued influence of SCF, IL-3, and 
GM-CSF. The colony-forming unit-granulocyte (CFU-G) is the neutrophil-committed 
product of the CFU-GM, under the influence of IL-3, GM-CSF, and granulocyte- 
colony stimulating factor (G-CSF), a cytokine that is specific for neutrophil 
development. In the presence of G-CSF and GM-CSF, the neutrophil myeloblast 
develops and is the first morphologically distinct cell in neutrophil development. All 
subsequent stages of neutrophil development occur in the setting of G-CSF and GM- 
CSF (52). 
It takes 4-6 days for maturation to pass through to the myelocyte stage in the 
bone marrow, and a further 5-7 days for the myelocyte to develop into a mature 
neutrophil. Following the myelocyte stage, the maturing neutrophil passes through the 
metamyelocyte and band stages before developing into a mature neutrophil (fig. 1.1). 
The mature neutrophil measures 10-12ýtm, and has a highly condensed, segmented, 
multilobulated nucleus with 3-5 lobes. Approximately lxlO11 neutrophils are generated 
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daily, and this number can increase by another order of magnitude in the setting of 
infection. The calculated circulating granulocyte pool is 0.3xlO9 cells per kilogram of 
blood, and the marginated pool is OAxI09 cells per kilogram of blood, comprising 3% 
and 4% of the total granulocyte pool, respectively (53). The normal mechanisms by 
which neutrophils exit the bone marrow are unclear. However, administered cytokines 
such as GM-CSF and G-CSF lead to substantial increases in neutroPhil production and 
release. Neutrophils have a circulating half-life of about 6 hours and survive in the 
tissue for 1-2 days. 
1.3.2 Granule content andfunction 
Characteristic neutrophil cytoplasmic granules are first found at the 
promyelocyte stage of development. The first granules that can be recognized are called 
primary granules or azurophilic, because they stain blue with Wright's stain in bone 
marrow preparations. Primary granules arise by the budding of vacuoles from the 
concave face of the Golgi apparatus (54). The promyelocyte develops into the 
myelocyte, during which stage, secondary or specific granule synthesis occurs from the 
convex surface of the Golgi apparatus. The secondary granules fuse with incoming 
phagocytic vacuoles containing ingested organisms and release their contents, which 
include lactoferrin (which scavenges available iron), the N-formyl-methionyl-leucyl- 
phenylalanine fMLP receptor (FPR), complement receptor 3 (CR3), and cytochrome 
558, the membrane bound component of the nicotinamide dehydrogenase phosphate 
(NADPH) oxidase that is required for the generation of superoxide, hydrogen peroxide, 
and hypohalous acid. By 3 minutes after ingestion, the primary granules have fused to 
the phagolysosome and this results in a marked lowering of the intravacuolar pH due to 
the release of MPO, lysozyme, acid hydrolases, and defensins. MPO, a primary granule 
component, catalyzes the conversion of hydrogen peroxide (H202) to hypohalous acid 
which has anti-microbial action. Lack of development of neutrophil granules and their 
contents can lead to serious and frequent infections in early life. 
Chediak-Higashi syndrome is a rare autosomal recessive disorder with a 
generalized abnormality of development of the primary granules. These patients show 
impaired bacterial killing by phagocytes leading to recurrent infections. Natural Killer 
(NK) cell function is also defective and many patients die in childhood from infection. 
Neutrophil specific granule deficiency is a rare autosomal recessive condition clinically 
characterized by a profound susceptibility to bacterial infections. There is a paucity of 
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neutrophil specific granules and specific granule proteins and their respective 
messenger ribonucleic acids (mRNAs), and there are very low levels of the primary 
granule products defensins and their mRNAs. This is thought to be due to loss of a 
tissue-specific transcriptional factor (55). 
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1.3.3 Chemoattractants and chemotaxis 
Neutrophils are able to move toward very slight gradients of chemical signals 
(56), and this process of chernotaxis involves the complex machinery of cellular 
redirection, orientation, and locomotion. The classical chemoattractants include N- 
formyl-methionyl-leucyl-phenylalanine (fMLP), C5a, LTB4, and PAF. More recently, a 
class of small (<10 kDa), proteins called alpha or cysteine-X-cysteine (CXC) 
chemokines have been shown to be potent chemoattractants for neutrophils, and are 
characterized by a CXC pattern in the amino terminal portion of the molecule. Among 
the alpha chemokines, the peptide sequence, glutamic acid-leucine-arginine (ELR) 
immediately proximal to the C-X-C motif confers potent neutrophil chemoattraction. 
IL-8 is the most extensively studied of the chemokines, and is a very potent 
chemoattractant and neutrophil activator. Many different cellular sources for IL-8 have 
been identified, including neutrophils, monocytes, T-cells, B-cells, NK cells, basophils, 
eosinophils, fibroblasts, endothelial cells, keratinocytes, and smooth muscle. Blockade 
of IL-8 by neutralizing anti-IL-8 antibody in rabbit models of pulmonary inflammation 
have been to be successful in preventing neutrophil accumulation and reperfusion 
injury, confirming the central role for this chemokine in neutrophil recruitment to sites 
of inflammation (57). 
Neutrophil movement toward a source of stimulus involves complex changes in 
the viscosity of the cytoplasm, and relocation of the nucleus, centriole, and organelles. 
The cell projects a pseudopod in the direction of motion and trails a uropod behind. 
Retraction fibres may extend from the uropod that are resorbed or that break off as the 
cell moves forward (58). The creation of structures within the cell that can permit 
locomotion depends on the ability of actin to move from sol to gel to sol as shape 
changes. Actin monomers (G-actin) can polymerize into double-helical actin filaments 
(F-actin). Crosslinking of these filaments by actin-binding protein results in the 
formation of a rigid gel. Actin monomers are kept from polymerization in leukocytes by 
proteins that bind them, such as profilin. Actin polymerization is also controlled at the 
level of the growing filament end. Gelsolin binds to the rapidly growing end of the 
actin filament, preventing further elongation, and severs the existing filament. 
Gelsolin's binding to actin, prevention of filament elongation, and filament scission are 
all calcium regulated. Therefore, the rise in intracellular calcium caused by the 
stimulation of a chemoattractant receptor has an influence on the cell cytoskeleton 
through the assembly and disassembly of actin filaments. 
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1.3.4 Neutrophil adhesion to endothelium 
Neutrophils are designed to roll along the endothelium, recognize sites of 
inflammation, adhere to inflamed sites, and traverse the endothelium in order to enter 
the involved tissue and fight infection. The physical interaction of neutrophils with 
endotheliurn and other leukocytes is mediated by three main sets of molecules: 
selectins, integrins, and members of the immunoglobulin supergene family 
(intercellular adhesion molecules, or ICAMs). The selectins are designated E 
(endothelial), P (platelet), and L (leukocyte). Endothelial cells express E-selectin 
(CD62E) and P-selectin (CD62P), whereas leukocytes express L-selectin (CD62L) 
(59). This family of molecules mediates the low-affinity rolling of neutrophils along the 
endothelium. Although E-selectin and P-selectin bind to the sialyl Lewis X (SLex) 
antigen on neutrophils, L-selectin on neutrophils binds to distinct antigens on 
endothelium, including CD34. L-selectin is shed by neutrophils on activation and is 
absent in exudate cells, implying that release of L-selectin and migration into sites of 
inflammation are linked (60). The identification of sites of inflammation is 
accomplished largely through chemoattractants, which trigger high-affinity binding by 
integrins (fig. 1.2). 
The integrins are heterodimers consisting of a specific alpha (oc) chain bound to a 
common beta (P) subunit, CD 18. CD 18 is a 95 kiloDalton (kDa) protein expressed on 
phagocytes, monocytes, macrophages, and lymphocytes and is obligatory for 
expression of the respective alpha chains. Integrins are required for the neutrophil's 
tight adherence to endothelium, and to other leukocytes, complement, and bacteria (61). 
The heterodimers of the integrin family include CD II a/CD 18 (LFA- 1), CD II b/CD 18 
(Mac-1, Mo-1, or CR-3), and CDlIc/CD18 (p150,95 or CR4). The CDIlb/CDl8 
complex mediates the binding of cleavage products of C3 (62). 
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Fig. 1.2 Leukocyte trafficking. CD62L mediates the initial low affinity rolling of 
neutrophils along the endothelium. Integrins such as CD11b, then allow neutrophils to 
bind tightly to endothelium, other leukocytes, complement and bacteria. 
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1.3.5 Phagocytosis 
Neutrophils bind Immunoglobulin G (IgG) antibodies via receptors for the Fc 
portions of IgG (Fc7R). Fc7RI (CD64) is a receptor for IgGl and IgG3 on monocytes 
and macrophages and is expressed on neutrophils after interferon-7 stimulation (63). 
Fc7RII (CD32) on neutrophils binds IgG with low affinity while Fc7RIII (CD16) binds 
IgGI and IgG3 with intermediate affinity. Crosslinking of these receptors by antibody 
leads to rapid engulfment of targets with release of granule contents and oxygen 
metabolites into the phagosome. Neutrophils also have several complement receptors 
on their surface. Complement receptor I (CRI) is designated CD35, and binds Ob and 
enhances its degradation to C3dg by factor 1, thereby removing that molecule from 
further activation of the alternative pathway. CR3 is the integrin CD I 8/CD IIb, and it 
binds i0b, fibrinogen, and bacteria. CRI and CR3 per se, are not able to stimulate 
phagocytosis. However, in the presence of a second signal, for example, through Fc7R 
or by cytokines, phagocytosis proceeds. After engulfment of a particle, fusion of the 
preformed specific (secondary) granules occurs first, followed by fusion of the 
azurophilie (primary) granules. 
1.3.6 Exudative Neutrophils 
Exudative neutrophils differ from peripheral blood neutrophils and acquire a 
ruffled irregular membrane, extend pseudopods, assume a triangular shape, and cap 
certain membrane components, such as concanavilin A binding sites. These changes in 
exudative neutrophils can be mimicked in vitro by exposing peripheral blood 
neutrophils to chernotactic factors. Neutrophil exudation is also associated with 
shedding of L-selectin (60), and up regulation of certain plasma membrane components 
such as CR3, FcyRIII, and cytochrome b558. Exudative neutrophils also acquire the 
protein synthetic apparatus for IL-8 and are capable of producing, and storing IL-8 in a 
readily mobilizable, compartment distinct from primary or secondary granules in 
amounts comparable to mononuclear phagocytes (64) 
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1.3.7 Mechanisms of killing 
These mechanisms fall into two categories: those that are dependent on the 
generation of oxygen metabolites, and those that are independent. In addition to 
mobilizing its own resources, neutrophils can produce a variety of cytokines such as IL- 
I P, IL-6, IL-8, and TNF-(x, which may significantly affect processes such as 
modulation of the immune responses (65) by stimulating and attracting other 
neutrophils as well as monocytes and lymphocytes 
1.3.7.1 Oxygen-Independent Pathways 
Bacterial permeability increasing protein (BPI) is a highly potent antibacterial 
granule protein stored in the primary granules. BPI is a highly basic and is cytotoxic to 
gram-negative bacteria but much less effective against gram-positive organisms. The 
defensins are small (<4 kDa) cationic proteins found in the primary granules of 
neutrophils, which appear to be involved in the killing of ingested gram-positive and 
gram-negative bacteria (66). Defensins are capable of killing transformed mammalian 
cells, as well as prokaryotes and yeasts. Lactoferrin is an iron-binding protein present in 
specific granules of neutrophils but also in mucosal secretions. It is inhibitory to gram 
positive and gram-negative bacteria and some fungi. Although lactoferrin exerts much 
of its antimicrobial action through the depletion of iron from an organism's 
environment, it may possess independent antimicrobial activity as well (67). 
1.3.7.2 Oxygen-Dependent Pathways 
Neutrophils can produce toxic oxygen metabolites in response to activation by IL- 
8ý TNF-cc, C5a, or fMLP through the assembly of the reduced nicotinamide 
dehydrogenase phosphate (NADPH) oxidase complex. This enzyme complex catalyzes 
the addition of an electron to molecular oxygen, leading to the formation of superoxide 
anion in a reaction known as the oxidative respiratory burst. Superoxide anion is 
rapidly converted by the enzyme superoxide dismutase to H202 and hydroxyl radicals. 
In the presence of MPO, H202and halide ions (usually chloride) form hypohalous acids 
that are intensely microbicidal (fig. 1.3). H202 in the presence of iron salts leads to the 
production of hydroxyl radicals, which can remove single electrons from other 
compounds and turn them into powerful oxidants (68,69). 
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1.3.8 Neutrophils and tissue damage 
Neutrophils contain many inflammatory mediators capable of not only killing 
microbial pathogens, but also injuring host tissues and amplifying the inflammatory 
response. These inflammatory mediators have been implicated in the pathogenesis of 
many inflammatory diseases, including bronchial asthma. 
1.3.8.1 Neutrophil elastase 
Neutrophil elastase is a serine protease released by neutrophils on activation in 
response to inflammatory stimuli, and can potentially damage tissues in many ways. In 
vitro, neutrophil elastase induces proteolysis of elastin, fibronectin, type 3 collagen, and 
type 4 procollagen (70). Neutrophil elastase cleaves and inactivates al-proteinase 
inhibitor, tissue inhibitor of metalloproteinases, complement fragments (0), and CRI 
(71). It can also cause airway epithelial cell damage (72), reduce ciliary beat frequency 
(73), and stimulate epithelial surface and airway gland cell secretion. Other actions of 
neutrophil elastase that can be harmful to host tissue include injuring pulmonary 
endothelial cells (in part through release of PAF) (74), increasing endotheliall cell 
permeability (75), causing degranulation of eosinophils resulting in release of 
inflammatory mediators such as eosinophilic cationic protein (ECP) (76), and 
modulation of neutrophil adhesion (77). In vivo experiments in animals have show that 
human neutrophil elastase induces airway constriction and hyperresponsiveness, 
increases lung permeability, causes secretory cell metaplasia and pulmonary 
emphysema (78). 
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Fig. 1.3 Oxidative burst. NADPH oxidase catalyzes the addition of an electron (e) to 
oxygen (02), leading to the formation of superoxide anion (02-*). This is then converted to 
H202 and hydroxyl radicals by the enzyme superoxide dismutase (SOD). H202 is then 
converted to hypochlorus acid, (which is microbiocidal), in the presence of MPO and 
chloride ions (Cl-). 
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1.3.8.2 Oxidants 
Oxidants produced as a result of the respiratory burst, can produce many of the 
airway lesions associated with asthma, including ciliary dysfunction and mucus 
hypersecretion (79), airway epithelial cell damage, bronchial smooth muscle 
contraction, and airway hyperresponsiveness (80). It has also been shown that oxidants 
may activate mast cells to release histamine (8 1). 
1.4 Granulocyte priming in peripheral blood 
Although the main site of action for neutrophils and eosinophils is probably the 
lung, several studies that show that these cells are already activated or primed in the 
circulation of asthmatic patients. For example, Sedgwick et al (82) showed that 
hypodense eosinophils isolated from the peripheral blood of asthmatic patients 
generated significantly more superoxide anion when activated with fMLP or opsonized 
zymosan (OZ), compared to eosinophils from normal controls. Furthermore, eosinophil 
populations and corresponding neutrophil isolates, from asthma patients generated 
significantly more superoxide anions (02-) than control granulocytes when activated by 
phorbol myristate acetate (PMA). 
Kato et al (83) showed that the ability of neutrophils from asthmatic 
children to generate02- and other active oxygen species was significantly greater than 
that of neutrophils from control subjects when stimulated with OZ, PMA, or fMLP. In 
the same asthmatic children, the generation0f 02- and other active oxygen species was 
found to be significantly higher during asthma attacks. Warringa et al (84) showed that 
eosinophils from allergic asthmatics exhibited a markedly increased sensitivity in their 
chemotactic response toward PAF compared with eosinophils from normal donors. This 
in vivo-primed phenotype could be mimicked in vitro, by preincubating eosinophils 
from peripheral blood of healthy individuals with either GM-CSF, IL-3, or IL-5 
suggesting that release of cytokines may be an important in-vivo priming mechanism in 
the circulation of allergic asthmatic patients. Similarly, Hakansson et al (85) showed 
that IL-3 primed the migratory function of both eosinophils and neutrophils, while IL-5 
was a more potent primer of eosinophil than of neutrophil migration in response to 
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chemoattractants such as LTB4, PAF, fMLP, and C5a. Leckie et al (86) showed 
significant differences in the amount of light scatter by peripheral blood neutrophil 
populations in severe symptomatic asthmatics compared with the normal controls, 
using the Bayer haematology analyser. Further, when whole blood was activated in 
vitro with fMLP, similar changes were seen in neutrophil light scatter, suggesting that 
neutrophil activation is Present in the peripheral blood of symptomatic asthmatics. 
1.5 Expression of activation molecules on neutrophils and eosinophils in allergic 
asthma 
Using flow cytometry techniques, Berends et al (87) studied the expression of 
CD3 5 and CD IIb on neutrophils and eosinophils from asthmatic and non-asthmatic 
children using whole blood. CD35 mediates the binding and phagocytosis of Ob 
coated particles and immune complexes. CD IIb not only mediates the phagocytosis of 
opsonized particles, but is also involved in cell adhesion. Results showed that on resting 
cells, only CD35 on neutrophils was significantly elevated in asthmatic children. After 
stimulation with fMLP, the CD11b expression on neutrophils and eosinophils was 
significantly higher in asthmatic children than in controls, suggesting that the inducible 
expression of CD IIb on neutrophils and eosinophils in allergic asthmatic children is 
primed in vivo. 
In contrast, Int Veen et al (88) showed that in stable disease, CD I lb and CD62L 
expression on eosinophils or neutrophils from blood and sputum did not differ between 
normal, mild, or moderate-severe asthmatics that were on high dose inhaled 
corticosteroids (ICS). However, sputum eosinophils showed a higher expression of 
CD IIb and lower expression of CD62L compared with peripheral blood eosinophils. 
The level of bronchial hyperreactivity as measured by PC20, in the patients with 
moderate to severe asthma was shown to be related to CD IIb expression on blood and 
sputum eosinophils. One explanation for these findings was that the modulation of 
CD11b and CD62L on airway granulocytes is not specific for asthmatic airway 
inflammation, but probably the result of tissue migration per se. Further, Maestrelli et 
al showed no difference between CD IIa, CD IIb, or CD IIc in blood mononuclear cells 
between controls and asthmatics (89). However, in contrast to the findings of Int Veen 
et al, sputum CD IIa and CD 11 b expression on mononuclear cells in asthmatics were 
expressed at a lower level compared with blood, but not in normal subjects. In both 
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control and asthmatics, sputum neutrophils tended to decrease their expression of 
integrin alpha chains compared to circulating neutrophils, suggesting that there is a 
downregulation of integrins in asthmatic airways after cell recruitment from the 
circulation. 
1.6 Effect of corticosteroids on neutrophil function 
1.6.1 Inhibitory effect of systemic corticosteroids on neutrophilfunction 
Most studies of the effect of glucocorticoids on circulating neutrophils have 
been done in-vitro, using high doses of synthetic steroids such as dexamethasone. Most 
of these studies show that the effects of glucocorticoids on neutrophils are inhibitory 
and therapeutically this can be couterproductive as one of the most notable side effects 
of high dose steroids is decreased resistance to infection due to impaired neutrophil 
bactericidal activity. Corticosteroids have been shown to modulate neutrophil- 
endothelial cell interactions. Yoshida et al (90) showed that treatment of human 
umbilical vein endothelial cells (HUVEC) with methylprednisolone inhibited adherence 
and migration of neutrophils. Methylprednisolone also inhibited the IL-IP induced 
upregulation of E selectin and ICAMI on HUVEC. Studies of neutrophil adhesion 
molecule expression in rheumatology patients (91) showed that methylprednisolone in 
doses of Ig decreased radiolabelled neutroPhil ingress into inflamed joints. Burton et al 
(92) showed that 3 days treatment with dexamethasone in cows reduced CD62L and 
CD18 expression on bovine neutrophils. Glucocorticoids can also inhibit expression of 
the adhesion molecules ELAM- I and ICAM- I on endothelial cells (93). 
The effect of dexamethasone on leucocyte extravasation in the post capillary 
venules of the hamster cheek pouch was studied by Mancuso et al (94) using intravital 
microscopy technique. Pretreatment with dexamethasone was shown to reduce 
neutrophil transmigration. Corticosteroids have been shown to have an inhibitory effect 
on cytokine production. Pang et al (95) looked at sputum and blood in patients with 
chronic bronchial sepsis and showed that in sputum, increased neutrophil numbers 
correlated with increased concentrations of IL-8, IL- I P, and TNF-(X. Cytokine secretion 
was shown to be inhibited by dexamethasone. Dexamethasone also inhibited 
lipopolysaccharide (LPS) induced production of IL-6 (96) and IL-8 (97) by human 
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neutrophils. Petroni et al (98) showed that dexamethasone decreased interferon gamma 
(IFN-7) stimulated phagocytosis by neutrophils, as well as reducing the IFN-7 induced 
increase in Fc7RI receptor sites per cell by 39-73%. 
Pretreatment with methylprednisolone inhibited the LPS induced superoxide 
production by pulmonary and circulating blood neutrophils in rats (99). The inhibitory 
effect of methylprednisolone on pulmonary neutrophils was greater than that on 
circulating blood neutrophils. Neutrophils pre-treated with hydrocortisone or 
dexamethasone showed a reduced percentage of Aspergillus fumigatus hyphal damage 
(100). Pre-treatment of neutrophils with GCSF and/or IFN-y prevented the suppression 
of hyphal damage that occurred in the presence of hydrocortisone or dexamethasone. 
Similarly, Abe et al (101) showed that prednisolone inhibited neutrophil activity versus 
candida. albicans. 
1.6.2 Effect of glucocorticoids on adhesion molecules on resting neutrophils 
The mechanisms by which glucocorticoids reduce leukocy-te influx and 
inflammation are not fully understood. Some of the mechanisms of anti-inflammatory 
action of glucocorticoids that have been put forward include inhibition of 
phopholipases, inhibition of the transcription of various cytokines, and stabilization of 
lysosomal and other cell membranes. However, none of these hypotheses is sufficient 
to account for their effects on leucocyte traffic into inflamed tissues. 
Several animal studies have looked at the effect of in-vivo glucocorticoids on 
surface molecule expression on neutrophils. Burton et al (102) treated dairy cows for 3 
days with placebo (PBO), cortisol or dexamethasone using whole blood that was 
unstimulated or treated with PAF. Dexamethasone almost completely down-regulated 
CD62L and and reduced expression of CD18 by 50%. Dexamethasone also caused a 
reduction in the proportion of cells staining positive for CD62L, but did not alter the 
number of cells staining for CD 18. Cortisol had a similar effect. This suggests that one 
mechanism of the anti-inflammatory action of glucocorticoids is to induce dramatic 
down-regulation of CD62L and CD 18 adhesion molecules on blood neutrophils. Burton 
et al also showed that in-vivo glucocorticoid treatment induced significant 
down-regulation of both CD62L and CD18 expression on resting bovine neutrophils. 
However these effects of glucocorticoids were detectable only 8 to 16 hours and 2 to 3 
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days after treatment respectively. As neutrophils reside in the peripheral blood for only 
a few hours, it would suggest that in this situation, glucocorticoids are affecting 
neutrophil precursors in the bone marrow rather than circulating neutrophils. 
Studies in rabbits show that inflammatory stimuli cause the release of 
polymorphonuclear cells (PMNs) from the bone-marrow which show an increase in the 
expression of CD62L. This is in contrast to glucocorticoid induced granulocytosis 
which is associated with decreased CD62L expression on peripheral neutrophils (103). 
Intravenous (i. v. ) dexamethasone given to rabbits showed that dexamethasone 
decreased CD62L expression on segmented neutrophils in the bone marrow but not on 
neutrophils already in the circulation. 
In contrast to the studies showing downregulation of surface molecule 
expression with glucocorticoids, Trowald et al (104) investigated the in-vivo effect of 
prednisolone on canine neutrophil function in whole blood and found no change in the 
expression of CD II b/CD 18 expression. However, their results showed that neutrophil 
adherence was reduced, whilst chemiluminescence and chemotaxis were increased. 
O'Learry et al showed that neutrophils in BAL fluid in rats showed increased CD IIb 
and reduced CD62L compared to blood neutrophils (10 5). This upregulation of CD IIb 
was insensitive to dexamethasone pretreatment, and may in part explain the lack of 
efficacy of steroids in the management of acute respiratory distress syndrome (ARDS). 
In human studies of in-vivo glucocorticoid treatment, Jilma et al (106) showed that 
repeated administration of i. v. dexamethasone over a 48 hour period downregulated 
basal CD62L expression on human neutrophils. Crockard et al (107) studied 15 
patients with multiple sclerosis (MS) receiving i. v. methylpredniso lone prior to and at 6 
and 24 hrs following the initial 500mg dose. A follow up sample was obtained 48 hrs 
after a5 day course. Neutrophil counts were elevated at 6 hrs (3 fold) and 24 hrs (2 
fold) and this was associated with a 40% reduction in CD62L expression at 6 and 24 
hrs and a 35% reduction in CD IIb expression at 6 hrs. Short term in-vitro cultures at 6 
and 24 hrs of blood samples from untreated MS patients and controls showed minimal 
reductions in neutrophil CD62L and CD IIb expression. 
Cardiopulmonary bypass (CPB) is known to upregulate CD IIb in humans. In a 
randomized trial, patients were given Igi. v. methylprednisolone 5 minutes prior to 
CPB compared to another group which received no steroid. (108). In the non-treatment 
group, CD11b was significantly upregulated, whilst in the treatment group, no 
significant changes were seen. During CPB, IL- I P, TNF-cc, and endotoxin are released 
in humans and it is known that glucocorticoids suppress the release of these cytokines. 
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Therefore it has been hypothesised that the blunting effect by glucocorticoids on 
CD 11 b expression on neutrophils during and after CPB in humans is due to suppression 
of cytokine release by steroids. 
V- 
.L bussef et al (109) looked at the effect of Igi. v. methylprednisolone on the 
expression of cell adhesion molecules on peripheral blood and synovial fluid 
neutrophils in rheumatoid arthritis. A significant decrease was seen in CD11b and 
CD18 expression on synovial fluid neutrophils at both 4 and 24 hours post 
methylprednisolone and an increase in CD62L expression. There was less effect on 
peripheral blood neutrophils although results approached statistical significance. In a 
study of oral prednisolone in humans, Laroche et al (110) looked at the effect of 
ketoprofen and prednisolone on CRI and CR3 and FcyRIII receptor expression on 
PMN in an ex-vivo study using a randomised, single blind PBO controlled parallel 
design. Twenty four healthy males were given prednisolone 5mg bd or PBO for 7.5 
days. No significant difference in CRI, CR3 and FcyRIII expression on unstimulated 
and fMLP stimulated neutrophils using monoclonal antibodies and flow cytometry. 
1.6.3 Effect of glucocorticoids on adhesion molecules on stimulated neutrophils 
Filep et al (111) showed that dexamethasone at clinically relevant 
concentrations attenuated the PAF induced downregulation of CD62L and upregulation 
of CD II b/ 18 adhesion molecules on human neutrophils. There was no detectable effect 
on the expression of adhesion molecules on resting neutrophils The effects of 
dexamethasone were aborted by RU486 which blocks transcriptional activation of the 
glucocorticoid receptor and by the protein synthesis inhibitor cycloheximide. In 
addition to the effects of glucocorticoids, Spoelstra et al showed that theophylline at a 
pharmacological dose also inhibited the CD1 lb upregulation and L-selectin shedding 
induced by PAF on both eosinophils and neutrophils (112). In animal experiments, 
Fraile et al (113) showed that dexamethasone caused a dose-dependant inhibition of 
LPS induced CD I lb expression, while Za zhi et al showed that dexamethasone 
inhibited the increase in CD18 on rabbit neutrophils caused by TNF-(x and this 
inhibitory effect was reversed by RU486 suggesting that it was mediated through the 
glucocorticoid receptor (114). 
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1.6.4 Effect of inhaled corticosteroids in asthma 
Inhaled cortico steroids are the most effective treatment available for the 
treatment of chronic asthma. Regular treatment with ICS reduces airway inflammation 
and can improve lung function in asthmatics. In addition, there is improvement in 
airway hyperresponsiveness and improved asthma control. datakanon et al (115) 
showed significant improvement in the forced expiratory volume in I second (FEVI) 
following treatment with inhaled fluticasone propionate (FP) 400ýtg/day or 1600ýtg/day 
budesonide for 4 weeks compared to PBO, and this was accompanied by significant 
reductions in eosinophil numbers in induced sputum. Levels of exhaled nitric oxide 
(NO) , which is an indirect marker of airway inflammation, were reduced following 
doses of budesonide as low as I 00ýtg/day, whilst PC20 was improved only after the high 
dose was used. Similarly, van Rensen et al (116) showed significant increase in PC20 
with a decrease in sputum eosinophil and decreased exhaled NO compared to baseline 
at 2 and 4 weeks of treatment with inhaled FP 500ýtg/day for 4 weeks compared to 
PBO. Treatment with inhaled beclomethasone dipropionate (BDP) for 3 weeks at a dose 
of I 000[tg/day produced no significant change in FEV I or forced vital capacity (FVC), 
but PC20 methacholine rose significantly. Exhaled NO fell after I week of ICS therapy, 
and then increased at I week after treatment was stopped (117). 
The relatively short lived effects of ICS was confirmed by Gershman et al (118) 
who showed significant increase in FEV I with high (1000ýtg/day) and low (100ýtg/day) 
FP therapy for 6 weeks, and reduction of sputum eosinophil counts. In addition there 
were improved symptoms and morning peak expiratory flow rates (PEFR), PC20, and 
sputum ECP and tryptase measurements. After stopping therapy, only improvements in 
PEFR and tryptase activity persisted in both groups, with improvement in sputum 
eosinophilia persisting only in the high dose group. This study suggests that low dose 
inhaled FP is effective but the effects seen are short lived after treatment is stopped. 
Similarly, in a dose response study of inhaled FP, O'Sullivan et al (119) showed that 
optimal improvement in lung function and markers of airway inflammation occurred at 
a dose of 500[tg/day with no evidence of a dose response relationship at the higher dose 
of 2000ýtg/day. This provides evidence for the importance of add on therapy over 
increasing doses of ICS. 
That exhaled NO may be useful in monitoring asthma control with ICS therapy, 
was suggested by the study 
by Kharitonov et al (120) who showed that exhaled NO was 
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increased significantly compared to baseline after the dose of budesonide in asthmatics 
was reduced by 200ýtg/day but this was not accompanied by a significant decrease in 
spirometry or PEF variability. An increase in nocturnal symptoms however was 
reported. The levels of exhaled NO were decreased when the dose of inhaled 
budesonide was subsequently increased by 200ýtg/day, and this was accompanied by a 
decrease in diurnal variability and nocturnal symptoms. Khartinov et al also showed 
that a significant and progressive fall in exhaled NO occurred from week I to week 3 
following treatment with budesonide 800ýtg/day for 3 weeks in mild steroid naYve 
asthmatics with no significant change in FEVI but an improvement in methacholine 
PC20 (121). Carra et al also showed a reduction of exhaled NO following 6 weeks 
treatment with budesonide in stable asthmatic children in the absence of changes in lung 
function (122). The reduction in NO is thought to be due to an inhibitory effect of ICS 
on the induction of the enzyme NO synthase in the respiratory tract (12 1). 
Inoue et al (123) showed that 4 weeks treatment with budesonide 800ýtg/day 
resulted in improved lung function along with a mean reduction in the percentage of 
eosinophils in induced sputum but not in the percentage of neutrophils. In addition, 
mean levels of sputum supernatant IL-8 and GM-CSF were also decreased significantly 
after treatment. The improvement in lung function and airway inflammation may thus 
be, in part, due to the inhibition of the synthesis of inflammatory cytokines such as IL-8 
and GM-CSF. 
Systemic corticosteroids are used in the management of acute severe asthma as 
opposed to ICS, as aerosol penetration is poor in the presence of bronchoconstriction. 
Time course studies have shown that i. v. administered hydrocortisone can cause 
bronchodilation within 3-4 hours of administration, and also improve the bronchodilator 
response of an inhaled beta-adrenergic agonist (124). More recently, studies have shown 
that inhalation of large doses of corticosteroids can also be beneficial in patients 
presenting with acute severe asthma. In one double blind study (125), 94 patients with 
an acute exacerbation of asthma admitted to the emergency room were randomised to 
receive inhaled salbutamol and PBO (n=: 47) or salbutamol and inhaled flunisolide 
(n--47) through metered dose inhaler (MDI) and volumatic. Combined therapy produced 
significantly better results at all time points up to 180 minutes, suggesting that 
ICS 
added to salbutamol are an effective therapy for patients with acute asthma. 
Levy et al 
(126) showed that high dose FP (2mg) was as effective as a short course of prednisolone 
(40mg per day, decreasing by 5mg every other day) in treating an exacerbation of 
asthma not severe enough to need 
hospital treatment. In total, 413 patients were 
47 
recruited from 47 GP practices in the UK. No difference was seen in the efficacy 
between reducing dose of oral prednisolone and high dose inhaled FP in mild 
exacerbations of asthma that did not need hospital admission. 
Studies with inhaled budesonide (800ýtg bd) indicate that improvements in 
FEV I and PC20 occurred after the first dose, and this was maximal at 6 hours. Further, 
these parameters returned to baseline within 36 hours of stopping the last dose 
following 6 week regular treatment (127). Large dose of budesonide (dose up to 
1600ýtg) have been shown to cause maximal bronchodilation at 5-6 hours following 
administration in patients with asthma, with significant effects already observed by 2 
hours of administration. There were also falls in blood eosinophils and serum ECP 
occuring 3-5 hours after budesonide inhalation (128). These studies indicate that there is 
a rapid component to the effect of ICS, starting as early as 2 hours. In a recent study, 
Gibson et al showed that high dose inhaled budesonide (2400[tg) via turbohaler was 
associated with a 2.2 fold improvement in airway responsiveness compared to PBO, 6 
hours after inhalation of inhaled budesonide. No significant effect was seen on mast 
cells, apoptotic eosinophils, symptoms or lung function (129). 
The mechanisms of these early rapid changes are not entirely clear, since it is 
thought that many of the mechanisms of corticosteroids may involve interference with 
transcriptional mechanisms. However, it is possible that acute non-transciptional 
mechanisms may be important. Corticosteroids may, for instance, interfere with 
mechanisms of oedema formation or of cytokine release. In addition, it is possible that 
transcriptional mechanisms may occur more rapidly in-vivo than in-vitro. 
Interestingly, Green et al (130) demonstrated a distinct subgroup of patients 
with mild to moderate asthma who showed a predominantly neutrophilic airway 
inflammation in their sputum and responded less well to ICS in terms of improvement 
in symptoms, FEVI, and PC20. The presence of increased neutrophils in asthmatic 
airways may thus account for less improvement following ICS therapy in such patients. 
Gauvveau et al (13 1) showed that ICS attenuated allergen induced airways 
inflammation but were less effective at inhibiting allergen induced sputum eosinophils 
after challenge in asthmatics that had increased levels of sputum neutrophils at baseline. 
This suggests that ICS are less effective in attenuating allergen induced airway 
inflammation in subjects with increased levels of neutrophils and that the heterogeneity 
of airway inflammation in some asthmatics may influence response to steroid treatment. 
This lends support to the fact that alternative therapy should be considered in addition to 
steroids for treating patients with increased neutrophilic inflammation in their airways. 
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1.6.5 Histone deactylation and effect of corticosteroids in asthma 
Glucocorticoids are effective at repressing inflammation in asthma. One possible 
mechanism of action involves the binding of activated glucocorticoid receptor (GR) to 
several transcription co-repressor molecules that associate with proteins with histone 
deacetylase activity (HDAC), resulting in increased coiling of deoxyribonucleic acid 
(DNA) around core histone proteins, and thus preventing binding of transcription 
factors, leading to gene repression (132). 
In resting cells, DNA is tightly packaged into chromatin which is a highly 
organized protein-DNA complex. Chromatin is made up of subunits called nucleosomes 
which are composed of core histone proteins, surrounded by 146 base pair DNA (132). 
In this state, DNA is tightly compacted to prevent accessibility of transcription factors 
which are capable of switching on inflammatory genes. When the cell is activated, local 
unwinding of nucleosomal. DNA occurs so that the DNA is accessible to transcription 
factors and to RNA polymerase 2, thus allowing gene transcription to occur. This 
unwinding is regulated by acetylation of specific lysine residues in the N-terminal tails 
of the core histone proteins. This histone acetylation is carried out by a group of 
enzymes with histone acetlytransferase (HAT) and HDAC activity that regulate the 
chromatin structure, and through this effect, the inflammatory gene expression. (Fig. 
1.4) 
Transcription factors such as STATs, AP-1 and NF-YB, bind to co-activator 
molecules such as CREB -binding protein (CBP) or p300, which have intrinsic HAT 
activity, resulting in acetylation of histone residues. This leads to unwinding of DNA 
and allows increased binding of transcription factors resulting in increased gene 
transcription. (133). The process of deacetylation involves the binding of hormone or 
vitamin receptors to co-repressor molecules such as nuclear receptor co-repressor (N- 
CoR), which forms a complex with another repressor molecule, Sin3, and a histone 
deacetylase (134,135). Deacetylation of histone increases the winding of DNA round 
histone residues, resulting in dense chromatin structure and reduced access of 
transcription factors to their binding sites, thereby leading to repressed transcription of 
inflammatory genes (136). 
Ito et al (13 7) have shown an increased HAT activity in bronchial biopsies from 
asthmatics, which returned to normal following treatment with ICS. This suggests that 
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the use of steroids can lead to histone deacetylation, which represents one mechanism of 
their anti-inflammatory action. 
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Fig. 1.4 Model of histone acetylation and histone deacetylation. HAT complex induces 
acetylation of lysines in the core histone. This reduces affinity of histone N-terminal 
domains for DNA, resulting in unwrapping of DNA from core histone. This allows large 
molecules, such as RNA polymerase II, to gain access to DNA, allowing gene transcription. 
In contrast, HDAC causes deacetylation of histones, resulting in tightening of the DNA 
coiling to core histone proteins. (From reference 137). 
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1.7 Allergic basis of asthma 
1.7.1 Asthma and atopy 
The onset of asthma commonly begins in early life, and childhood asthma is 
frequently associated with atopy to common environmental allergens, such as dust 
mites, tree and grass pollens, and animal dander (138). Atopy is the genetic 
predisposition for the development of an IgE-mediated response to common 
aeroallergens. Allergens play an important role in the development of adult-onset 
asthma, but not all adults who develop asthma have IgE antibodies to allergens or a 
family history of asthma (13 9). Asthma has been shown to be associated with increased 
levels of total IgE, even in subjects negative for specific IgE to common allergens (140). 
It is known that allergen exposure can result in increased airway hyperresponsiveness in 
sensitized subjects. In one survey of 875 young adults aged between 20-41 years, 
elevated serum IgE levels were associated with a 3-fold increase in bronchial 
hyperresponsiveness, independently of the presence of asthma symptoms or specific IgE 
(141). These results suggest that asthma is frequently associated with some type of IgE- 
related reaction and therefore has an allergic basis (140). 
A minority of asthmatic patients have late onset of asthma associated with 
negative skin tests to common allergens and a normal circulating IgE. These patients 
who have non-atopic, or 'intrinsic, asthma tend to have more severe disease. Recently, 
patients with 'intrinsic' asthma have been shown to produce IgE widely in the airways 
(142) suggesting that IgE also plays a role in these patients. 
1.7.2 Mechanism of allergic response 
During an allergic immune response, allergen-specific B cells are stimulated to 
produce IgE antibodies following stimulation by IL-4 and IL- 13 cytokines provided by 
T-helper type 2 (Th2) cells. IgE antibodies bind to the surface of effector cells (mast 
cells and basoPhils) bearing high-affinity (FcFRI) or low-affinity (Fc6RII or CD23) 
receptors which subsequently become sensitized. The subsequent interaction of allergen 
with IgE-FcFRl complexes on mast cells and basophils causes crosslinking and 
aggregation of IgE receptors leading to effector cell degranulation and release of 
inflammatory mediators such as histamine (143). These mediators are thought to 
produce the airway smooth muscle contraction, mucosal hypersecretion and mucosal 
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edema representative of the immediate bronchoconstriction of the early asthmatic 
response (fig. 1.5). 
The bronchoconstriction associated with the late phase asthmatic response 
occurs two or more hours after allergen inhalation and is associated with increased 
airway reactivity to non-specific stimuli. The role of IgE and its high and low-affinity 
receptors in the release of inflammatory mediators in the late asthmatic response to 
inhaled allergen is not well established. However, human lung mast cells can generate 
and release, via IgE-dependent signalling, a wide variety of cytokines (144,145) 
suggesting that IgE has an important role in the ongoing airway inflammation 
associated with the late asthmatic response. 
1.7.3 Difficult1severe asthma- possible alternative therapy in severe asthma 
The majority of asthmatic patients can be managed with short acting P2- 
agonists, along with maintenance low dose ICS, or combination therapy with a long 
acting bronchodilator. A minority of asthmatics however, show persistent symptoms 
and experience frequent exacerbations despite high dose ICS and sometimes oral 
corticosteroid therapy (146). Although this group constitutes only 1% of asthmatics 
(147), they account for a larger share of total asthma costs. Difficult asthma represents a 
real challenge for physicians, patients, and the community. Apart from the economic 
impact of this condition, other implications include an increase in mortality and 
psychological problems, with an increased prevalence of depression in severe 
asthmatics. The pathogenesis and mechanism(s) involved in the development of this 
severe asthmatic state have not been fully elucidated. Patients may present with 
different clinical patterns including intermittent severe exacerbations, persistent chronic 
symptoms or with rapid catastrophic attacks. Many of these patients have 
corticosteroid-dependent asthma (146). 
Treatment of severe asthma is currently limited since corticosteroids are not 
entirely effective and long-term treatment with corticosteroids is associated with a 
variety of side-effects. Current evidence suggests that methotrexateý cyclosporin, and 
gold salts may be considered for their 'steroid-sparing' effects in severe asthmatics, but 
the possibility of short and long-term side effects should be borne in mind. On the other 
hand, the anti-leukotriene agents may provide safe and effective alternatives in the 
treatment of certain groups of patients, such as exercise-induced, aspirin- sensitive and 
possibly corticosteroid-dependent asthmatics. The efficacy and place of these agents the 
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treatment of asthma is still being determined. Anti-IgE therapy represents a new 
therapeutic approach for the treatment of allergic disease and has been shown to be 
effective in treating patients with mild and severe asthma, with very few side-effects. 
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Fig. 1.5 Overview of the allergic immune response. Specific antigens are processed and 
presented to Th2 cells by antigen presenting cells (APC). Allergen-specific B cells are 
stimulated to produce IgE antibodies following stimulation by IL-4 and IL-13 cytokines 
provided by Th2 cells. IgE antibodies then bind to the surface of effector cells (mast cells) 
bearing high-affinity or low-affinity receptors which subsequently become sensitized. The 
subsequent interaction of allergen with IgE-FceRl complexes on effector cells causes 
crosslinking and aggregation of IgE receptors leading to effector cell degranulation and 
release of inflammatory mediators such as histamine, which mediate various clinical 
effects. (BGP-basic granule proteins. PAF-platelet activating factor. ) 
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NMI- Antigen 
1.7.4 Overview of anti-IgE therapy 
Genentech and Novartis have developed a murine monoclonal antibody which 
binds to circulating IgE at the same site on the Fc portion of the IgE molecule as the 
high-affinity receptor IgE receptor (fig. 1.6). Due to a number of problems with the 
clinical use of murine antibodies (e. g. stimulation of human immune response), 
humanization of this murine antibody was undertaken to avoid these problems (148). 
The best of several humanized variants, version 25 (rhuMAb-E25), was selected 
because it possessed IgE binding affinity and biologic activity comparable to the murine 
antibody (149). In-vitro assays showed that the recombinant humanized anti-IgE 
monoclonal antibody bound to free IgE but not to IgA or IgG, and did not bind to mast- 
cell or basophil bound IgE as this would cause release of inflammatory mediators. The 
monoclonal antibody blocked the binding of IgE to FcE; RI, its specific high-affinity 
receptor, and inhibited mast cell degranulation following challenge with ragweed 
allergen (150). These results confirmed that rhuMAb-E25 was effective at blocking 
mast cell degranulation and subsequent release of inflammatory mediators. 
1.7.5 Dose of rh uAM b-E25 
To achieve therapeutic efficacy with anti-IgE antibodies, a dose that greatly 
decreases IgE levels must be used. The experiments of MacGlashan et al (15 1) showed 
that only about 2000 IgE molecules are required for a half maximal release of histamine 
from basophils exposed to specific allergen. Their study also showed that FcF'Rl 
receptor density on IgE effector cells is regulated by circulating levels of IgE. They 
found that treatment with rhuMAb-E25 decreased free IgE levels to 1% of pretreatment 
levels and resulted in marked down-regulation of FcFR1 on basophils. Median receptor 
densities were approximately 220,000 receptors per basophil at baseline and decreased 
to approximately 8,300 receptors per basophil after 3 months of treatment. Ideally, 
serum IgE levels should be suppressed to below 25ng/ml. This explains why anything 
less than near-complete suppression of IgE levels allows sufficient IgE binding to 
FccR1 receptors to occur resulting in full basoPhil activation. From a therapeutic 
standpoint, this means that anti-IgE dosing needs to be individualized and depends on 
the patient's total IgE level, and body weight. RhuMAb-E25 can be given by i. v. or 
subcutaneous routes, but nebulized rhuMAb-E25 has not been shown to cause reduction 
in circulating IgE levels. 
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Fig. 1.6 RhuMab-E25 binds to circulating IgE at the same site on the Fe portion of the IgE 
molecule as the high-affinity receptor IgE receptor. This blocks the binding of IgE to the 
high affinity IgE receptor on effector cells and thus inhibits mast cell degranulation and 
subsequent release of inflammatory mediators. 
57 
1.7.6 Safety of anti-IgE therapy 
The 3 main safety concerns surrounding the anti-IgE treatment strategy were, 
firstly, that it may cause anaphylaxis; secondly it could predispose the patient to 
parasitic infections; and finally it may provoke immune responses, including 
complement fixation or antibody formation. The first concern was eliminated by the 
development of non-anaphylactogenic antibodies, as described above. 
The second concern arises from data suggesting an important role for IgE in 
eliminating parasites (152). However, studies of the role of IgE in host defence against 
parasitic infections, such as Schistosoma mansoni, have produced conflicting reports. 
Amiri et al (153) treated mice with a rabbit polyclonal antimouse anti-IgE or with an 
isotype control antibody and then infected them with S. mansoni. Results showed that 
reduction of the IgE response by anti-IgE antibody decreased the worm burden, the 
number of eggs per worm, and the number of hepatic granulomas. Amiri et al concluded 
that IgE plays a detrimental, rather than beneficial, role for the host in schistosomiasis. 
In contrast, King et al (154) infected normal mice and IgE-deficient mice (animals with 
a null mutation of the relevant gene and thus incapable of making IgE) with S. mansoni 
and found that the IgE-deficient mice were significantly more susceptible to primary 
infection, developing worm burdens twofold greater than those of wild-type mice, 
suggesting that IgE participates in parasite elimination in primary infection with 
S. mansoni. Overall, however, there is evidence for a potentially important role for IgE 
in host defense against parasites and clinical trials of anti-IgE treatment will need to 
monitor the incidence of parasitic infections closely. 
The third concern was that anti-IgE may provoke an immune response. This is 
generic to all protein therapeutics but is considerably reduced by the "humanization 
step" in the engineering of anti-IgE molecules (155). Thus the development of 
antibodies against rhuMAb-E25 has not been detected in studies of more than 1000 
patients in which the drug has been administered parenterally (156-158). Interestingly, 
the aerosol route of administration may be more immunogenic than the i. v. or 
subcutaneous route. One study of aerosolized rhuMAb-E25 treatment in 20 patients 
showed the presence of an antibody to rhuMAb-E25 in 1 patient (159). 
Although rhuMAb-E25 has an IgG I -kappa structural framework, it does not fix 
complement. In addition, rhuMAb-E25: IgE complexes are of limited size (I million 
MW or smaller) (160,161) and no precipitating immune complexes were detected. 
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These complexes cannot bind IgE receptors and thus lack the biological activity of IgE. 
Studies in cynomolgus monkeys (which have naturally high levels of IgE) indicate that 
these relatively small complexes do not accumulate in any body organs, including the 
kidney (161). In human studies, treatment with rhuMAb-E25 has been well tolerated in 
all studies to date, with no specific adverse effects apart from an urticarial rash after the 
first dose in a small number of subjects (3%) in a trial of 300 patients (162). 
1.7.7 Clinical Studies 
The efficacy of rhuMAb-E25 in mild atopic asthma was shown in two studies 
which looked at the effect of rhuMAb-E25 on bronchial challenge with allergen and on 
allergen-induced skin tests (158,164). The effect of rhuMAb-E25 on the provocation 
concentration of allergen and methacholine causing a 15 and 20% fall (PC15 and PC20, 
respectively) in FEVI during the allergen-induced early asthmatic response was 
assessed in 20 atopic patients with mild asthma (158). RhuMAb-E25 produced 
significant inhibitory effects on allergen-induced bronchospasm relative to PBO. The 
methacholine PC20 improved slightly but significantly after rhuMAb-E25 treatment 
while no change was observed with PBO. RhuMAb-E25 treatment reduced mean serum 
free IgE levels by 89% while no changes were observed with PBO. Free IgE levels fell 
to below the threshold for detection in 7 of 10 patients. Overall, these results showed 
that rhuMAb-E25, administered at regular intervals over 10 wýeeks, effectively 
suppressed allergen-induced early asthmatic response in patients with asthma. 
A further randomized double-blind study showed that rhuMAb-E25 (0.5 mg/kg 
or placebo weekly for 9 weeks) suppressed both the early- and late-phase responses to 
inhaled allergen in 19 atopic patients with asthma (163). RhuMAb-E25 significantly 
reduced maximal bronchoconstriction to airway challenge during the early and late 
phases by 40% and 63% as evidenced by the reduction in magnitude of fall in FEVI. 
The PC20 improved slightly but not significantly, in the rhuMAb-E25 group relative to 
the PBO group. At 24 hours after allergen challenge, eosinophilia in induced sputum 
was reduced 11 fold, while free serum IgE levels fell by about 90% in the rhuMAb-E25 
group and were unchanged in the PBO group. The reduction in the number of 
eosinophils in the sputum and improved airway hyperresponsiveness (15 8,164), suggest 
that rhuMAb-E25 has a long-term anti-inflammatory effect. 
The clinical efficacy and safety of rhuMAb-E25 has recently been assessed in a 
large multicentre, randomized, double-blind, PBO-controlled study in 317 patients with 
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moderate to severe allergic asthma requiring ICS and/or oral corticosterolds (164). 
Following a 4-week run-in period, patients received either PBO, or low dose or high 
dose rhuMAb-E25 i. v. biweekly for 20 weeks. During the last 8 weeks of treatment, the 
dosages of corticosteroids were tapered in an attempt to discontinue this therapy. Both 
high and low dose rhuMAb-E25 produced a greater than 95% mean decrease in serum 
IgE levels (164). The proportion of patients in the high-dose and low dose rhuMab-E25 
groups experiencing a ý! 50 % reduction in asthma symptom scores (the primary 
outcome measure) was significantly higher than in the PBO group. A significantly 
higher proportion of patients in the high-dose group than in the low dose and PBO 
groups were able to achieve a ý! 50% reduction in oral cortico steroids. For high dose, 
low dose and PBO groups, respectively, oral corticosteroids were discontinued in 33, 
43, and 17% of patients and ICS were discontinued in 18% (p=0.27), 23% (p=0.048) 
and 12% of patients. 
Compared with PBO, rhuMAb-E25 significantly reduced the symptoms of 
asthma and improved the subjects' quality of life, with a moderate increase in airway 
function and a reduced need for the use of bronchodilators as rescue medication. The 
proportions of patients experiencing asthma exacerbation during the 20-week treatment 
period were 30% (p=0.03) in the high dose, 28% (p=0.01) in the low dose as compared 
with 45% in the PBO group. There were no significant differences in adverse events 
between the active -treatment and PBO groups, and no serious drug-related adverse 
events were reported. This suggests that rhuMAb-E25 may be a useful steroid-sparing 
therapy in patients with severe asthma (165). Subcutaneous rhuMab-E25 has also been 
shown to produce improvements in daily nasal symptoms (sneezing, itchy nose, runny 
nose and stuffy nose), concomitant antihistamine rescue medication use, and rhinitis- 
specific quality of life in patients with seasonal allergic rhinitis (166,167). The 
improvement in seasonal allergic rhinitis and reduction in rescue medication use was 
directly related to reduction in free IgE levels (166). 
Interestingly, Yamaoka et al showed that neutrophils can synthesize CD23 
molecules following stimulation with GM-CSF, and this CD23 expression might be of 
pathophysiological relevance in IgE dependent activation during allergic processes 
(168). In addition, Gounni et al showed that peripheral blood and BAL neutrophils from 
asthmatics expressed FcE; Rl, which is the main receptor involved in binding IgE 
molecules to the surface of mediator cells. Further, activation of these FcSRI receptors 
induced the release of IL-8 by neutrophils (169). These studies suggest that neutrophils 
may play a role in allergic inflammation through an IgE-dependent activation 
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mechanism. In the context of severe allergic asthma, this is important as increased 
numbers of neutrophils have been demonstrated in sputum and bronchial biopsy 
samples in patients with severe corticosteroid-dependent asthma. 
1.8 Aim of study 
Neutrophils have been shown to have an important role in the pathogenesis of 
asthma. Recent studies have shown that patients with severe asthma have increased 
numbers of activated neutrophils in their airways, both in BAL samples and in sputum. 
Activated neutrophils can lead to increased airway inflammation and damage and 
consequently airway wall remodelling through the release of toxic enzymes and 
chemicals. In vitro, neutrophils can also activate eosinophils through the release of 
stored enzymes and cytokines. Further, it has been shown that corticosteroids may lead 
to increased neutrophil survival and hence activation by inhibiting their apoptosis. The 
hypothesis of this thesis is that concomitant activation of both eosinophils and 
neutrophils may be important in patients with severe asthma through the enhancement 
of mediator release and subsequent remodelling of the airways. Further, as 
corticosteroids may lead to continued activation of neutrophils, this form of treatment 
may allow the inflammatory process to persist in severe asthmatics. 
Little is known about the level of activation of neutrophils in the peripheral 
blood of asthmatic patients. The aim of this research was to investigate neutrophil 
activation and function in severe corticosteroid-dependent asthmatics, and to compare 
this with mild, and moderate asthmatics and normal control subjects. The relevance of 
this is important as neutrophils may lead to airway remodelling and fixed airway disease 
in more severe asthmatics, requiring further treatment with corticosteroids and the 
development of potential side-effects of treatment. Using a fluorescent activated cell 
sorter (FACS) scan and peripheral whole blood, several aspects of neutrophil function 
were analysed including surface marker expression, measurement of neutrophil elastase 
and oxidative burst, and measurement of IL-8 levels in cultured whole blood. Further, 
the effect of a standard therapeutic dose of prednisolone (30mg for I week) on these 
functional markers on neutrophils was studied. 
The level of expression of HDAC in isolated blood neutrophils from asthmatics 
was studied and compared to levels in isolated peripheral blood mononuclear cells and 
BAL alveolar macrophages, and the effect of corticosteroids on HDAC activity in these 
cell populations investigated. The immediate effect of ICS on various parameters 
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including neutrophil numbers, cytokine production and clinical parameters were studied. 
Finally, the efficacy and tolerability of subcutaneous administration of anti-IgE therapy 
over a one year period was studied in patients with severe atopie asthma. 
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Chapter 2 
2.1 Clinical methods 
2.1.1 Ethics 
Written infonned consent to participate in the studies was obtained and all 
studies were approved by the Ethics Committee of The Royal Brompton NHS Trust. 
Clinical studies were done in accordance with the guidelines on 'Good Clinical 
Practice'. Each subject was allocated a hospital number and a set of medical notes that 
were kept in the asthma laboratory at the Royal Brompton Hospital. 
2.1.2 Subjects 
Asthmatic patients were recruited from the outpatients department at The Royal 
Brompton Hospital as well as from advertisements. Asthma was clinically diagnosed by 
a history of recurrent wheezing and chest tightness and by a previous physician 
diagnosis. The diagnosis was confirmed either by measuring methacholine airway 
hyperresponsiveness (PC20<4mg/ml) when the FEVI was >70%, or by demonstrating 
> 15% improvement in baseline FEV I or > 10% predicted FEV I after inhaled salbutamol 
200ýtg, when the FEVI was < 70%. 
Normal subjects had no history of chest symptoms and an FEVI >90% 
predicted. All subjects were either lifelong non-smokers, or had not smoked for at least 
one year, and had a total smoking history of less than 10 pack years. Asthmatics were 
stable with no changes in asthma symptoms and medication for at least one month, 
except for the use of short acting inhaled beta-2 agonists. No subjects had a history of 
an upper respiratory tract infection within the previous 6 weeks. Asthma severity was 
documented by [1] asthma questionnaire and previous medical records involving 
asthma history and asthma medication required to maintain asthma control, [2] 
symptom diary card, and [3] spirometry. 
Asthma severity was classified according to guidelines produced by the National 
Heart and Lung Institiute (170) into 3 groups depending on level of symptoms, 
spirometry, and medication required in order to maintain control: 
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Group 1: mild intermittent, if symptoms less than or equal to 2 times a week, with 
normal lung function. These patients required only a short acting inhaled beta-2 agonist 
as required. 
Group 2: moderate persistent asthmatics had daily asthma symptoms requiring daily use 
of inhaled short acting beta-2 agonists and medium dose ICS (BDP 400 to 1000ýtg daily 
or equivalent) via an MDI. 
Group 3: severe persistent asthmatics had continuous symptoms, frequent 
exacerbations, limited physical activity, frequent night-time symptoms with FEV1 or 
PEF<60 % predicted. These patients were all treated with high dose ICS (BDP 
2000ýtg/day or equivalent), and were taking maintenance oral prednisolone tablets, 
along with any other asthma medication in order to control symptoms. 
2.1.3 Skin prick testing 
These were performed on the anterior aspect of one forearm. The test site was 
marked with a ball point pen. A lancet was used to breach the surface epidermis through 
a drop of allergen extract on the skin, and inserted at a 90 degree angle. It is important 
that blood is not drawn. Any surplus fluid was blotted with a tissue. After 10 minutes, 
the skin was examined visually and the reaction to individual allergens measured by 
placing a transparent ruler over the wheal matching one of a number of drawn circles of 
known diameters to the wheal size. The measurements were recorded in the notes. The 
allergens tested were Dermatophago ides pteronyssimus, mixed grass pollen, cat hair, 
and aspergillus fumigatus, with histamine (I Omg/ml) and normal saline serving as 
positive and negative controls respectively. Each solution was placed about 3 
centimetres apart. A reaction is positive reaction if 3 millimetres or more in diameter. 
2.1.4 Lungfunction measurements 
Baseline lung function was measured in all subjects. FEVI and FVC were 
measured with calibrated, dry wedge spirometer (Vitalograph, Buckingham, UK). For 
all experiments, baseline lung function was measured following a standardised protocol. 
On arrival in the laboratory, each subject rested for 15 minutes prior to three 
measurements of FEVI and FVC. The procedure was performed with the subject 
standing. The subject was asked to take a full inspiration, seal his/her lips around the 
64 
cardboard mouthpiece tube, and perform an expiratory manoeuvre as rapidly and 
forcefully as possible. The subject was then encouraged to breathe out for a full 6 
seconds or until a2 second plateau was achieved as indicated by the stylus on the 
Vitalograph chart. The manoeuvre was repeated a further 2 times with a one minute rest 
between each manoeuvre, and the best of three attempts recorded. 
2.1.5 Measurement of airway hyperresponsiveness 
A standard procedure was employed for bronchial challenge with methacholine. 
On arrival in the laboratory, subjects were required to rest for 15 minutes before 
assessment of lung function. The best of 3 technically acceptable recordings of FEVI 
taken at I minute intervals, was taken and had to be 70% of predicted value before 
histamine challenge. Following this baseline assessment, subjects inhaled five breaths 
of 0.9% saline nebulised from a breath activated dosimeter by inspiring slowly from 
functional residual capacity (FRC) to total lung capacity (TLC) over 3 seconds and then 
breath holding for 6 seconds. The subject then exhales from TLC, as hard and as fast as 
possible for one second and the FEVI noted. This measurement is performed at 30 
seconds, 90 seconds and 180 seconds post nebulization. At each time period (30,90, 
and 180 seconds) at least 3 measurements of FEVI are made to confirm reproducibility, 
and the highest of each three taken. Unless a fall in FEV I of greater than 10% from 
baseline is seen, subjects then inhale doubling increments of methacholine until a. 20% 
fall in FEVI from the post saline value is achieved. This concentration of methacholine 
is known as the PC20. FEVI is recorded 1.5 and 2.5 minutes after each concentration of 
methacholine. The starting concentration for methacholine was 0.03 lmg/ml. In the 
event of a post saline fall in FEV I of > 10% from baseline, subjects are rested once only 
for 30 minutes before the procedure is repeated. Patients were given beta-2 agonist if 
required 
2.1.6 Exhaled NO measurement 
Exhaled NO was measured using a chemilurninescence analyzer (Model 
LR2000; Logan Research, Rochester, UK) sensitive to NO from I to 5000 parts per 
billion (ppb, by volume), and a resolution of 0.3 ppb. In addition to NO, the analyzer 
also measured carbon dioxide 
(C02), (resolution 0.1%C02) and sample pressure and 
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volume in real time. The sampling rate of the analyzer was 250ml/min for all 
measurements. The analyzer was calibrated daily by the asthma clinic staff using 
certified NO mixtures (90ppb and 500ppb) in nitrogen and certifiedC02 (BOC special 
gases, Surrey Research Park, Guildford UK). Ambient air NO was recorded before and 
after each subject was studied. 
Measurements of exhaled NO-obstructed, were made by exhalation from TLC 
via a wide bore Teflon tube into the analyzer, with a flow of approximately I L/minute, 
and therefore provided resistance to flow (exhaled NO-obstructed). Peak exhaled NO 
values were measured during the obstructed maneuver. Subjects then performed a 
similar maneuver with slow exhalation for 30 seconds from TLC with a flow of 5L/min, 
bypassing the analyzer and thus with minimal resistance to flow; NO was sampled from 
a side-arm (end-exhaled NO-unobstructed). For unobstructed end-exhaled NO 
concentrations, the value corresponding to the plateau of the end-exhaledC02 reading 
(5%CO2)was taken as representative of an alveolar sample. This measurement using 
free flow was repeated following a 20 second breath hold (end-exhaled NO breath- 
hold). In all these maneuvers subjects wore a nose clip, and the pressure during 
expiration was kept constant (3 +/- 0.4mm Hg) by using a visual display of expiratory 
flow measured by pressure and volume sensors in the analyzer. 
2.2 Laboratory methods 
2.2.1 Sputum induction andprocessing 
Sputum induction was performed using the method described by Keatings et al 
(172). Inhaled salbutamol was given 15 minutes before sputum induction. Hypertonic 
saline solution was prepared by adding 57mls of water for injection to 43mls of 7% 
sodium chloride. Twenty mls of this solution was placed into the cup of the ultrasonic 
nebuliser. After baseline spirometry was recorded, patients were instructed to wash their 
mouths thoroughly with water, and then inhale (breathing normally) 3% nebulized 
saline using an ultrasonic nebulizer (DeVilbiss Co, Heston, UK) at the maximal saline 
output (4 ml/min), for 5 minutes. The subject must wear a nose clip for the procedure, 
as is monitored closely for adverse effects such as dyspnoea and wheezing. The total 
period of sputum induction was 15 minutes and subjects were encouraged to cough 
deeply at 3 minute intervals until the 15 minute induction time had elapsed, 
Mouthwashing before each cough was encouraged in order to minimize salivary 
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contamination. Following sputum induction, spirometry was repeated and if there was 
> 15 % fall in FEV 1, the patients were required to stay for obervation until it returned to 
baseline values, and given a salbutamol nebuliser if required. Sputum was collected into 
a 50ml polypropylene tube, and processed within 2 hours. 
Sputum was processed by adding Iml Hank's balanced salt solution (HBSS, 
Sigma Aldridge, Irvine, UK) containing 1% dithiothreitol (DTT) (Sigma chemicals, 
Poole, UK). The mixture was vortexed and aspirated repeatedly at room temperature 
until the sputum was homogenized. Sputum volume was then recorded and further 
diluted with HBSS to 5 ml, vortexed briefly and centrifuged at 400g for 10 minutes at 
4'C. Sputum supernatants were removed and kept at -70' C until needed for subsequent 
cytokine assays. Total cell counts were performed by resuspending the cell pellets and 
then counting using a haernocytometer after staining with Kimura stain. Cytopinslides 
were then prepared (Shandon, Runcorn, UK) and stained with May- Grunwald- Giemsa 
for differential cell counts. At least 400 inflammatory cells were counted in each sample 
2.2.2 Isolation of PBMC and granulocytes by Ficoll-Hypaque gradient centrifugation 
Twenty millilitres of heparinised blood were diluted in an equal volume of 
RPMI 1640 (Gibco, Invitrogen, UK) in a 50mls polypropylene tube and carefully 
layered on top of I Oml Ficoll-Hypaque (Amersham Biosciences, UK) taking care not to 
disturb the interface. The tube was then centrifuged at 2000 rpm at 20'C for 20 minutes, 
following which the PBMC layer was withdrawn with a pipette and transferred to a new 
polyproplene tube and washed by adding 5mls phosphate-buffered saline (PBS, Gibco, 
Invitrogen, UK) and centrifuging at 18OOrpm for 5 minutes. The supernatant was 
discarded and the cell pellet resuspended in I ml PBS. The cells were counted using a 
haernocytometer and Kimura stain and the cell concentration adjusted to IX106 in PBS. 
Cells were placed on ice until required. 
To obtain granulocytes, all the layers above the red cell layer were removed and 
10ml PBS and 3ml 3% Dextran T-500 (Pharmacia Biotech, Uppsala, Sweden) were 
added and left at room temperature for 40 minutes. The supernatant was carefully 
removed and centrifuged at 200g for 10 minutes. The red cells were lysed by adding 
2ml 10% HBSS in distilled water for 20 seconds, following which excess HBSS 
(minimum 12 ml) was added and the contents of the tube mixed and centrifuged at 
180or pm for 5 minutes. The cells were washed twice in HBSS (Ca and Mg free) 
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containing 15% fetal calf serum. Cells were counted with Kimura stain on a 
haemocytometer and resuspended at IX 106 /ml, and viability checked using trypan 
blue. 
2.2.3 Use offlow cytometryfor measurement of neutrophil activation 
Several aspects of neutrophil activation can be evaluated by flow cytometry 
including phagocytosis, respiratory burst (superoxide anion generation, intracellular 
H202 production), intracellular pH, actin polymerisation, degranulation and surface 
marker expression. Flow cytometry also has the advantage in that it allows the 
identification of neutrophils from anticoagulated blood, without any isolation procedure. 
Some neutrophil functions, such as phagocytosis, respiratory burst, and surface marker 
expression can be studied using whole blood, whilst other aspects of neutrophil 
physiology such as actin polymerization and cytotoxicity require the use of purified 
neutrophils (173). 
For operation of a flow cytometer, cells must be kept in suspension so that they 
can flow in single file and this is accomplished by injecting the sample into a sheath 
fluid as it passes through a small (50-300ýtm) orifice. The cells then pass through a light 
source focused on the same point where cells have been focused and the amount of light 
scattered in the forward direction (along the same axis that the laser light is travelling) is 
detected in the forward scatter channel. The intensity of the forward scatter is 
proportional to the size, shape and optical homogeneity of the cells (or other particles). 
The amount of light scattered to the side (perpendicular to the axis that the laser light is 
travelling) is detected in the side or 90' scatter channel. The intensity of side scatter is 
proportional to the size, shape and optical homogeneity of the cells (or other particles). 
Forward scatter tends to be more sensitive to surface properties of particles (eg. cell 
ruffling) than side scatter, and can be used to distinguish live from dead cells. Side 
scatter tends to be more sensitive to inclusions within cells than forward scatter and can 
be used to distinguish granulated from non granulated cells. 
The fluorescence emitted by each flurochrome is usually detected in a unique 
fluorescence channel. The specificity of detection is controlled by the wavelength 
selectivity of optical filters and mirrors. Optical filters are constructed from materials 
that absorb certain wavelengths while transmitting others. Long pass filters transmit 
wavelengths above a certain wavelength, whilst short pass filters transmit wavelengths 
below a cut off wavelength. To measure more than one scatter or fluorescence from 
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each cell, multiple channel/detectors are used. The fluoresence is collected, filtered and 
electronics converted to digital values that are stored on a computer for analysis (fig 
2.1). 
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Fig. 2.1 A schematic of the primary components that comprise a flow cytometer. Dark 
arrows indicate the flow of particles and information. A fluidic system transports particles 
or cells from a prepared suspension past a focused laser beam that is generated by an 
illuminated system. Particle interrogation takes place, one cell at a time, in a flow 
chamber. The resulting scattered light and fluorescence is gathered by an optical and 
electronics system that translates the light signals into information that is saved by the 
data storage and comport system. After data has been stored, retrospective graphical data 
analysis can be performed with the aid of software. 
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2.2.3.1 Use of whole bloodfor neutrophil activation studies andflow cytometry 
The use of whole blood methods to measure neutrophil function has been shown 
to be very specific and sensitive and avoids the artificial changes resulting from 
collection and isolation procedures. For example, the functional behaviour of 
neutrophils as well as the number and the affinity of their surface receptors can be 
affected by the type of anticoagulant used to collect the blood. Repo et al (174) showed 
that calcium chelating agents such as EDTA should be avoided when using monoclonal 
antibodies whose binding are cation dependent or when measuring functions that are 
calcium dependent. 
Artificial upregulation of sensitive adhesion receptors such as CD IIb ex-vivo 
can be minimized by cooling blood samples on ice. However, whether cells are kept at 
room temperature or cooled, further procedures such as cell labelling and fixation 
should be completed at the same temperaure as fluctuations in temperature have a 
significant effect on the expression of receptors such as CD IIb and CD62L (174). 
Haslett et al (175) pointed out the importance of ensuring that reagents were pyrogen 
free and of tissue culture grade and the importance of avoiding endotoxin contamination 
of reagents or buffers as bacterial components can lead to artificial upregulation of 
certain activation markers. Certain procedures such as density centrifugation (176) and 
hypotonic lysis of red cells (177) can artificially increase expression of certain adhesion 
molecules. If purified neutrophils are used, then the interpretation of sensitive surface 
markers such as CD IIb should be reserved (176). 
2.2.3.2 FACS analysis 
Flow cytometry was performed using a FACScan analyser (Becton Dickinson, 
Oxford, UK) with Argon-ion laser. Fluorescence gain was adjusted using a gate drawn 
around the granulocyte population on an unstained lysed whole blood sample, and then 
placing this population in the first log decade. Compensation was set by using blood 
incubated with either fluorescein isothiocyanate (FITC) or phycoerythrin (PE) 
monoclonal antibodies in order to correct for spectral overlap. As an instrumental 
control measure, CaliBRITE beads (Becton Dickinson, Oxford, UK) were used to 
ensure the correct alignirnent and calibration of the 
flow cytometer. Ten thousand events 
were collected from each sample. 
Granulocytes were discriminated from other cell 
populations in lysed whole 
blood by their characteristic high side scatter and forward 
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light scatter characteristics. A gate was drawn around the granulocytes (RI or region 1) 
and this population was reflected into a dot plot of side-scatter and CD16. Two 
populations are then produced. Neutrophils are CD16 positive cells whilst cell sorting 
studies (176) have shown that CD16 negative cells with high side scatter properties 
represent eosinoPhils. A further gate can then be drawn around the neutrophil (CD 16+) 
or eosinophils (CD16-) populations and reflected into a histogram so that cells labelled 
with a further fluorochrome (eg. CD IIb or CD 18) are produced (fig. 2.2). Results were 
recorded as mean fluorescence intensity (MFI) which represents the receptor density on 
the cell surface. 
2.2.3.3 Discrimination of cell populations in lysed whole blood usingflow cytometry 
A typical dot plot pattern of lysed whole blood showing three main cell 
populations can be seen (fig 2.3). Lymphocytes are small and relatively agranular, and 
therefore display low forward and side scatter. Granulocytes have a high forward scatter 
corresponding to increased cell size and high side scatter corresponding to increased 
granularity and therefore appear in the upper right hand of the dot plot. Monocytes have 
intermediate scattering properties. As previously mentioned, a gate can be drawn around 
the granulocyte population (RI or region 1) and this population can be reflected into a 
dot plot of side scatter and CD16. CD16 is also known as the FcyIll receptor and is 
found on neutrophils, and is involved in phagocytosis, antibody dependent cell mediated 
cytotoxicity (ADCC), and cytokine production. CD16 is expressed initially at the 
metamyelocyte stage and is almost uniformly expressed on neutrophil band forms and 
segmented neutrophils. Two populations are then produced. Neutrophils are CD16 
positive cells whilst cell sorting studies done by Gopinath et al (178) have shown that 
CD16 negative cells with a high side scatter represent eosinophils. A further gate can 
then be drawn around the neutrophil (CD16+) or eosinophils (CD16-) populations and 
reflected into a histogram so that cells labelled with a further fluorochrome (eg. CD IIb 
or CD18) are produced. The appropriate isotype control is also shown and this is a 
marker of background staining. Eosinophils, in contrast, are for the most part CD16 
negative, although they can express a low level of this marker if stimulated in vitro by 
IFNy. 
72 
R3 
CD - 
0 
1023 
Forward Scafter 
Dot plot of lysed whole blood showing different cell populations based on forward and side scatter 
properties. RI -gated cells represent granulocytes, R2 cells are monocytes, and R3 cells are lymphocytes. 
16pe 
CD16 positive cells are neutrophils (gated), whilst CID negative cells with high side scatter represent 
eosinophils. 
CC) I 
isotype control 
ce) 
C'4 
CD 
C. ) 
C, ) 
l) 
V 
C, ) 
i'O -10 4. 
kdl 6+/cdl lb+ 
LU 
CD 
ioll, i'o: 
" .o 
11 bfftc 
CD 16 postive cells are then reflected into a histogram so that cells labelled with another flourochrome, 
eg. CD IIb can be studied. 
Fig. 2.2 Discrimination of cell populations using flow cytometry. 
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2.2.3.4 Direct immunofluorescence stainingforflow cytometry 
Venous blood was drawn into a heparinised syringe and processed within 2 
hours. Ten microlitres (ýtl) of conjugated antibody (FITC or PE labelled) were added to 
100ýtl of whole blood and incubated at 40C for 30 minutes in the dark. The appropriate 
isotype-matched control samples were included to detect any background staining. After 
the incubation period, the cells were washed by adding 2mls PBS, (Gibco, Invitrogen, 
UK) containing 0.5% bovine serum albumin (Sigma Aldridge, Poole, UK) and 0.5% 
sodium azide (Sigma Aldridge, Poole, UK), (PBA-BA) and centrifuged for 5 minutes at 
400g. The supernatant was discarded and 2mls of freshly prepared Erythrolyse (Serotec 
Ltd, Oxford, UK) added and followed by incubation for 10 minutes at room 
temperature. After further centrifugation the supernatant was discarded. Cells were then 
washed with 2ml PBS-BA and centrifuged as above. The supernatant was discarded and 
the cells were resuspended in 0.5mls of 0.5% paraformaldehyde (PFA, Sigma Chemical 
Co, Poole, UK) prior to analysis by flow cytometry. Duplicate samples prepared and 
analysed. 
2.2.3.5 Indirect immunofluorescence stainingforflow cytometry 
Heparinized whole blood (100ýd) or PBMC at a concentration of 1XI06 were 
added to round bottom glass tubes (Marathon Ltd, UK) and the appropriate volume of 
primary antibody added at the recommended dilution. The cells were mixed and 
incubated at VC for 30 minutes in the dark. The cells were washed by adding 2 mls of 
PBS-BA, followed by centrifugation at 400g for 5 minutes. The supernatant was 
discarded and the appropriate volume of secondary conjugated antibody was added at 
the recommended dilution, and incubated as above. If using PBMC, the cells were 
washed with PBS-BA, centrifuged, the supernatant discarded and the cells resuspended 
with 0.5% PFA prior to aquiring data by flow cytometry. If using whole blood, red 
blood cells were lysed by adding 2 mls of freshly prepared Erythrolyse, mixing well and 
incubating for 10 minutes at room temperature. The tubes were then centrifuged and the 
supernatant discarded, followed by washing and further centrifugation as described 
above. Finally cells were resuspended in 0.5% PFA prior to flow cytometry. Duplicate 
samples were prepared and analysed. 
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2.2.3.6 Indirect immunofluorescence staining for measurement of Fc. 6R] receptors 
on basophils 
30mls of venous blood were venesected into a heparinised syringe and diluted in 
an equal volume of RPMI 1640 (Gibco, Invitrogen UK) in a conical tube. The diluted 
blood was then carefully layered onto Ficoll Paque medium (Amersham Biosciences, 
Uppsala, Sweden). The blood was then centrifuged at 2000 revolutions per minute 
(rpm) for 20 minutes at 20'C, following which, the PBMC layer was carefully drawn 
off with a pipette and transferred to another conical tube. Phosphate buffered saline 
(Gibco, Invitrogen, UK) was added and the PBMC fraction was washed and centrifuged 
again for 5 minutes as above. Any remaining red blood cells were removed by adding 5 
mls of distilled water to the cell pellet and slowly resuspending the cell pellet several 
times. After a further wash with PBS, the cell concentration was adjusted to IX105 to 
IX106 with PBS. The cells were then stained with 10[d rabbit anti-human FccRI 
antibody (Upstate biotechnology, Lake Placid, USA) for 30 minutes in the dark at 4'C. 
After washing with PBS, the cells were stained with FITC conjugated swine anti-rabbit 
secondary antibody (I in 40 dilution, Dako, Denmark) again for 30 minutes at 4'C in 
the dark. The cells were washed in PBS and then stained with 10ýtl CD123 PE 
(Pharmingen International, Europe) and HLA-DR RPE-Cy5 (Serotec Ltd, Oxford, UK) 
conjugated monoclonal antibodies for 30 minutes at 4'C in the dark. Appropriate 
isotype controls were purchased from the companies mentioned above. After this final 
incubation, the cells were washed and resuspended in 0.5ml 0.5% PFA (Sigma 
Chemical Co, Poole, UK) prior to analysis by flow cytometry. Duplicate samples were 
prepared and analysed. 
2.2.3.7 Monocytes and FcaRl receptor expression 
PBMCs were isolated from venesected venous blood as outlined in section 2.2.1. 
Indirect staining for Fcf; R1 subunit was performed as described in section 2.2.3.6. After 
washing and centrifugation, the cells were resuspended in PBS (Gibco, Invitrogen, UK) 
working solution and incubated with mouse anti-human CD14 PE monoclonal antibody 
along with appropriate isotype controls (Serotec Ltd, Oxford, UK) 
for 30 minutes at 4'C 
in the dark in order to identify monocytes in the PBMC population. After further 
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washing, the cells were resuspended in 0.5ml of 0.5% PFA (Sigma Chemical Co, Poole, 
UK) before analysis by flow cytometry. 
2.2.3.8L ed whole blood cell surface marker analysis- rhuMab E25study IYS 
I 00ýd of whole blood were added to round bottom tubes (BD Falcon, Oxon, 
UK) following which 10ýd FITC or PE conjugated mouse anti-human monoclonal 
antibodies were added and the cells incubated for 30 minutes at VC in the dark. FITC 
conjugated CD95, CD23, and PE conjugated CD9, CD14 and CD4 along with the 
appropriate isotype controls were purchased from Serotec Ltd, Oxford, UK. FITC 
conjugated rat anti-human CCR3 and appropriate isotype control was purchased from 
R&D systems Europe, Oxon, UK. Aft, er incubation, the red blood cells were lysed by 
adding 2 mls Erythrolyse (Serotec Ltd, Oxford, UK) for 10 minutes at room 
temperature. After further centrifugation, the supernatant was discarded, and cells 
washed with 2ml PBS and centrifuged again. Cells were then resuspended in 0.5 mls of 
0.5% PFA (Sigma Chemical Co, Poole, UK) before analysis by flow cytometry. 
2.2.4 Enzyme-linked immunosorbent assay (ELISA) measurements 
IL-8 (duoset, R&D systems, Oxon, UK), MPO (Calbiochem, San Diego, USA), 
IL-5 (duoset R&D systems, Oxon, UK) concentrations were measured in the culture 
supernatants with specific immunoassay kits according to the manufacturer's 
instructions. The detection limit was 31.2pg/ml for IL8,1.6ng/ml for MPO, and 
15.6pg/ml for IL-5. Samples were prepared and analysed in duplicate. 
2.2.5 Stimulation of whole blood 
Prior to incubation with conjugated monoclonal antibodies, blood was 
incubated with fN4LP, (Sigma Aldridge, Poole, UK) dissolved in dimethyl sulfoxide 
(Sigma Aldridge, Poole, UK) at a concentration of 10-7M, or PAF at a concentration 
of 10-6M (Sigma Aldridge, Poole, UK) dissolved in PBS (Gibco, Invitrogen, UK) for 
10 mins at 370C. The reaction was stopped by adding cold PBS solution. The tubes 
were then centrifuged for 5 minutes at 1800rpm and the supernatant discarded. The 
blood was then incubated with monoclonal antibodies as previously described. 
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2.2.6 Incubation of whole blood or isolated granulocytes with dexamethasone 
100ýd whole blood or IX106 isolated granulocytes were preincubated at 37'C, 
5% C02 with 10ýtl dexamethasone at concentrations ranging from 10-12 to 10-6 for up to 
24 hours. After each incubation period, the blood was stimulated with fN4LP at a final 
concentration of 10-7 M at 3 7'C for a further 10 minutes. The reaction was stopped with 
cold PBS, following which the supernatant was decanted, washed and centrifuged and 
finally resuspended in 100ýd PBS working solution. Staining was then carried using a 
direct method as outlined previously. 
2.2.7 Oxidative hurst 
The most widely used standard methods to assess the oxidative burst in 
neutrophils measure the extracellular release of 02- or H202by their ability to reduce or 
oxidise substrates to coloured or fluorescent products (179). The major disadvantages 
of these assay methods are that cells must be separated from red cells and plasma and 
that relatively large numbers of neutrophils are needed. In these assays, the measured 
response is of a population and individual response cannot be assessed. 
In 1983, Bass et al (180) developed a method to measure 'oxidant product 
formation' by flow cytometry using 27-dichlorofluorescein (DCF). In this method, 
neutrophils are incubated with the diacetate form of 27-dichlorofluorescein (DCFH), 
which is transported across the plasma membrane into the cytoplasm where the acetate 
groups are removed by esterases concentrating the polar non-fluorescent DCFH in the 
cytoplasm. During the oxidative burst, DCFH is converted to DCF through mainly by 
H202. Dihydrorhodamine 123 (DHR123) is used in a similar way, resulting in red 
fluorescence (181,182). DHR 123 is the uncharged and nonfluorescent reduction 
product of the mitochondrion selective dye rhodamine 123. This leuco dye passively 
diffuses across most cell membranes and is oxidized to cationic rhodamine 123, which 
localises in mitochondria. Strong non-physiological stimuli such as PMA and calcium 
ionophores cause a sustained respiratory burst resulting in a high fluorescence that can 
be detected by flow cytometry. DHR 123 has been reported to be more sensitive than 
DCFH for detecting granulocyte respiratory burst activity (183). The use of flow 
cytometry to measure the products of the oxidative burst offers an easy semi- 
quantitative technique that is applicable to a few thousand unpurified cells, and can be 
performed in mixed cell samples including whole blood where neutrophil responses can 
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be determined using gating techniques. The small number of unpurified cells necessary 
for the flow cytometry assay allows studies on small sample volumes such as neonatal 
blood. 
Studies of granulocyte oxidative burst in asthmatics have shown that eosinophils 
from atopic asthmatics stimulated with PMA and fMLP showed increased free radical 
production versus normal patients (184). No significant difference was seen in 
neutrophil chemiluminescence activated by PMA and fMLP between asthmatics and 
normal patients. Teramoto et al however (185), showed that PMA and zymosan 
stimulated blood in asthma and/or COPD showed increased 0 2- generation versus 
normals controls, but increased resting neutrophil 0 2- production in asthmatic patients 
only. 
In animal experiments, Carey et al (186) showed that neutrophils are primed as 
shown by the 2.7 times increase in 0 2- production above baseline from neutrophils 
isolated from sheep given a low dose endotoxin infusion compared to control animals. 
The effect of glucocorticoids on oxidative burst in bovine granulocytes was investigated 
by Hoeben et al (187) who showed that prednisolone resulted in inhibition of 
respiratory burst at therapeutic doses, but no effect was seen on neutrophil 
myeloperoxidase activity. In normal subjects, i. v. hydrocortisone decreases reactive 
oxygen species production by neutrophils and monocytes as measured by 
chemiluminometry (188). Bekesi et al showed that human neutrophils incubated with 
various steroids such as oestradiol, progesterone, testosterone and hydrocortisone, 
showed decreased 02- production, but this effect was not seen with the mineralocorticoid 
aldosterone (189). In a negative study of the effect of corticosteroids, Toft et al showed 
that pretreatment of patients undergoing cardiopulmonary bypass surgery with 
methylprednisolone had no effect on oxidative burst as measured with DHR123 versus 
control patients (190). 
2.2.7.1 Oxidative burst measurement 
Respiratory burst was measured according to the method of Rothe and Valet 
(191). 3ml of heparinised blood were layered onto 3ml of Ficoll Hypaque medium 
(Amersham Biosciences, UK) and left at room temperature for 45 minutes. 800ýtl of the 
supernatant was then removed and transferred to an 
Eppendorf tube and stored on ice. 
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I ml of HBSS, (Sigma Aldridge, Irvine, UK) was added to 20ýLl of cell suspension and 
10ýtl of DHR123, IxIO-'M, (Molecular Probes, Upsaala, Sweden), and the cells 
incubated for 5 minutes at 37'C. Following this, PMA, (Sigma Aldridge, Poole, UK) 
was added to a final concentration of I [tM and the samples incubated for 20 minutes at 
37'C. Reagent blank tubes were prepared by adding only PBS to the cell suspension, 
while resting cells were initially incubated with PBS, followed by the addition of 
DHR123. 
After the final incubation, 25041 of the sample was analysed immediately on the 
FACS scanner. The FACS machine was set up so that unstimulated cells were placed in 
the first log decade. DHR 123 reacts with H202as a result of the respiratory burst to give 
rhodamine, which emits a green fluorescence which can be measured on the FLI 
channel of the FACS machine (wavelength 530 nm). Samples were prepared and 
analysed in duplicate. 
2.2.8 Neutrophil elastase measurement 
Neutrophil elastase was also measured according to the method described by 
Rothe and Valet (192). 3 mls of heparinised blood was layered on top of 3 ml Ficoll 
Hypaque medium (Amersham Biosciences, UK), and the erythrocytes allowed to 
sediment for 40 minutes at room temperature. The plasma supernatant (800ýtl) was 
withdrawn and stored on ice. One ml of HBSS supplemented with 10mM HEPES 
(Sigma Aldridge, Poole, UK) was added, along with 20ýtl cell suspension, and I ýtl (N- 
benzyloxycarbonyl-Ala-Ala)2-rhodamine 110 (Molecular probes, Upsaala, Sweden) at a 
final concentration of 4ýtM. The samples were incubated at 37'C and analysed on the 
flow cytometer after 20 minutes. 
2.2.9 Whole blood culturefor serum cytokine measurement 
Much of the work carried out using Elisa quantitation of cytokines has been 
carried out on supernatants from isolated cell culture systems. The whole blood culture 
method is thought to be more representative of an in-vivo environment than other 
methods which involve isolated cell populations and may give better elucidation of the 
actual events occuring in-vivo, as the natural cell to cell interactions are preserved and 
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circulating stimulatory and inhibitory mediators are also present in their normal 
concentrations. This method does not, however, allow determination of which cell type 
is involved in cytokine production. With undiluted whole blood only early produced 
cytokines can be studied due to the poor stability of long term undiluted whole blood 
(193,179). Samples were prepared and analysed in duplicate. 
2.2.9.1 Whole blood culture-methodology 
Venous blood was collected in heparinized tubes and diluted 1: 10 with RPMI 
1640 (Gibco, Invitrogen, UK) containing 10% fetal calf serum (FCS), 100u/ml 
penicillin, 100mcg/ml streptomycin and 2mM L-glutamine. The blood was distributed 
in 1 ml wells and the plates were incubated at 37'C with 5%CO2 for 24hours. In 
addition, in duplicate wells, diluted blood was stimulated with IL-lP (10ng/ml final 
concentration), LPS (IOng/ml), and GMCSF (Ing/ml) prior to incubation. The plates 
were then centrifuged at 1800 rpm for 5minutes, following which the supernatants were 
removed and frozen at minus 70'C until analysed. Samples were prepared and analysed 
in duplicate. 
2.2.10 Neutrophil Myeloperoxidase measurement 
Granulocytes were isolated as described in section 2.2.2. One million granuloc- 
ytes per ml were then added to I ml wells of a 48 well plate and incubated with IL- 1P 
(IOng/ml), or PBS for 0, and 30 minutes and incubated at 37'C and 5%CO2. After each 
time point, the plates were centrifuged at 1800rpm for 5 minutes following which the 
supernatant was withdrawn and stored at -70'C until analysed by ELISA. Samples were 
prepared and analysed in duplicate. 
2.2.11 Fiberoptic bronchoscopy, BAL collection andprocessing of BAL macrophages. 
Bronchoscopies were performed by Dr. B. Cosio. Volunteer subjects attended 
the bronchoscopy suite at 8.30 a. m. after having fasted overnight. They were sedated 
with midazolam (5-7.5 mg i. v. ) and alfentanyl (0.5 mg i-v. ). Local anaesthesia was 
provided by linocaine gel to each nostril, and lidocaine 2% to the upper airways and 
larynx. After passing the fiberoptic bronchoscope (Olympus BF30 Key-Med, Southall, 
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UK) through the nasal passages into the trachea, warmed saline (4 x 60 ml) was instilled 
and aspirated from the right middle lobe. BAL cells were spun down (5 OOg for 10 min) 
and washed twice with HBSS. Cytospins were prepared and stained with May- 
Grunwald stain for differential cell count. Cell viability was assessed by using the 
trypan-blue exclusion method. 
2.2.12 Measurement ofHDAC activity. 
HDAC activity of nuclear extracts was measured with a non-isotopic assay using 
a fluorescent derivative of epsilon-acetyl lysine (HDAC fluorescent Activity Assay Kit, 
BIOMOL, Plymouth, PA, USA) by Dr B. Cosio. This assay was based on the Fluor de 
Lys TM (Fluorogenic Histone deAcetylase Lysyl Substrate/Developer) Substrate and 
Developer combination. The assay was performed as recommended by the manufacturer 
and emitted light detected at 460nm in a fluorometric plate reader. Activity was 
measured in AFU (arbitrary fluorescence units). 
2.3 Statistical methods 
Unless otherwise stated, data are expressed as mean ± standard error of the mean 
(SEM). Differences in surface marker expression between two groups were analysed 
using the Unpaired-t test. Differences in surface marker expression between more than 
two groups were evaluated using one way analysis of variance (ANOVA). Where there 
was one independent treatment variable, one way ANOVA with Bonferroni post testing 
was carried out to take into account the effect of multiple comparison. If there were 2 
independent treatment variables, 2 way ANOVA with Boferroni correction was carried 
out. The effect of a treatment within a single group was analysed using a Paired-t test. 
Where a PBO group was included in the study design, any positive results were 
compared with the PBO group. Ap value of 0.05 or less was considered to be 
statistically significant. 
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Chapter 3 
Peripheral blood neutrophil activation in mild, moderate and severe asthmatics 
and the effect of corticosteroids on neutrophil function in mild and severe 
asthmatics 
3.1 Introduction 
Techniques such as flow cytometry allow investigation of the state of activation 
of peripheral blood cells by looking at the expression of specific surface activation 
markers. This allows comparison of neutrophil activation in peripheral blood samples 
between severe asthmatics and milder asthmatics, and avoids the need to do more 
invasive procedures which have potential complications such as bronchoscopy and 
biopsies. The use of blood samples also allows the effect of any treatment to be assessed 
(in this case, oral prednisolone), without having to repeat investigations such as 
bronchoscopy. Recruitment for studies using more invasive investigations can be 
particularly difficult, especially in the more severe group of patients. 
Although the effect of corticosteroids on neutrophil function has been 
investigated, there is no data on the effect of a standard course of prednisolone on 
neutrophil activation markers in asthmatics, which more closely resembles the situation 
when dealing with asthmatics in a clinical setting. The findings of other workers that 
neutrophils are important mediator cells in severe asthmatics, and that corticosteroids 
may prolong survival of neutrophils by inhibiting their apoptosis, would allow these 
cells to potentially cause more tissue damage and airway remodelling through the 
release of their chemical mediators. This suggests that corticosteroids may in fact be 
causing more harm in certain asthmatics and lends weight to the argument that 
alternative therapies are needed, rather than persisting with a form of treatment which 
can be potentially harmfal and which is associated with significant long term side 
effects. 
Use of a whole blood system enables the usual interaction between various 
cellular components, cytokines and specific messengers in the inflammatory cascade to 
proceed as far as possible as in the real life situation, whereas this vital interaction may 
be lost in situations where cells are isolated from whole blood. 
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3.2 Methods and materials 
3.2.1 Study design 
Subjects attended the laboratory on two occasions. During the screening visit a 
standard questionnaire was completed and clinical examination was performed, 
followed by skin prick testing, spirometry, methacholine challenge test, or reversibility 
testing as described in section 2.1 in order to assess asthma severity and inclusion and 
exlusion criteria. Atopic status was defined as having a positive skin prick test to at least 
one of four common aeroallergens (grass pollen, cat dander, Dermatophagoides 
pteronyssinus, and Aspergillus furnigatus and skin prick testing was performed as 
outlined in section 2.1.3. Sputum induction was performed and blood was taken for 
investigation of surface activation marker expression, oxidative burst and neutrophil 
elastase measurement using FACS analysis, and cytokine and mediator release 
measurements using ELISA, as described in section 2.2 on laboratory methods. 
To investigate the effect of corticosteroid therapy, mild asthmatics were given 
30mg of prednisolone for I week, whilst corticosteroid-dependent asthmatics took an 
extra 30 mg of prednisolone for I week on top of their usual maintenance prednisolone 
dose. Patients were asked to return after I week for repeat spirometry and to provide 
blood and sputum samples. Blood was also taken for prednisolone and cortisol 
measurements to ensure compliance with prednisolone treatment. Patients with the 
following conditions were not given prednisolone: diabetes, hypertension, high risk of 
osteoporosis, and active peptic ulceration. Compliance with asthma medication was 
reinforced and inhaler technique was checked at all clinic visits by asthma nurses. 
3.2.2 Flow cytometry 
Direct flow cytometry was performed on whole blood as described in section 
2.2.3.4. FITC-conjugated monoclonal antibodies against CD11b, CD62L, CD35 and 
CD18, along with the appropriate isotype controls were purchased from Serotec Ltd, 
Oxford, UK. PE-conjugated CD16 monoclonal antibody was purchased from Becton 
Dickinson, Oxford, UK. 
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3.3 Results 
3.3.1 Patient characteristics 
In order to study the baseline expression of neutrophil activation in asthmatic 
patients, 10 patients with mild asthma, 10 patients with moderate asthma, 10 severe 
corticosteroid-dependent asthmatics, and 10 healthy normal subjects were included in 
the initial part of the study. The characteristics of normal and asthmatic subjects are 
shown in table 3.1, and the individual characteristics of mild and severe asthmatics 
taking oral prednisolone are shown in table 3.2 and table 3.3 respectively. 
Characteristics of the moderate patients are shown in appendix 5.1 (page 262). 
Mild asthmatics had symptoms less than once weekly, requiring only a short 
acting inhaled P2-agonist as needed; moderate asthmatics had asthma symptoms 
requiring daily use of ICS (BDP 1000-2000ýtg/day or equivalent), but not requiring 
chronic oral prednisolone therapy; severe steroid-dependent asthmatics had persistent 
symptoms with frequent exacerbations, limited physical activity and frequent night-time 
symptoms requiring high dose ICS (BDP 2000ýtg/day or equivalent), with maintenance 
oral prednisolone (> 5mg per day for at least one year). The mean maintenance dose of 
oral prednisolone was l4mg/day (range 10-20mg/day). 
3.3.2 Pilot study 
Initial experiments involving the stimulation of lysed whole blood with fMLP 
were carried out to look at effect of fMLP on surface marker expression on neutrophils 
and eosinophils. These consistently showed that CD 11 b expression on neutrophils was 
significantly upregulated. with a concentration of fMLP of between 10-8 M and 10-5 M, 
and in addition, CD62L was significantly down regulated in a dose dependent manner at 
doses of fMLP of 10-7 M and 10-5 M. This characteristic pattern of change in CD IIb 
and CD62L surface marker expression was demonstrated initially in 10 subjects who 
included normal volunteers and asthmatics of varying severity. CD63 was not 
significantly changed in neutrophils or eosinophils following stimulation with fMLP, 
and therefore this marker was not used for later studies. This marker was replaced by 
CD 18 and CD3 5, which showed similar up regulation to CD IIb following stimulation 
with fMLP. The dose of fMLP chosen for future studies was 10-7M (fig 3.1), following 
a time course study done on 3 normal subjects. The effect of PAF on peripheral blood 
neutrophils in whole blood produced similar results to fMLP, again in a dose dependent 
manner. However the effect of PAF on CD62L was less marked than with fMLP (fig 
3.2). In contrast to the effect on neutrophils, fMLP did not cause a significant increase 
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in CD IIb or reduction in CD62L on eosinophils (fig. 3-3). Time course studies on 3 
normal subjects showed that fMLP caused upregulation of CD IIb and downregulation 
of CD62L within two minutes of stimulation, with submaximal changes occurring at 
approximately 10 minutes (fig. 3.4). After these initial experiments, the aim was to see 
if there was any difference in surface marker expression between normal subjects and 
asthmatics of different severities. 
Table 3.1 Clinical characteristics of asthmatic patients and non asthma controls 
Variable 
Mild asthma 
N=10 
Moderate asthma 
N=10 
Severe asthma 
N=10 
Non asthma 
control. n= 10. 
Sex 2M/8F 4M/6F 4M/6F 7M/3F 
Age (years) 33.4+/-3.2 47.7+/-4.0 51.3+/-2.7 36.0+/-0.7 
Mean FEV I (L) 95.8+/-3.3 66.7+/-5.0 51.4+/-3.7 95.5+/-1.8 
Inhaled corticosteroid: 
[ig/day BDP (or 
equivalent) 
I patient on 400 
gg/day only 
1500+1- 166.7 All patients taking 
2000 ýtg/clay 
0 
Atopy 7Y/3N loy 5Y/5N 0 
NO (ppb) 27.1+/-8.9 18.7+/-3.4 30.9+/-6.0 ND 
M: male; F: female: NO: nitric oxide; ND: not determined 
Patients were non-smokers or had a total smoking history of less than 10 pack years and 
had not smoked for at least one year. 
Results expressed as mean +/- SEM. 
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Table 3.2 ', haracteristics of mild patients taking oral prednisolone (30mg/day) for I week. All patients 
took s only, except [gjI, who took BDP 400 mcg/day as maintenance therapy. 
patient Age- Neutrophil count Eosinophil count FEV P (% predicted) Prednisolone Cortisol NO (ppb) 
years (x I 0"/I) (X 109/1) (nmol/1) (nmol/1) 
SS 49 2.5 0.3 1.8(98%) 116 52 7. 
45 3.2 0.1 1.65 (95%) 1057 <20 14 
Sm 
22 1.8 0.2 4.64(104%) 1540 <20 39.7 
mm 
45 5.6 0.2 2.95(77%) 961 34 13 
ap 
24 3.9 0.1 2.56(88%) 2143 124 53.4 
bp 
36 4.7 0.7 4.04(106%) 914 37 19.2 
st 
36 3.2 0.4 4.26(92%) 823 53 8.9 
jh 
25 6.2 0.2 3.53 (100%) N/A N/A 22.7 
gm 
23 5.4 0.3 3.17 (111.9%) 749 <20 7.6 
Im 
29 5.1 0.1 2.78(91%) 1582 <20 6.2 
Table 3.3 Characteristics of severe patients taking oral prednisolone (30mg/day) for I week. All patients 
took salbutamol and atrovent MDI/nebs. 
patient Age- Neutrophil Eosinophil FEV (L) Treatment Prednisol Cortisol NO (ppb) 
years Count Count (% -one (nmol/1) (X 109/1) (X 109/1) predicted) (nmol/1) 
ah 60 6.5 1.21 1.62 (70.7%) BDP 20OOgg/day <20 <20 53.5 
Formoterol 12 [tg bd 
PNL 20mg/day 
50 13.7 0.3 1.24 (48.4%) BDP 2000 [tg /day 1555 <20 27.1 
ir PNL 15mg/day 
52 9.7 0.6 1.5 (49.8%) Seretide 500 ýtg bd 580 <20 65.2 
Mg PNL II mg/day 
49 15.5 0.2 1.65(64%) Seretide 500 ýtg bd 1381 47 33.4 
jM Theophylline 225mg 
bd; PNL 20mg/day 
49 14.4 0.4 1.52(42%) Seretide 500 ýtg bd 983 <20 20.1 
MnIm PNL 5mg/day 
51 5.2 1.2 0.95(30%) BDP 2000 ýtg /day 798 35 30.9 
rs Formoterol 12 ptg bd 
PNL 5mg/day 
53 7.1 2.1 1.76(56%) BDP 2000 ýtg /day 408 <20 13.2 
Is Formoterol 12 ýtg bd 
PN-L I Omg/day 
Aminophylline 225mg 
53 8.9 0.1 0.96 (41.7%) Seretide 500 ýtg bd 701 <20 ND 
jr PNL 5mg/day 
65 12.9 0.2 1.7(61%) BDP 2000 ýtg /day 1207 <20 53.5 
vb Formoterol 12 [tg bd 
PNL 5mg/day 
tj 31 13.2 1.4 1.4(51%) Seretide, 500 ýtg bd N/A 27 .I ; PNL 20mg/day 
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Fig. 3.1 Dose response of surface molecules CD11b, CD62L, and CD63 on peripheral blood 
neutrophils in lysed whole blood to fMLP, (10-5_ 10-9M). DMSO- diluent for fMLP. 
control =isotype control. mfi = mean fluorescence intensity. fMLP upregulated CD11b 
expression and reduced CD62L expression on neutrophils in lysed whole blood. There was 
no effect on CD63 expression. (* p <0.01 compared to markers in unstimulated whole 
blood. ) n=3, normal subjects. 
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Fig. 3.2 Dose response of CD11b and CD62L to PAF (10-4-10-9M) on neutrophils in lysed 
whole blood. For CD11b, expression is increased with PAIT (10-'M) compared to 
unstimulated sample (control, *p<0.05). For CD62L, expression is reduced with PAF 
(104M) compared to PAF 
(10-69 10-7 , 10-8M), (*p<0.05). n=3, normal subjects. 
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3.3.3 Surface molecule expression on unstimulated lysed whole blood 
Study of the baseline expression of activation molecules in unstimulated whole 
blood from normal subjects and in asthmatics showed that there was increased 
expression of CD3 5 and CD I lb on neutrophils in patients with severe corticosteroid - 
dependent asthma compared to normal subjects (p<0.05), but not compared to mild and 
moderate asthmatics. There was no difference in the expression of CD62L or CD18, 
(fig 3.5). 
3.3.4 Surface molecule expression on stimulated lysed whole blood 
Stimulation of neutrophils in lysed whole blood by fMLP resulted in a 
significant increase in CD IIb, CD3 5, and CD 18 surface molecules on neutrophils in 
normal subjects and all patient groups as well as a significant decrease in CD62L (fig 
3.6). Stimulation of peripheral blood neutrophils with PAF also resulted in significant 
upregulation of CD IIb, CD 18, and CD3 5 in all groups, with downregulation of CD62L 
only in normal subjects, and not in asthmatics (fig 3.7). In eosinophils, there was no 
difference in the expression of surface molecules on unstimulated eosinophils in lysed 
whole blood between the patient groups or normal subjects. CD IIb and CD62L levels 
were increased on eosinophils after stimulation with fMLP in normal subjects (CD1 lb 
only), and in mild and moderate asthmatics (CD IIb and CD62L), but not in severe 
asthmatics (figs 3.8 and 3.9). 
3.3.5 Effect of prednisolone on surface molecule expression on neutrophils in mild 
and severe asthmatics 
Prednisolone at a dose of 30 mg for one week had no effect on the baseline level 
of expression of CD11b, CD62L, CD35 or CD18 in severe patients, but in mild 
asthmatics there was a significant reduction in the level of CD62L expression (p< 0.05), 
(fig. 3.10). In contrast, there was significant reduction in the expression of surface 
molecules CD IIb and CD62L on eosinophils in both mild and severe patients (fig. 
3.11), and reduction in CD18 levels in mild asthmatics, with no effect on CD35 
expression in either group. The mean prednisolone level in mild patients was 1098+/- 
195 nmol/l, compared with 848.1+/- 162.7 nmol/1 in the severe group. Levels were not 
available for I patient in each group, and at least I severe patient 
had not taken 
prednisolone according to levels or else was not absorbing 
it. Otherwise patients were 
compliantwithsteroids. 
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Fig. 3.5 Expression of CD11b, CD62L, CD35, and CD18 in normal subjects, and mild, 
moderate and severe patients in neutrophils in lysed whole blood showing increased 
expression of CD11b and CD35 in corticosteroid-dependent asthmatics compared with 
normal subjects. (*P<0.05). 
92 
normal mild moderate severe 
n=10 n=10 n=10 n=10 
normal mild moderate severe 
n=10 n=10 n=10 n=10 
normal mild moderate severe 
n=10 n=10 n=10 n=10 
normal mild moderate severe 
n=10 n=10 n=10 n=10 
MFI 
CD11b 
MFI 
CD62L 
CD35 
MFI 
CD18 
MFI 
225- 
200- 
... 
... 
175- T 
150- 
125- 
100- 
75- 
50- 
25- 
0-- 
18 18fm 18 18fM 18 18frn 18 18fm 
normal mild moderate severe 
n=10 n=10 n=10 n=10 
Fig. 3.6. Stimulation of lysed whole blood with fMLP in normal subjects and asthmatics of 
different severity showing significant upregulation of CD11b, CD18, CD35 and 
downregulation of CD62L on neutroPhils compared to unstimulated neutrophils. 
Asterisks indicate a significant difference compared to resting levels. No difference was 
seen between stimulated samples between the four groups with any of the surface 
markers. (**P<0.01, ***P<0.0001) 
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Fig. 3.7 Effect of PAF (10-6M) stimulation on CD11b, CD62L, CD18, and CD35 expression 
on neutrophils in lysed whole blood. in normal subjects and asthmatics of different 
severity. Upregualtion of CD11b, CD18, and ýCD35 in normal subjects and asthmatics, and 
down regulation of CD62L in normal subjects only (***p <0.0001, **p <0.002, * P<0.05). 
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Fig. 3.8 Expression of CD11b, CD62L, CD18, and CD35 on resting eosinophils in lysed 
whole blood in normal subjects and asthmatics of different severity. No significant 
difference was seen in surface marker expression between the groups. 
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Fig. 3.9 Effect of stimulation of whole blood with fMLP (10-7M) on expression of CD11b, 
CD62L, CD35, and CD18 on eosinophils in normal subjects and asthmatics of different 
severity. CD11b expression is increased in normal subjects and mild and moderate 
asthmatics after fMLP compared to unstimulated blood (*p<0.05). CD62L expression is 
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Fig. 3.10 Effect of aI week course of prednisolone 30mg/day on surface activation 
molecules on peripheral blood neutrophils in mild and severe asthmatics. CD62L 
expression was decreased on neutrophils in mild asthmatics following prednisolone, but no 
effect was seen on neutrophils from patients with corticosteroid-dependent asthma. 
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Fig. 3.11 Effect of prednisolone 30mg for 1 week on surface activation molecules on 
peripheral blood eosinophils, showing reduced expression of surface molecules on 
eosinophils from both mild and severe asthmatics. No effect was seen on CD 35 
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3.3.6 Effect of dexamethasone on activation molecule expression in peripheral whole 
blood 
Whole blood pre-incubated ex-vivo with dexamethasone (10-6 to 10-8 M) for I 
hour or 3 hours, produced no difference in the expression of CD IIb or CD62L on 
neutrophils or eosinophils in unstimulated or fMLP stimulated blood (figs. 3.12-3.14). 
3.3.7 Surface molecule expression on isolated granulocytes 
In order to see if the lack of effect of dexamethasone on surface molecule 
expression in peripheral blood neutrophils and eosinophils was due to an inhibitor of 
dexamethasone function present in whole blood, the above studies were carried out on 
isolated granulocytes (lXlO 5 cells per well). 
Baseline expression of surface molecules was higher in isolated neutrophils and 
eosinophils compared to granulocytes in lysed whole blood and this may represent 
activation of granulocytes by the separation techniques involved, such as Ficoll 
separation and centrifugation. In the severe group, there was significant increase in 
CD IIb expression and decrease in CD62L on isolated neutrophils after stimulation with 
fMLP and PAF but not in the mild group (fig. 3.15). Increased CD IIb expression was 
seen on unstimulated isolated eosinophils in the mild group compared to the severe 
group, and there was no significant change following stimulation with f1\4LP and PAF 
(fig 3.16). Similar to the effect of prednisolone on peripheral blood neutrophils in mild 
asthmatics, isolated neutrophils from mild asthmatics showed reduction in the 
expression of CD62L and CD18 after prednisolone, with no effect of prednisolone on 
isolated neutrophils from severe asthmatics (fig 3.17). Isolated eosinophils from both 
mild and severe asthmatics showed a reduction in CD11b and CD62L following 
prednisolone, in addition to a decrease in CD18 in mild asthmatics (fig 3.17). 
Interestingly, in severe asthmatic group, fMLP stimulated isolated neutrophils showed 
an increase in CD11b expression after additional prednisolone suggesting that 
prednisolone may have resulted in further neutrophil activation in this situation. 
However, prednisolone caused a significant downregulation in CD11b, CD62L, and 
CD18 on isolated eosinophils in mild asthmatics, with a corresponding reduction in 
CDI lb approaching significance on isolated eosinophils in the severe group (P=0.06) 
(fig. 3.18). Preincubation of isolated granulocytes with dexamethasone again appeared 
to have no effect on the expression of surface molecules on either unstimulated or 
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stimulated cells on neutrophils or eosinophils, confirming the results seen in whole 
blood pre-incubated ex-vivo with dexamethasone (figs. 3.19 and 3.20). 
3.3.8 Neutrophil oxidative burst in normal subjects, and mild and severe asthmatics, 
and effect of prednisolone 
Dose response studies of oxidative burst measurement in neutrophils using flow 
cytometry showed that PMA stimulated neutrophil oxidative burst in a dose dependent 
manner, and maximal stimulation was achieved after 20 minutes as seen on a time 
course study (n=3, normal subjects, fig. 3.21). The results showed that the oxidative 
burst in mild asthmatics was significantly greater than in normal subjects and severe 
patients whilst similar levels were seen between normal subjects and severe patients 
(fig. 3.22). Further, the oxidative burst was reduced in mild patients after prednisolone 
but not in the severe patients. 
3.3.9 Neutrophil elastase in peripheral blood neutrophils 
Following the recommended protocol for measurement of neutrophil elastase, a 
dose of I [d of DHR I 10 resulted in an MFI similar to that of 5 [d and 10 ýd, and time 
course study suggested 20 minutes incubation was optimal (n=3, normal subjects, fig 
3.23). No significant difference was seen in the levels of neutrophil elastase in 
peripheral blood neutrophils between normal subjects, mild, and severe asthmatics. 
Although there appeared to be reduction in neutrophil elastase levels after prednisolone, 
this was not statically significant (fig 3.24). 
3.3.10 Serum cytokine levels and the effect of prednisolone 
IL-8 was not detectable in serum in mild or severe asthmatics at baseline (visit 
in unstimulated blood. After 24 hours blood culture however, IL-8 levels were 
detectable in both groups. IL-8 levels in mild asthmatics appeared elevated after 
stimulation with IL- I P, LPS, and GM-CSF compared to severe asthmatics, but this was 
not statisitically significant. In the mild group however, there was a significant decrease 
in LPS and GM-CSF induced IL-8 production after prednisolone therapy, and this effect 
of prednisolone was not seen in the severe group (fig 3.25). 
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3.3.11 Neutrophil myeloperoxidase release 
No difference was seen in the basal or IL- IP stimulated MPO levels in isolated 
granulocytes between mild and severe asthmatics, and there was no obvious effect of 
prednisolone therapy (fig 3.26). 
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Fig. 3.12 Effect of dexamethasone (10-6M) on CD11b and CD62L expression on peripheral 
blood neutrophils, in unstimulated and fMLP (10-7M) stimulated whole blood. No 
significant effect of dexamethasone was seen in unstimulated or stimulated neutrophils. 
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Fig. 3.13 Effect of dexamethasone (10-6M) on CD11b and CD62L expression on peripheral 
blood eosinophils, in unstimulated and fMLP (10-7M) stimulated whole blood. No effect of 
dexamethasone was seen in stimulated or unstimulated whole blood. 
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Fig. 3.14 Effect of dexamethasone (10-6_ 10-8 M) on whole blood neutrophils and 
eosinophils stimulated with fMLP (10-7 M) and incubated for 1 hour. No effect of 
dexamethasone was seen. 
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Fig. 3.15 Expression of CD11b, CD62L, and CD18 on resting and fMLP (10-7 M) and PAF 
(10-6M) stimulated isolated neutrophils in mild and severe asthmatics. CD11b was 
increased, and CD62L reduced after stimulation with fMLP and PAF in severe asthmatics 
only. No effect was seen on CD18 expression in either group (** p <0.001, *p <0.03). 
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Fig. 3.16 Expression of CD11b, CD62L, and CD18 on unstimulated and fMLP (10-7 M) and 
PAF (10-6M) stimulated isolated eosinophils in mild and severe asthmatics. n=6 mild, and 6 
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Fig. 3.17 Effect of prednisolone 30mg PO for I week on CD11b, CD62L, and CD18 
expression on unstimulated isolated neutrophils and eosinophils in mild and severe 
asthmatics. Prednisolone reduced CD62L and CD18 expression on isolated neutrophils in 
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Fig. 3.18 Effect of prednisolone 30mg PO for 1 week on CD11b, CD62L, and CD18 
expression on fMLP (10-7M) stimulated isolated neutrophils and eosinophils in mild and 
severe asthmatics. (**p< 0.006, *p<0.01). Prednisolone decreased surface marker 
expression on isolated stimulated eosinophils in mild asthmatics only, and increased 
CD11b expression on isolated stimulated neutrophils in severe asthmatics. 
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Fig. 3.19 Effect of dexamethasone (10-6M) on CD11b, CD62L, CD18 expression on 
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(10-6M) stimulated isolated neutrophils. dex = 
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6M) 
stimulated isolated eosinophils. dex= preincubated with dexamethasone. 
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Fig. 3.22 Effect of prednisolone (30mg/day PO) on oxidative burst in peripheral blood in 
mild and severe asthmatics using rhodamine 125 and flow cytometry. Baseline oxidative 
burst was higher in mild asthmatics compared with normal subjects and severe 
asthmatics. Prednisolone reduced oxidative burst in mild, but not severe asthmatics. 
pre= before prednisolone, post =after prednisolone (* p= <0.03). 
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Fig. 3.23 Dose and time response studies of neutrophil elastase using Rhodamine 110 (IýLl). 
* p<0.05 compared with time=O, and 2 minutes. 1ýd Rhodamine 110 equivalent to other 
doses. n=3, normal subjects. 
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Fig. 3.24 Neutrophil elastase in normal subjects and mild and severe asthmatics (pre = 
baseline), and effect of prednisolone 30mg PO for I week (post), using flow cytometry and 
rhodamine 110. No significant difference was seen at baseline between the groups, and no 
effect of prednisolone. 
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Fig. 3.25 IL-8 levels in mild and severe asthmatics, after 24 hour diluted whole blood 
(1: 10) culture and stimulation with IL-10 (10ng/ml final concentration), LPS (10ng/ml), 
and GM-CSF (lng/ml). Levels are shown before (pre) and after (post) prednisolone, 
30mg/day for I week. Prednisolone significantly reduced the LPS and GMCSF stimulated 
production of IL-8 in mild patients. (*P-0.03, **P=0.004). 
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Fig. 3.26 Effect of prednisolone 30mg/day PO for I week on MPO release from resting and 
11-10 isolated granulocytes, in mild and severe asthmatics. Time intervals: baseline, IL-O= 
immediately after adding IL-10; IL-30= 30 minutes after adding IL-10. Pre= before 
prednisolone, post-- after prednisolone. No significant difference was seen between mild 
and severe asthmatics, and there was no effect of prednisolone. 
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3.4 Discussion 
The results from this study showed that CD35 and CD IIb expression was higher 
on resting peripheral blood neutrophils in severe corticosteroid-dependent asthmatics 
compared to normal subjects, suggesting that neutrophils may be in a state of higher 
activation in the circulation of severe asthmatics, compared to normal subjects. No 
difference was seen between severe corticosteroid-dependent asthmatics and mild or 
moderate asthmatics. One explanation for this difference may be related to the effect of 
chronic oral corticosteroid therapy on surface molecule expression in the more severe 
group. It would be difficult to completely exclude the effect of oral corticosteroids on 
surface molecule expression, as by definition, corticosteroid-dependent asthmatics 
require maintenance oral steroids for control of their symptoms, and thus stopping their 
steroids to exclude a possible steroid treatment effect would not be possible. The 
moderate patients in this study were of similar age to the severe group, and taking high 
doses of ICS, suggesting that high dose ICS do not affect surface marker expression. 
Many of the subjects in this study were non smokers, or else had not smoked for at least 
one year prior to the start of the study, and thus it was not felt that this had a direct 
bearing on granulocyte surface molecule expression. 
The power of the study may have been insufficient to detect whether there was a 
true difference between severe asthmatics and other asthmatic groups, and a repeat study 
with larger numbers of patients in each group would help to answer this question. As it 
was only possible to recruit 10 severe patients who agreed to take additional 
prednisolone on top of their usual maintenance prednisolone dose, it was decided to 
recruit 10 patients in the other groups to keep patient numbers equal. In addition, the 
normal subjects were generally younger and non-atopic compared to the more severe 
group, and this may have some influence on results. A better control group including 
more age matched controls containing more atopic individuals, and more equal gender 
mix (most of the the normal subjects were male, and most of the mild asthmatics were 
female) may have allowed better comparison between groups. 
No difference in the expression of the surface molecules was seen on resting 
eosinophils in any of the groups. Stimulation of neutrophils in lysed whole blood with 
fMLP and PAF led to activation of neutrophils in all groups as demonstrated by an 
increase in expression of CD IIb, CD 18 and CD3 5 surface markers, and down regulation 
of CD62L levels. PAF was less potent in reducing CD62L expression than fMLP, and a 
significant reduction was seen only in the normal subjects and not in the asthmatic 
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groups. Stimulation of eosinophils with fMLP led to increased levels of CD IIb and 
CD62L in mild and moderate asthmatics but not in severe asthmatics, suggesting that 
further inducible expression of these markers is not possible in severe corticosteroid- 
dependent asthmatics, or else, modulation of expression is prevented by prednisolone 
therapy. These results are similar to a study done in asthmatic children by Berends et al 
(87) who showed that baseline CD35 expression on peripheral blood neutrophils was 
significantly elevated in mild allergic asthmatic children (inhaled beta-2 agonist only) 
and stimulation with fMLP increased expression of CD11b on neutrophils and 
eosinophils in asthmatics versus control subjects, suggesting that inducible expression of 
CD 11 b on granulocytes in allergic children is primed in-vivo. In this study however, no 
increase in surface molecules was seen in mild adult asthmatics compared to normal 
subjects. In contrast, Int Veen et al (88) showed that in stable disease, CD11b and 
CD62L on eosinophils and neutrophils from blood did not differ between normal, mild 
or moderately severe asthmatics. However, the most severe group in their study was on 
high dose ICS and not on maintenance oral steroids. It is interesting that the enhanced 
expression of CD11b was not accompanied by an associated increase in CD18 
expression, since CD 11 b and CD 18 constitute the Mac- I integrin. One explanation is 
that there may be enhanced shedding of CD 18 or redistribution of CD 18 complexes 
within the CD II family upon activation of neutrophils. 
As previously mentioned, the increased expression of surface molecules on 
resting neutrophils seen in the severe group in this study could have been due to the 
effect of chronic steroid therapy which results in persistent activation of circulating 
neutrophils. In general however, both in-vitro and in-vivo studies have shown that 
corticosteroids have an inhibitory effect on neutrophil function and result in down 
regulation of surface molecules such as integrins. In this study, additional 30 mg 
prednisolone per day for I week had no effect on surface molecule expression in the 
severe group. It is possible that higher doses of prednisolone given for a longer duration 
may have been required to see an effect on surface molecule expression in this group. 
Prednisolone did however, significantly decrease CD62L expression on neutrophils in 
mild asthmatic patients. This finding in humans is similar to in-vivo experiments in 
cows (102) which showed that i. v. dexamethasone induced down regulation of the 
adhesion molecules CD62L and CD 18 on peripheral blood neutrophils. Jilma et al (106) 
have also shown down regulation of CD62L expression on neutrophils in healthy men 
following administration of i. v. dexamethasone. This reduction of surface molecule 
expression by glucocorticoids is thought to occur on segmented PMNs 
in the maturation 
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pool of the bone marrow rather than on PMNs already in the circulation (103). This may 
be one mechanism of the anti-inflammatory action of glucocorticoids in mild asthma, 
whereby the initial weak binding of leucocytes to the endothelium which is mediated by 
L-selectin molecules, is reduced. The adhesion molecules on neutrophils in severe 
asthmatics may be more resistant to the effects of steroids, thus allowing granulocyte 
recruitment into inflammatory sites to continue. In contrast, the results show that 
surface molecule expression on eosinophils from both mild and severe patients were 
reduced by prednisolone suggesting that eosinophils from both groups are more 
sensitive to the effects of prednisolone than neutrophils, implying relative steroid 
resistance in the neutrophil population. 
Previous human studies on the effects of corticosteroids on granulocyte surface 
molecules have used high i. v. doses in patients. For example, i. v. methylprednisolone at 
a dose of 500mg for 5 days in multiple sclerosis Patients resulted in a 40% decrease in 
CD62L and a 35% decrease in CD11b at 6hours (107). Hill et al showed that Ig of 
methylprednisolone inhibited the upregulation of CD IIb usually induced by CPB, 
probably by suppressing cytokine release such as IL- I P, TNF-Ot, and endotoxin during 
CPB and which are known to be suppressed by steroids (108). Laroche et al (I 10) 
showed that in a randomised single blind PBO controlled parallel study in 24 healthy 
males, prednisolone 5mg bd for 7.5 days showed no significant effect on CD35, CDl Ib 
or FcyIII expression on unstimulated and fMLP stimulated neutrophils. However, this 
dose is lower than that which is usually given during an asthma exacerbation and in a 
clinical setting. 
There appeared to be no effect of dexamethasone (10-5 to 10-9M) on either 
resting or stimulated neutrophil or eosinophil surface molecule expression in peripheral 
whole blood in-vitro. This discrepancy between in-vivo and in-vitro results has been 
confirmed by other workers in respect to glucocorticoid induced shedding of L-selectin, 
and suggests that glucocorticoids do not directly affect neutrophil L-selectin expression 
but instead act via an additional second messenger in vivo, thought to be annexin I 
(111). 
Studies on isolated granulocytes showed similar results to peripheral blood 
neutrophils and eosinophils. Baseline expression of surface molecules (as demonstrated 
by the mfi), was higher in isolated granulocytes and this may reflect activation of 
granulocytes through separation and isolation procedures such as Ficoll separation and 
density centrifugation. No difference was seen in the baseline expression of surface 
markers on isolated neutrophils between mild and severe asthmatics and this may be 
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due to the fact that the number of patients analysed was too small. Isolated neutrophils 
from severe asthmatics did however show significant activation of neutrophils after 
stimulation with fMLP and PAF but this was not seen in the mild group. This suggests 
that neutrophils from severe patients may be more activated after an exacerbation, with 
the possibility of causing tissue damage from release of stored mediators. 
Isolated eosinophils from mild patients did show increased CD 11 b expression 
compared to severe patients. As with peripheral blood eosinophils, isolated eosinophils 
did not show significant activation after stimulation with fMLP or PAF. It has been 
shown that eosinophils are more sensitive to the effects of steroids than neutrophils, and 
the maintenance steroids in the severe patient group may be important in modulating 
surface marker expression on eosinophils in this group. 
As with peripheral blood neutrophils, prednisolone reduced levels of CD62L and 
CD18 on isolated neutrophils in mild patients only, suggesting that the reduction in 
adhesion molecules in mild asthmatics may be one mechanism for the anti- 
inflammatory action of corticosteroids in these patients. Again prednisolone did not 
appear to have any effect on neutrophils from severe patients, suggesting that these 
neutrophils from steroid-dependent patients are resistant to this action of cortico steroids. 
Isolated eosinophils from both groups again demonstrated sensitivity to prednisolone, 
and this was also the case for fMLP stimulated isolated eosinophils in mild asthmatics. 
Interestingly, fMLP stimulated isolated neutrophils in severe patients showed further 
activation with increased CD 11 b expression after prednisolone therapy. Dexamethasone 
showed no reduction in surface molecule expression in resting or stimulated isolated 
neutrophils or eosinophils in either group, giving weight to the hypothesis that a second 
messenger in-vivo is required for modulation of adhesion molecule expression. 
It is known that cytokines such as GM-CSF may be able to increase the in-vitro 
inducible expression of adhesion molecules such as CD11b (106). Further, 
administration of i. v. methylprednisolone or dexamethasone reduces serum cytokine 
secretion (107,108). In this study, the levels of IL-8 after whole blood culture were not 
significantly different between mild and severe steroid-dependent asthmatics, either 
before or after prednisolone. In mild patients however, there was a significant reduction 
in LPS and GM-CSF induced IL-8 production following prednisolone therapy, which 
was not seen in severe patients. This would suggest that induceable cytokine levels can 
be suppressed by corticosteroids in mild asthmatics, thus dampening the inflammatory 
response. This effect is not seen in severe asthmatics and it is therefore possible that this 
may allow the inflammatory cascade to continue in these severe patients allowing on 
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going tissue damage and remodelling to occur. It must be noted that although 
neutrophils stimulated with IL- I P, LPS and GM-CSF may be an important source of IL- 
8, other cells such as monocytes may also be contributory. 
Results from this study showed that the oxidative burst activity of granulocytes 
was greater in mild asthmatics compared to normal subjects. Further, prednisolone 
decreased oxidative burst activity in mild asthmatics but there was no significant effect 
in patients on chronic steroid therapy. This is in agreement with studies that have shown 
PMA and zymozan stimulated blood in asthmatics patients showed increased 
superoxide anion generation compared to normal subjects (184). Hoeben et al showed 
that prednisolone inhibited respiratory burst activity in bovine granulocytes at 
therapeutic doses (187). The reduced oxidative burst seen in corticosteroid-dependent 
asthmatics is partly explained by a study by Fukushima et al (t94) which showed that 
prolonged corticosteroid therapy in patients receiving steroids for a variety of reasons 
such as neurological, collagen vascular diseases, and respiratory conditions showed 
inhibition of PN4N superoxide production as measured by cytochrome C and 
spectometry following fMLP and PMA stimulation. One possible mechanism for this is 
thought to be inhibition of NADPH oxidation or impairment of transduction reactions in 
the respiratory burst. In addition, the loss of suppressibility of the oxidative burst to 
prednisolone in severe asthma could be due to the reduced basal release possibly 
induced by chronic prednisolone therapy. Examination of the effect of prednisolone in 
normal volunteers, in whom the baseline respiratory burst is similar to that of severe 
asthmatics, would resolve the issue as to whether further suppression is possible. 
In comparison to whole blood culture results, no difference was seen in the basal 
or IL-lP stimulated MPO release in isolated granulocytes between normal subjects, 
mild, or severe asthmatics. This may be explained by the fact that the isolation 
procedure itself may be responsible for causing cellular degranulation and release of 
MPO from granulocytes from all samples. This study showed no difference in 
peripheral blood neutrophil elastase levels between normal subjects, mild and severe 
asthmatics using a flow cytometric method of analysis. Increased levels of neutrophil 
elastase have been reported in sputum from asthmatics with an exacerbation due to a 
respiratory tract infection (22), and in patients with status asthmaticus undergoing 
mechanical ventilation in the absence of infection (195). The negative result seen in 
peripheral blood suggests that a severe insult, either inflammatory or infectious is 
required before any increase in neutrophil elastase is seen and even then, perhaps only 
in the lung compartment rather than in the peripheral blood. 
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Conclusion and future studies 
This study shows that the constitutive expression of surface activation markers 
CD35 and CD IIb on peripheral blood neutrophils from severe corticosteroid-dependent 
asthmatics is elevated compared to normal subjects. Further, stimulation with fMLP and 
PAF results in further activation of certain adhesion molecules in isolated neutrophils 
from severe asthmatics. Adhesion molecule expression on peripheral neutrophils from 
the severe asthmatic group remains unchanged following an additional dose of 
cortico steroids, whilst CD62L and CD 18 levels are reduced in mild asthmatics, both in 
peripheral and isolated neutrophils using a clinically relevant dose of prednisolone. This 
suggests that circulating neutrophils may be in a more activated state in steroid- 
dependent asthmatics compared with normal subjects, and that steroids may be less able 
to reduce recruitment of these cells into areas of inflammation in the more severe group, 
possibly as a result of their inability to directly reduce surface molecule expression, or 
indirectly, through failure of inhibition of cytokines that may be important in 
recruitment and activation of these cells. This study showed that inducible levels of IL-8 
are significantly reduced by prednisolone in mild asthmatics, but the lack of this effect 
in severe asthmatics may allow continuing activation and uncontrolled inflammatory 
response to continue in the more severe patients, with further scope for tissue damage to 
occur. 
Corticosteroids may have a differential effect on the activation and function of 
neutrophils in severe steroid-dependent asthmatics, as oxidative burst capacity in steroid 
dependent-asthmatics is reduced by their long term steroid therapy. This 
immunosuppresive effect may play a role in the pathogenesis of the severe phenotype 
by allowing recurrent episodes of infection to occur in these patients. Eosinophils from 
both mild and severe groups appear to be sensitive to the effects of corticosteroids and 
this has been shown to be the case in peripheral blood eosinophils and eosinophils from 
isolated granulocytes. 
The dual nature of corticosteroids in the treatment of asthma was confirmed in a 
study by Fukakusa et al (196) who looked at the effect of a2 week course of oral 
methylprednisolone (40mg/day) on the expression of chemokines in bronchial biopsy 
samples from 13 patients with moderate-to severe asthma using immunocytochernistry 
techniques. Corticosteroids reduced the number of CD3-positive T cells and major basic 
protein-positive eosinophils, whereas the number of neutrophils were increased. 
Corticosteroids also reduced the number of eotaxin, and monocyte chernotactic protein 
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(MCP) 3 and 4 mRNA positive cells. However, corticosteroids caused a significant 
increase in the epithelial expression of IL-8, and MCP-2 mRNAs. The failure of oral 
corticosteroids to inhibit IL-8 mRNA may contribute to the persistent airway 
neutrophilia in patients with severe asthma, despite treatment with corticosteroids. 
Apart from the possible damage to airway tissue in asthma, animal experiments 
have shown that neutrophils are important in the ischaemia and subsequent reperfusion 
injury in other organs. Upon reperfusion, neutrophils accumulate in an ischaemic area 
through activation of their surface adhesion molecules, and produce an inflammatory 
response through the production of free radicals, proteases and leukotrienes, with 
deleterious effects on cell membranes and endothelial cells. Tajra et al (197) showed 
that renal ischaemia could be decreased in rats by administering anti-CD IIb antibodies 
prior to reperfusion, resulting in less tubular necrosis, neutrophil infiltration, and 
decreased CD 11 b expression on neutrophils as seen by flow cytometry. Jaeschke et al 
(198) showed that in rats treated with anti-CD11b antibodies, hepatic ischaemia 
followed by reperfusion resulted in decreased neutrophil numbers in post-ischaemic 
liver by 59% and decreased superoxide formation by neutrophils by 56%. 
In dogs, a positive correlation was seen between neutrophil count and severity of 
coronary artery disease (199). Using anti-CD II b/CD 18 monoclonal antibodies it was 
possible to limit myocardial infarct size. Neutrophil activation during angioplasty 
(PTCA) resulted in release of oxygen free radicals which may aggravate the endothelial 
damage induced by PTCA, and further stimulate platelets, with important implications 
for restenosis. Neutrophils also release LTC4 which causes vasoconstriction and a 
reduction in coronary blood flow. 
Antibodies to the surface adhesion molecules CD62L, CD18, and ICAM- I in a 
cat model of myocardial ischaemic reperfasion injury, have shown attenuated coronary 
endothelial dysfunction, lower MPO activity in areas of ischaemic tissue, and 
attenuation of neutrophil accumulation (200), as well as lower plasma creatinine kinase 
levels, and a reduced area of cardiac necrosis (201,202), suggesting that inhibition of 
neutrophil adherence to the endothelium exerts protective effects in reperfusion injury. 
Further, monoclonal antibodies to sialyl Lewis antigen, which is a ligand to the selectin 
molecules involved in slow rolling of leucocytes along the endothelium, reduced the 
extent of myocardial infarction after ischaemia followed by reperfusion in a rat model 
of myocardial reperfusion injury (203). 
In humans, Kamimura et al (204) showed that anti-CD11b and anti-CD18 
monoclonal-antibodies inhibited migration of neutrophils 
into middle ear effusion in an 
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in-vitro study of acute otitis media in children, suggesting this maybe useful in the 
future treatment of human otitis media. In man, increased production of oxygen radicals 
and neutrophil elastase, have been noted in patients with coronary artery disease, in 
chronic lower limb arteriopathy, and in association with vascular risk factors such as 
diabetes (205). The use of pentoxifylline has been shown to decrease neutrophil 
adherence and free radical production and decrease TNF-cc cytokine levels. Further, 
other cytokines such as IL-4 and IL-10 have been shown to decrease the formation of 
tissue factor. Therefore, multiple pharmacological targets are possible but their use in 
vascular disease is at preliminary stage. 
In studies involving the NF-kappa B inhibitor, tepoxalin, suppression of the cell 
surface adhesion molecules CD 11 b/CD 18, inhibited adhesion of neutrophils to IL- IP 
activated HUVEC (206). Tepoxalin also inhibited the secretion of IL-8, which is a 
known inducer of CD II b/CD 18 expression. Tepaxolin may therefore be useful in 
treating adhesion molecule mediated events such as leukocyte migration. Neutrophils 
can therefore contribute to tissue injury by release of oxygen derived free radicals, 
proteases and leukotrienes, and interventions aimed at neutrophil inhibition may exert 
protective effects. Corticosteroids alone may not be able to suppress these actions and a 
specific targeted approach to therapy may be more beneficial when these are developed 
in the future, especially in the more severe asthmatic group. 
The experiments in this chapter could have improved in many respects. 
Recruiting more age, gender and atopy matched normal control subjects as well as 
asthmatic subjects would have removed the effects of these confounding variables on 
the results. There may have been selection bias in the study as the normal subjects were 
selected from doctors working in the asthma laboratory at the Royal Brompton hospital, 
at the time of this study. The study could have been better powered by consulting a 
statistician before the start of the study. There was no statistician in place at the 
Brompton at the start of the study. It would have been interesting to look at the effect of 
oral corticosteroids on neutrophil activation parameters in the moderate asthmatic group 
on high dose ICS. This was attempted, but difficult to achieve because the moderate 
asthmatic patients were not keen to take oral cortico steroids in view of their potential 
side-effects. In addition, the prednisolone study would have been strengthened if there 
was PBO group. The design could have been improved by using a double blind, PBO 
controlled crossover trial with mild and severe asthmatics having placebo or 
prednisolone after a wash out period of a week. This might be difficult however, as 
ingestion of prednisolone tablets, even for a short period may be associated with some 
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adverse effects (e. g. insomnia, euphoria, minor weight gain) in some patients, compared 
with PBO. Looking at the effect of prednisolone on granulocyte surface markers in 
normal subjects was attempted, but not possible due to the reluctance of normal subjects 
to take prednisolone tablets. The dose of prednisolone used and duration of treatment 
was felt to closely resemble the clinical response to treatment during an exacerbation, 
but using higher doses of prednisolone, such as 40-50mg for a longer period of time, for 
example 2 weeks, may have provided different results, especially in the severe group. 
The effect of corticosteroids on the expression of surface markers is difficult to exclude, 
but investigation of a subgroup of severe asthmatics who are felt to be severe enough to 
require long term maintenance corticosteroid therapy, can be undertaken to look at 
peripheral blood neutrophil surface markers before and 2-4 weeks after starting 
cortico steroids, to see if there is any difference as a result of steroid therapy. However, 
recruitment is likely to be difficult and require some time to achieve. 
Neutrophil elastase in the blood was measured by a relatively new method using 
FACS scanning techniques. Perhaps using an ELISA technique may have been better. 
Neutrophil elastase could also have been measured in sputum supernatant before and 
after a course of steroids. The method of defining a neutrophil population in lysed whole 
blood using a FACS scanner according to the literature was correct, although this could 
have been refined by using a FACS machine incorporating a cell sorter, although this 
type of FACS scanner was not available for use. Further, CD49 staining on a CD16 
negative cell population may help to further exclude eosinophils from a neutrophil 
population. It would have been interesting to look at surface marker expression in 
sputum/BAL samples in addition to peripheral blood in the various asthmatic groups 
compared to control subjects. However, this can be technically difficult given the 
background 'noise' in these samples, and perhaps due to the lack of cellular material 
obtained. 
Performing ELISA on blood samples for IL-8, MPO, and neutrophil elastase 
before and after fMLP stimulation, would be useful to see if the level of neutrophil 
surface marker expression correlated with mediator release. Newer FACS scanning 
techniques now allow measurement of cytokines using specific monoclonal antibodies 
and only a small peripheral blood sample, thus allowing an exciting and rapid means of 
analysing neutrophil activation markers in patients. Despite the advantages of whole 
blood culture techniques, it is important to remember that other cells in the blood are a 
potential source of IL-8, and thus isolating and culturing neutrophils specificily from the 
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blood to look at release of IL-8 before and after prednisolone therapy, rather than using 
whole blood culture, would be interesting for comparison. 
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Chapter 4 
Investigation of histone deacetylase activity in peripheral blood neutrophils in mild 
and moderate asthmatics compared to peripheral blood mononuclear cells and 
alveolar macrophages, and the effect of corticosteroids on histone deacetylase 
activity. 
4.1 Introduction 
Asthma is a chronic inflammatory disease that is characterized by increased 
expression of multiple inflammatory genes. Acetylation of histones by histone 
acetyltransferases (HATS) is associated with increased gene transcription, whereas 
hypoacetylation induced by histone deacetylases (HDACs) is associated with 
suppression of gene expression. Studies on bronchial biopsies from patients with asthma 
and normal subjects, have shown reduced HDAC enzymatic activity in asthmatics, with 
greater HDAC activity seen in those asthmatics treated with ICS compared to untreated 
asthmatics, although still lower than control subjects. Further, the asthmatic group 
demonstrated increased HAT activity compared to controls, and this was reduced to 
control levels in asthmatics that were treated with ICS (137). Thus the increase in HAT 
activity and reduced HDAC activity in asthma may underlie the increased expression of 
multiple inflammatory genes. Corticosteroids have been shown to switch off 
inflammatory gene transcription in asthma through the inhibition of HAT activity and 
by the recruitment of histone deacetylase 2, (HDAC2) to the actively transcribing gene. 
HDAC activity is thus increased by treatment with cortico steroids, leading to repressed 
transcription of inflammatory genes. 
In the last chapter, it was shown that the expression of certain surface activation 
markers on neutrophils was increased in severe asthmatics, and oral prednisolone had 
little effect on the level of expression of these markers. The aim of this study was to 
investigate the activity of HDAC activity in peripheral blood neutrophils from normal, 
mild, and severe asthmatic subjects, and to compare this with HDAC activity in alveolar 
macrophages (AM) and peripheral blood monocytes (PBMCs). The effect of oral 
prednisolone on HDAC activity in these cell populations was also investigated. 
Measurement of HDAC activity in neutrophils allows assessment of the state of 
activation of these cells in the peripheral circulation of patients with varying severity of 
asthma. 
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Macrophages and monocytes play an important role in the regulation of the 
immune and inflammatory responses. AM and PBMCs from subjects with asthma have 
been reported to display an activated phenotype, with upregulated expression of surface 
markers such as HLA-DR, CD35 and CD23 receptors (207,208). AM play a critical Part 
in orchestrating the chronic inflammatory cascade through the release of proteases such 
as MMP-9, inflammatory cytokines such as TNFa, and chemokines such as IL-8 that 
attract neutrophils into the airways. Vicksman et al (209) reported evidence of activation 
of AM but not PBMC in subjects with allergic rhinitis and asthma. 
4.2 Methods 
4.2.1 Subjects 
The contribution of Dr B Cosio to this chapter is acknowledged in the author's 
declaration. Eighteen stable patients with asthma were recruited for bronchoscopy. Ten 
were mild asthmatics receiving only intermittent treatment with the inhaled P- 
adrenergic agonist, salbutamol. The other eight were moderate persistent asthmatics 
who were taking regular ICS (500 ýtg/day of FP or equivalent). All patients 
demonstrated greater than 15% improvement in FEVI after 200ýlg of salbutamol and 
airway responsiveness to a provocative concentration of methacholine producing a 20% 
fall in FEVI (PC20). All patients were atopic, as defined by two or more positive skin 
prick tests to common allergens. Current smokers or ex-smokers of more than 5 pack- 
years were excluded. Ten healthy non-atopic non-smoking volunteers were also 
recruited (Table 4.1). 
In a separate experiment, blood was venesected from 6 patients with mild 
persistent asthma and 6 patients with severe asthma receiving ICS (> 1000ýtg/day FP or 
equivalent), long acting inhaled P-adrenergic agonist, and oral corticosteroids if 
required (n=3), for control of asthma. Blood was taken before, and after a one week 
course of oral prednisolone 30 mg/day (in mild asthmatics) or an additional 30 mg/day 
of prednisolone for one week in severe asthmatics already on maintenance prednisolone. 
Prednisolone blood levels and cortisol were checked to ensure compliance and 
absorption of the treatment. Exhaled NO was also measured before and after treatment 
as described in section 2.1.6. 
128 
BAL was performed according to guidelines at the Royal Brompton Hospital. All 
patients gave written informed consent, and the study was given approval by the Royal 
Brompton Hospital's Ethics committee. 
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TABLE 4.1. Characteristics of subjects undergoing bronchoscopy 
Control Mild Asthma Moderate Asthma 
(n = 10) (n = 10) (n = 8) 
Age, yr 30.6 ±3 31 ±3 31.1 ± 2.5 
Sex, M: F 7: 3 5: 5 5: 3 
FEVI, (L) 4.5 ± 0.2 3.5 ± 0.3 3.5 ± 0.2 
FEV I, % predicted 104 ±3 88.1 ±5 91.8 ±2 
PC205 Mg/Ml ND I±0.2 1.3 ± 0.4 
BAL fluid recovered, ml 99.4 8 105.7 5 105.6 6 
Macrophage number, cells xI 03/Ml 92.9 11 102.4 14 120.1 17 
Eosinophils, % 0.2 0.03 1.8 ± 0.4 1.6 ± 0.3 
Neutrophils, % 3.3 0.1 4.1 ± 0.2 2.2 ± 0.1 
Definition of abbreviations: BAL = bronchoalveolar lavage; ND = not determined; PC20 
= provocative concentration of methacholine producing a 20% fall in FEVI. Results are 
presented as mean ± SEM. 
TABLE 4.2. Characteristics of subjects in whole blood culture and prednisolone study 
Mild Asthma Severe Asthma 
(n = 6) (n = 6) 
Age; yr 36.3 ±5 46.6 ±4 
Sex; M: F 3: 3 2: 4 
FEVI; % predicted 93.6 ± 3.6 43.75 8.2 
FEV 1; 1, pre 3.13 ± 0.2 1.29 0.3 
FEVI; 1, post 3.06 ± 0.2 1.74 0.3 
eNO; ppb, pre 42.5 ± 20 30.4 ±5 
eNO; ppb, post 23.5 ±9* 18.3 ±4 
Prednisolone; nmol/L 1ý588.6 ± 225** 983.6 ± 127** 
Definition of abbreviations: eNO = exhaled nitric oxide; ýre = before treatment with 
prednisolone; post = after treatment with prednisolone. p<0.05 compared with 
pretreatment levels. Results are presented as mean ± SEM. 
** Incomplete data available-see discussion. 
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TABLE 4.3. Bronchoalveolar lavage characteristics in subjects with asthma and control 
subj ects 
Subject TCC 
109.5 
Control 5.2 
126.4 
Mild asthma 2.1 
Moderate 136.5 
asthma 4.7 
Macro Neut Lym 
NN Eos (%) CV 
9.9 0.2 93.2 
85.1± 0.9 3.3 ± 0.1 0.9 0.03 1.3 
79.9 ± 1.3 4.1 ± 0.2 14 ± 1.1 1.8 ± 0.4t 89 ± 1.1 
87.8 ± 7.8 ±f 96.3 
0.9* 2.2 ± 0.1 0.3 1.6 ± 0.3 1.3 
- ------------- - 
Definition of abbreviations: CV = cell viability; Eos = eosinophil; Lym lymphocyte; 
Macro = macrophage; Neut = neutrophil; TCC = total cell count (cells x 103/ml) 
*p<0.05 versus subjects with mild asthma. 
tp<0.05 
versus control subjects. 
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4.2.2 Whole blood culturefor IL-8 measurement 
Whole blood from normal, mild and moderate asthmatics was cultured as 
described in section 2.2.9.1. The supernatant was removed and stored at -70'C until 
analysed. 
4.2.3 ELISA 
IL-8 levels in cultured whole blood were measured by duoset ELISA kit (R&D 
systems Europe, Oxon, UK). The lower limit of detection was 31.2 pg/ml. 
4.2.4 Isolation ofperipheral blood mononuclear cells (PBMCs) and granulocytes 
PBMCs and granulocytes were isolated from venesected whole blood as 
described in section 2.2.2. Cells were stained with Kimura stain for determination of 
total cell number, and the cell concentration was adjusted to 5x 106 with PBS. Cell 
viability, as determined by trypan blue exclusion was uniformly greater than or equal to 
97%. 
4.2.5 Fiberoptic Bronchoscopy, BAL collection and processing of BAL 
macrophages. 
The methods used for bronchoscopy and sample collection are described in section 
2.2.11. 
4.2.6 Measurement of HDAC activity. 
HDAC was measured as decribed in section 2.2.12. 
4.2.7 Statistics 
Results are expressed as mean ± standard error of the mean (SEM). All statistical 
testing was performed by using a two-sided 5% level of significance. 
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4.3 Results 
4.3.1 Patient characterization 
Baseline characteristics and investigation results of the patients undergoing 
bronchoscopy are summarized in Table 4.1. No differences were found in BAL total 
cell counts or BAL neutrophils between normal subjects and those with asthma, but the 
number of BAL macrophages was significantly higher in the group with moderate 
asthma than in the group with mild asthma (Table 4.3). The numbers of eosinophils 
were higher in subjects with asthma than in normal subjects, but there was no difference 
between the mild and moderate asthma groups. The number of macrophages per ml of 
recovered BAL fluid was significantly higher in moderate to severe patients receiving 
ICS (Table 4.3). Characteristics of the mild and severe asthmatics in whom blood 
studies were performed, are summarized in table 4.2, and are presented in more detail in 
appendix 2.1 (page 239), and 2.2 (page 240) . Three of the patients in the moderately- 
severe group were receiving maintenance prednisolone (5,10 and 15 mg/day). There 
was a trend toward an improvement in FEVI (from 1.29 ± 0.3 to 1.74 ± 0.2 L, p=0.32), 
and a decrease in eNO (30.4 ±5 to 18.3 ±4 ppb, p=0.09) in the group with severe 
asthma after receiving oral prednisolone, although this did not reach significance. 
4.3.2 HDAC activity in alveolar macrophages in mild and moderate asthmatics 
AM nuclear extracts from mild asthmatics (n-10) showed a reduced HDAC 
activity compared to healthy age-matched controls (n=10) (3017.9 vs. 4944 AFU/10ýxg, 
p<0.01). However, the group of patients with moderate persistent symptoms receiving 
ICS as a regular treatment (n=8), showed an increased HDAC activity (3540.2 
AFU/ 10 ýtg) although did not reach the levels of normal controls (fig. 4.1). There was no 
correlation between the levels of HDAC activity and post-bronchodilator FEVI or PC20- 
4.3.3 HDAC activity of PBMCs and granulocytes in mild and severe asthmatics and 
control subjects 
PBMCs did not show a significant difference in baseline HDAC activity when 
comparing mild or moderate asthmatics to normal controls. There was also no 
difference in granulocyte HDAC activity between normal subjects, and mild asthmatics 
and severe asthmatics (fig. 4.2). Granulocytes from whole blood showed a reduced 
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HDAC activity, when compared to PBMCs (1869.4±100 vs. 4788.7±1056 AFUAOýtgý 
p<0.001) in blood taken from asthmatics and normal subjects suggesting a different 
regulation or a predominant pro-inflammatory role of these cells. (Fig. 4-3) 
4.3.4 Effect of treatmen t with predn isolon e in creased HDA C activity in PBMCs 
Prednisolone 30mg/day for a week significantly increased HDAC activity in 
mild asthmatics (4303.2±16.22 vs. 5333.3±21.32 AFU/10ýtg, p<0.05) but this increase 
was not significant in the more severe group (fig. 4.4). An improvement in lung 
function was observed after treatment in the moderately severe group, and in both mild 
and moderate-severe group, a reduction in eNO was observed. 
4.3.5 Effect of treatment with prednisolone on HDAC activity in neutrophils 
No change in HDAC activity in granulocytes was seen after prednisolone 
treatment. 
4.3.6 Effect of treatment with prednisolone on IL-8 release in whole blood 
Whole blood IL-8 release was decreased after a week of prednisolone therapy in 
mild asthmatics but not in severe asthmatics (fig 4.5, p<0.05). 
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HDAC activity in alveolar macrophages in normal subjects and mild and 
moderate asthmatics 
, 7000 
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U- 
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n 
n =10 n= 10 n =8 
Fig. 4.1 HDAC activity in AM in BAL from normal subjects, and mild and moderate 
asthmatics, showing reduced HDAC activity in AM from mild asthmatics. Increased 
HDAC activity was seen in moderate group on ICS. (* p=0.05, ** p< 0.01). 
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Basal HDAC activity of PBMC in asthmatics with different severity 
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=L C: ) 6000 
5000 LL- 
4000 
Normal Mild Severe 
n=6 n=6 n=6 
Fig. 4.2 Basal HDAC activity in PBMCs in control, mild, and severe asthmatics. No difference in HDAC activity was seen between the groups. 
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HDAC activity in Granulocytes and PBMCs 
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Fig. 4.3 HDAC activity in peripheral blood granulocytes and PBMCs. Granulocytes from 
whole blood expressed less HDAC activity than did PBMCs (1869 +/- 40 vs. 4789 +/- 431 
AFU/10 ýLg, respectively; p<0.001) from peripheral blood from all groups. 
137 
GR PBMC 
Effect of Prednisolone (30 mg) on HDAC activity of PBMC in mild asthmatics 
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Effect of Prednisolone (30 mg) on HDAC activity of PBMC in 
severe asthmatics 
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Fig. 4.4 Effect of a1 week course of prednisolone 30mg/day on HDAC activity on PBMCs 
in mild and severe asthmatics. Prednisolone increased HDAC activity in PBMCs from 
mild but not severe asthmatics. 
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IL-8 in whole blood culture in mild and severe asthmatics 
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n=4 asthmatics n=4 
Fig. 4.5 IL-8 levels in cultured whole blood in normal subjects, and mild and severe asthmatics, 
before and after I week course of prednisolone 30mg/day. IL-8 release was decreased in mild 
asthmatics but not in severe asthmatics. (* p< 0.05). 
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4.4 Discussion 
Glucocorticoids are the most effective therapy for the treatment of chronic 
inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disease 
and autoirnmune diseases, all of which are associated with increased expression of 
inflammatory genes. Most glucocorticoid actions on cells are mediated via interaction 
with specific, intracellular type 2 glucocorticoid receptors (GR). The human type 2 GR is 
a member of the steroid receptor super-family with characterisitc 'zinc fingers' motifs for 
DNA binding. These receptors are expressed in monocytes, macrophages, granulocytes 
and all lymphocyte subpopulations, with the density and affinity of glucocorticoid 
receptors varying between leukocyte types. The number of GR depends on the ambient 
glucocorticoid concentration. For example, experimental adrenalectomy results in 
increased GR expression in most tissues. Conversely, prolonged glucocorticoid 
administration results in a fall in GR numbers (210). 
Glucocorticoids bind to GRs in the cytoplasm of target cells which then 
dimerize and translocate to the nucleus, where they bind to glucocorticoid response 
elements (GRE) on glucocorticoid-responsive genes, resulting in increased transcription 
of genes coding for anti-inflammatory proteins, including lipocortin-1, IL-10, IL-1 
receptor antagonist and neutral endopeptidase. Glucocorticoids inhibit the expression of 
multiple inflammatory genes through a direct inhibitory interaction between activated 
glucocorticoid receptors and activated transcription factors, such as nuclear factor-kappa 
B and activator protein-1, which regulate the inflammatory gene expression (210), (fig 
4.6). 
There has recently been increasing evidence that glucocorticoids may have 
effects on the chromatin structure. GR also interact with CBP, which acts as a co- 
activator of transcription, binding several other transcription factors that compete for 
binding sites on this molecule. Increased transcription is associated with uncoiling of 
DNA wound around core histone proteins and this is secondary to acetylation of the 
histone residues by the enzymatic action of CBP. Glucocorticoids may lead to 
deacetylation of histone proteins, resulting in tighter coiling of DNA and reduced access 
of transcription factors to their binding sites, thereby suppressing gene expression (211). 
This study showed that AM from asthmatics have a reduced HDAC activity 
compared to normal subjects, but there was no difference in HDAC activity in PBMCs 
between asthmatics and controls. The reduction in HDAC activity is associated with an 
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increased transcription of inflammatory proteins and thus an increase in inflammation 
(137). This suggests that AM from asthmatics show a higher level of activation in the 
lungs (the main site of inflammation), than PBMCs in the systemic circulation. 
Ito et al (13 7) found an increased HAT activity in bronchial biopsies from mild 
asthmatics and a reduced HDAC activity. Their study also showed that treatment with 
ICS reduced inflammation by increasing HDAC activity and suppressing NF-KB 
activation, which causes a reduction in HAT activity. It has previously been shown that 
glucocorticoids rýequire recruitment of HDAC2 to the p65-HAT complex for their 
repressive actions (212). The reduced HDAC activity found in AM confirms previous 
studies (213) while the increase in HDAC activity observed in the ICS-treated group 
would be consistent with the findings of Ito et al (137). 
An interesting finding in this study was the very low HDAC activity in 
granulocytes found generally in normal subjects and mild and severe asthmatics, 
suggesting a higher inflammatory potential of these cells in general compared to PBMCs 
and AM. No difference in HDAC activity in neutrophils was seen between normal 
subjects and mild or severe groups, and treatment with prednisolone did not increase 
HDAC activity in these cells, implying a reduced capacity of glucocorticoids to regulate 
neutrophil inflammatory potential. In contrast, prednisolone did increase HDAC activity 
in PBMCs in the mild group, suggesting that they can reduce the activation of these cells. 
In the severe group however, the increase in HDAC following prednisolone was not 
statistically significant possibly due to the effect of baseline steroid therapy and the 
sample size. In addition, prednisolone reduced IL-8 levels in whole blood culture in mild 
asthmatics but not in more severe asthmatics. It is not clear why it was possible to 
measure serum IL-8 levels in asthmatics in this study, whereas it was not possible to 
measure baseline serum IL-8 in the prednisolone study (chapter 3). The IL-8 ELISA 
experiments in this chapter were performed by Dr B Cosio, and thus a difference in 
operator technique may have been a factor. 
In both groups, there was a reduction of exhaled NO after treatment, which is an 
indirect estimation of the effect on the bronchial inflammation. The mean prednisolone 
level after one week of treatment was higher in mild asthmatics than in the more severe 
asthmatics. However, in the final analysis, only 3 patients in each group had prednisolone 
and cortisol levels available, and thus this is not an accurate reflection of compliance 
in 
these patients with prednisolone therapy. 
In conclusion, analysis of the HAT and HDAC status can give a reflection on the 
activation status of a cell population. Neutrophils 
in general have significantly reduced 
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HDAC activity suggesting increased inflammatory potential, and this was not altered by 
prednisolone, in contrast to the effect on PBMCs. This lack of modulation of neutrophil 
HDAC activity and prolonged survival of neutrophils by inhibition of their apoptosis, 
suggests that activated neutrophils at sites of inflammation can continue to release 
intracellular mediators potentially resulting in airway wall damage and remodelling. This 
pattern of activity in neutrophils is in direct contrast to HDAC activity in AM, as is the 
inhibitory effect of corticosteroids on PBMCs in mild asthmatics. 
The pattern of reduced HDAC activity and poor response to the anti- 
inflammatory actions of corticosteroids seen in neutrophils from patients with severe 
asthma is mirrored in chronic obstructive pulmonary disease (COPD) which also shows 
multiple activation of inflammatory genes. Interestingly, Ito et al (214) showed that 
patients with COPD have a progressive reduction in total HDAC activity in specimens of 
lung tissue obtained from patients with increasing severity of the disease. It is known that 
oxidative stress, which represents an imbalance between production of reactive oxygen 
species and antioxidant defences, and cigarette smoke increase histone acetylation and 
activate inflammatory gene transcription. Exhaled markers of oxidative stress, such as 8- 
isoprostane and ethane, are increased in healthy smokers but are raised to a much greater 
extent in patients with COPD (215,216). It has been proposed that oxidative stress 
impairs the function of HDAC2 in COPD resulting in resistance to cortico steroids, and 
that this is due in part, to the greater numbers of neutrophils and macrophages (215). In 
asthma, oxidative stress is low (217), but severe asthma is characterised by an increase in 
neutrophils resulting in greater oxidative stress, which could account for the reduced 
responsiveness to corticosteroids in these patients. 
The mechanisms whereby oxidative stress results in impaired HDAC activity are 
unclear, but one possibility is that the increased formation of NO results in the production 
of peroxynitrite which impairs the activity of HDAC2 by nitration of tyrosine residues on 
HDAC or associated proteins (218). The HDAC2 complex is now unable to reverse 
histone acetylation, and this may be a factor in the relative resistance to corticosteroids 
seen in severe asthmatics. The use of effective anti-oxidants that can neutralise oxidative 
stress may help to increase the response to corticosteroids. An alternative approach may 
be through blocking the production of peroxyntrite from NO, by inhibition of inducible 
No synthase (NOS). Initial studies have shown that the prodrug L-N6 is rapidly 
converted to 
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Fig 4.6 Mechanism of action of glucocorticoids. The glucocorticoid (GCS) enters the cellular 
cytoplasm and binds to a glucocorticoid receptor (GR) which is complexed with 2 molecules 
of a 90 kDa heat shock protein (hsp 90). GR then translocates to the nucleus, where, as a 
dimer, it binds to glucocorticoid response elements (GRE) on glucocorticoid-responsive 
genes, resulting in increased transcription of genes coding for anti-inflammatory proteins. 
In contrast, nGREs may decrease transcription, resulting in decreased mRNA and protein 
synthesis. Glucocorticoids inhibit the expression of multiple inflammatory genes through a 
direct inhibitory interaction between activated GRs and activated transcription factors, 
such as nuclear factor-kappa B and activator protein-1, which regulate the inflammatory 
gene expression. (From reference 136). COX-2, inducible cyclooxygenase; iNOS, inducible 
nitric oxide synthase. 
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an active metabolite which causes inhibition of iNOS in in-vitro experiments in human 
primary airway epithelial cells. A randomised, double blind, PBO crossover trial 
involving an oral form of this drug, decreased exhaled breathe NO levels to less than 2 
ppb in both groups within 15 minutes, representing greater than 90% inhibition of 
baseline levels of NO in asthmatics, with no effects on lung function and no significant 
side-effects. This suggests the potential use of iNOS inhibitors to treat a range of 
inflammatory clinical disorders including severe asthma (219). Further, new classes of 
drugs that can activate HDACs may be identified in the future. 
In this study, the level of HDAC activity was measured in isolated granulocytes. 
Specifically isolating neutrophils further from eosinophils would have allowed the 
difference in HDAC activity in these individual cell populations to be studied. It would 
be interesting to look at HDAC levels in asthmatic patients having exacerbations. This 
would be easier to do in blood samples rather than performing bronchoscopy. In addition, 
the level of oxidative stress in patients with severe steroid dependent asthma compared 
with milder asthmatics and normal subjects would be interesting to study. Repeating 
HDAC measurements in the blood study with more patient numbers in each of the mild 
and severe groups would increase the reliability of the results. In addition, the results 
would be more meaningful by ensuring that all patients were compliant with prednisolone 
therapy, by ensuring that serum prednisolone levels were available for all patients. 
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Chapter 5 
A study of the immediate effects of inhaled Fluticasone Propionate on lung 
function and neutrophil and cosinophil activation in patients with stable mild and 
moderately severe asthma. 
5.1 Introduction 
Inhaled corticosteroids are the most effective treatment available for the 
management of chronic asthma, and have been shown to improve airway 
hyperresponsiveness and lead to improved asthma control. Several studies have shown 
an improvement in asthma symptom scores, FEV I and PC20 measurements, reduction in 
sputum eosinophil counts and NO levels following treatment with ICS. 
Lemerre et al (128) demonstrated a reduction in blood eosinophils and serum 
ECP occuring after budesonide inhalation and in addition, Inoue et al (123) showed that 
ICS resulted in a significant decrease in the mean levels of sputum supernatant IL-8 and 
GM-CSF, suggesting that the improvement in lung function and airway inflammation 
may, in part, be due to the inhibition of the synthesis of inflammatory cytokines such as 
IL-8 and GM-CSF. ICS however, have not been shown in studies to reduce the number 
of sputum neutrophils, and it is known that there is a subgroup of asthmatics with 
predominantly airway neutrophilia who repond less well to ICS (130). ICS have been 
shown to produce early improvements in lung function and reduction in eosinophil 
counts within a few hours of their administration, indicating a rapid onset of effect, 
possibly through non-transcriptional mechanisms such as interference with cytokine 
release. 
5.2 Aims of study 
The objectives of this study were to examine the early effects of a single dose of 
inhaled fluticasone propionate (FP, Flixotide Accuhaler) in patients with mild asthma 
and moderately severe asthma, and to monitor changes in (1) lung function-FEV1 (L), 
ý(2) bronchial responsiveness: 
PC20 methacholine, (3) inflammatory markers in exhaled 
NO, (4) eosinophil and neutrophil counts, (5) serum IL-8 levels, and (6) IL-8 and IL-5 
levels in induced sputurn. 
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In particular, the early effects of ICS on peripheral blood neutrophil and eosinophil 
numbers, as well as any early effects on cytokine production were studied. 
5.3 Methods 
5.3.1 Study design 
This was a single centre study supported in part by Glaxo Wellcome 
Pharmaceutical Company. The study was approved by the Ethics committee of the 
Royal Brompton and Harefield NFIS Trust, and the National Heart and Lung Institute. 
The study was a double-blind, randomised, PBO controlled, cross-over trial involving 3 
separate days, separated by at least I week. 
5.3.2 Patients 
The study required 12 mild and 12 moderate patients to be recruited. However, 
12 patients with mild asthma and 9 patients with moderately severe asthma were 
recruited from outpatient clinics and by advertisement, in the time available. Patients 
(age 18-60 years) with mild asthma were on Step I or 2 of the asthma guidelines with 
normal lung function (FEVI>75%), while those with moderately-severe asthma 
required treatment equivalent to steps 3 and 4 of the asthma guidelines in order to 
maintain control of their symptoms, (Table 5.1). All patients showed evidence of 
reversibility following beta-2 agonist administration, and had stable asthma for 6 weeks 
prior to entering the trial. Patients on maintenance oral corticosteroid therapy or those 
requiring oral corticosteroids within the previous 6 weeks were excluded, as well as 
patients with significant other medical disease. Characteristics of the individual mild 
and moderate asthmatics are shown in tables 5.2 and 5.3 respectively. 
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Table 5.1 Patient characteristics for fluticasone stj1d Ly 
Mild asthma (n= 12) 
Age mean 35.8 +/- 2.9 years 
(range 23-52 ) 
Sex: 3 male/ 9 female 
FEV I (L)- mean 3.03 +/- 0.1 
FVC (L)- mean 3.79 +/- 0.2 
PC20 (Mg/Ml)- mean 1.31+/- 0.27 
NO (nitric oxide [ppb])- mean 26.6 
Mean dose BDP or equivalent 
471.8 +/- 56.5[tg/day 
Short acting P2 agonist alone, n=5 
Moderate asthma (n=9) 
Age mean 43.7 +/- 5.2 years 
(range 19-61) 
5 male/4 female 
FEV I (L)- mean 3.05 +/- 0.32 
FVC (L) - 4.03 +/- 0.35 
PC20 (Mg/Ml)- mean 1.32 +/- 0.31 
NO (nitric oxide [ppb])- mean 26.3 
Mean dose BDP or equivalent 
1000 +/- 145.3ýtg/day 
Long acting P2 agonist, n=4 
BDP-beclomethasone dipropionate 
ppb-parts per billion 
Results-mean+/-SEM 
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5.3.2 Fluticasone administration 
Two doses of FP and PBO were administered on separate days: 500ýLg and 
2000ýtg FP from an accuhaler. A single inhalation of each drug was given in the morning 
(8am) and the patients were observed hourly for 8 hours and then again at 24 hours. 
Patients already taking ICS were asked not take these for 48 hours prior to arrival at the 
laboratory. The use of rescue medication was prohibited within 6-8 hours of the study. 
The use of long-acting beta-agonists was prohibited for 48 hours prior to the start of the 
study. Leukotriene receptor antagonists were withheld for 24 hours. 
5.3.4 Protocol and measurements 
Lung function was measured regularly during the day using a vitalograph as described in 
section 2.1.4, and the best of 3 successive measurements recorded. 
PC20 methacholine was measured at baseline, at 6 hours and at 24 hours at each of the 3 
visits. After initial lung function measurement (FEVI), patients were asked to inhale 5 
breathes of 0.9% sodium chloride solution (control diluent), followed by repeat 
measurements of FEVI (section 2.1.5). Then increasing doubling concentrations of 
methacholine were inhaled every 5 minutes, and FEV I measured after each dose. The test 
was stopped when more than 20% fall in FEVI occurred. The PC20 is the concentration 
of methacholine needed to cause a 20% fall in FEVI measured after initial saline 
inhalation. The study protocol required measurement Of PC20 at baseline at initial 
screening for entry into the trial, but did not include measuring PC20 at time '0' at the start 
of the trial. Thus the PC20 measurements in the graphs at baseline were the same in each 
group (figs 5.5 and 5.6), but PC20 measurements were different at 6 and 24 hours in each 
group. 
NO was measured in exhaled air using a chemiluminescence machine as previously 
described in section 2.1.6. 
Blood was sampled through an indwelling cannula in a forearm vein of each subject at 
0,1,2,3,5,6,8 hours after inhalation of FP. Blood eosinophil count and neutrophil counts 
were measured in the laboratory at the Royal Brompton hospital using a haemocytometer. 
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In addition, whole blood was cultured at 1,4 and 24 hours to measure spontaneous and 
IL- IP induced release of the proinflammatory cytokine IL-8. 
Induced sputum was performed before and at 6 hours after inhaled therapy. 
Supernatant was assayed for IL-5, IL-8. The method for collecting and processing 
induced sputum was as described in section 2.2. 
ELISA: IL-8 and IL-5 levels were measured using Duoset ELISA kits purchased 
from R&D systems, Abingdon, Oxon, UK. The lower limit for detection was 31.25pg/ml 
for IL-8, and 15.65pg/ml for IL-5. The standards for IL-8 and IL-5 were prepared as 
recommended by the manufacturer, but when assaying sputum supernatant, 0.05% DTT 
was added to the reagent diluent in order to allow for the possible effect of the DTT on 
cytokine levels during processing of the sputum. 
5.4 Results 
5.4.1 Lungfunction 
No significant difference was seen in FEV I or FVC in mild patients over 24 hours 
following high or low dose inhaled FP, compared to PBO (figs. 5.1 and 5.2). In the 
moderate group however, an increase in FEV I was seen at 8 and 24 hours compared with 
time point '0' with high dose FP (p< 0.01, fig. 5.3), and an increase in FEVI at 8 hours 
compared with time point '0' with low dose FP (p< 0.05, fig 5.3). However, these were 
not significant when compared with PBO results at each time point. An increase in FVC 
(p= 0.01) was seen in moderate asthmatics at 24 hours with low dose inhaled FP 
compared to baseline (fig. 5.4), but this was not significant when compared to PBO at the 
same time point. 
5.4.2 Bronchial hyperreactivity 
In mild and moderate patients, PC20 was not significantly increased over 24 hours with 
highor low dose FP compared to baseline levels, or when compared with the PBO group 
(figs. 5.5 and 5-6). In the moderate group, all patients had PC20 measured at baseline, but 
during the trial, the FEVI of 3 patients fell below 65% predicted, and therefore these 
patients did not have further measurements of bronchial hyperreactivity. The number of 
moderate patients who completed PC20 measurements was therefore six. 
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Fig. 5.1 Effect of high and low dose inhaled FP and PBO on FEV1 in mild asthmatics. No 
significant effect of ICS was seenon FEVI in mild asthmatics, n=12. 
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Fig. 5.2 Effect of high and low dose FP and PBO on FVC in mild asthmatics. No significant 
effect of ICS was seen. N=12. 
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Fig. 5.3 Effect of high and low dose FP and PBO on FEV1 in moderate patients. Both doses 
increased FEVI at 8 hours (and at 24 hours in the high dose FP group) compared to time=O, 
but this was not significant compared to PBO. n=9. 
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Fig. 5.4 Effect of high and low dose FP and PBO on FVC in moderate patients. Low dose 
FP increased FVC in moderate patients at 24 hours, (*p = 0.01), but this was not significant 
when compared to PBO. 
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Fig. 5.5 Effect of high and low dose inhaled FP and PBO on PC20 (Mg/MI) in mild patients. 
No significant effect was seen. Baseline was done at screening visit and not at start of the 
study (see methodology). N=11. 
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Fig. 5.6 Effect of high and low dose inhaled FP and PBO On PC20 (Mg/Ml) in moderate 
patients. No significant effect was seen. Baseline was done at screening-see methodology. 
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5.4.3 Exhaled Nitric oxide 
In the mild asthma group, high dose FP consistently reduced exhaled NO levels after 3 
hours onwards, compared to the first 3 time points. Low dose FP reduced NO levels at 24 
hours, compared to preceding time points. However, NO levels were also reduced in the 
PBO group at 3,6 and 8 hours compared to baseline. Comparisons between the treatment 
groups showed that NO levels were significantly higher at 2 hours with low dose FP than 
high dose FP but not PBO. At 24 hours however, exhaled NO levels were significantly 
lower in mild asthmatics taking high dose FP group than compared to PBO (figs. 5.7 and 
5.8). In the moderate group, high dose FP decreased exhaled NO levels at 8 hours but this 
was not significant when compared to placebo. Low dose FP reduced NO consistently 
after the first hour compared with baseline, but this was significant against PBO only at 4 
hours. PBO did not reduce NO levels. Both high and low dose FP reduced NO levels 
significantly when compared to PBO, at 4 hours. 
5.4.4 Peripheral blood eosinophil and neutrophil counts 
High dose FP had no effect on eosinophil counts in mild or severe asthmatics. In 
mild asthmatics, only low dose FP resulted in a significant decrease in eosinophil count 
four hours post inhalation (p=0.01) compared with baseline, but this was not significant 
compared with PBO at the same time point. No reduction in eosinophil count was seen in 
moderate asthmatics with high or low FP (figs. 5.9,5.10). In the mild group, there was no 
significant effect on neutrophil count with high dose FP, but this dose did increase 
neutrophil counts at 8 hours in moderate asthmatics, though this was not significant when 
compared to PBO. Low dose FP led to a non-significant increase in neutrophil count after 
3 hours in mild asthmatics, and this dose had no significant effect in moderate asthmatics 
(fig. 5.11,5.12). Low dose FP increased neutrophil counts in mild asthmatics at 8 hours 
compared to PBO. Neutrophil counts were higher in moderate asthmatics receiving high 
dose FP in compared with PBO at I hour (p<0.05). 
5.4.5 Serum IL-8 levels 
Serum IL-8 levels were increased after whole blood incubation with IL- IP in mild 
patients receiving PBO at 4 hours, in moderate patients receiving PBO at I hour, and 
moderate asthmatics receiving high dose FP at 4 hours. A significant difference was seen 
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in baseline serum IL-8 levels in mild asthmatics receiving high dose FP, with lower levels 
of IL-8 seen in the blood cultured with IL-lP compared with serum IL-8 levels in blood 
which had not been cultured with IL-1P. The levels of baseline IL-8 seen in this group 
however were not statistically significant compared with PBO, and the significance of 
this effect is unclear. There was no significant difference in the effect of high or low dose 
FP treatment groups on IL-8 levels in mild asthmatics compared with PBO (figs. 5.13 and 
5.14). FP, at either dose, had little effect on reducing IL-8 levels in moderate patients, 
except at I hour, when IL-8 levels were significantly reduced with high dose FP 
compared with PBO. 
5.4.6 Sputum cytokine levels 
At baseline, sputum IL-8 levels in moderate asthmatics were higher than in mild 
asthmatics (fig. 5.15, p=0.01). There was no effect of high or low dose FP on IL-8 levels 
at 6 or 24 hours in either group compared with PBO (figs. 5.16 and 5.17). IL-5 levels 
were not detectable in sputum supernatants from mild or moderate asthmatics. 
5.4.7 Sputum neutrophil and eosinophil counts 
It was not possible to arrive at any meaningful conclusion on the effect of ICS on 
neutrophil and eosinophil counts as many patients were unable to produce adequate 
sputum samples for sputum slide analysis. 
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Fig. 5.7 Effect of high and low dose FP and PBO on NO levels in mild patients. High dose 
FP significantly reduced NO against PBO at 24 hours. (*p<0.05 as shown). 
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Fig. 5.8 Effect of high and low dose inhaled FP and PBO on exhaled NO in moderate 
patients. High and low dose FP reduced NO levels compared to PBO at 4 hours only. 
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Fig. 5.9 Effect of high and low dose inhaled FP and PBO on eosinophil count in mild 
asthmatics. No effect of either dose of FP on eosinophil count compared with PBO, in mild 
asthma. 
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Fig. 5.10 Effect of high and low dose inhaled FP and PBO on eosinophil counts in moderate 
asthmatics. No significant effect on eosinophil count compared with PBO. 
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Fig. 5.11 Effect of high and low dose inhaled FP on neutrophil count in mild asthmatics. 
* p<0.04 compared with time 0. Low dose FP increased neutrophil counts at 8 hours 
compared to PBO. 
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Fig. 5.13 Effect of high and low dose inhaled FP and PBO on serum IL-8 levels in mild 
patients. Time: b=baseline, 1,4,24 hrs whole blood incubation, += with IL-IP, -= without 
IL-1P. No significant effect of FP compared with PBO. N=8. 
166 
b+ b- 1+ 1- 4+ 4- 24+ 24- 
TIME-hours 
b+ b- 1+ 1- 4+ 4- 24+ 24- 
TIME-hours 
b+ b- 1+ 1- 4+ 4- 24+ 24- 
TIME-hours 
serum 11-8 in moderate patients-high dose FP IL8 pg/ml 
600- 
500- 
400- 
300- 
200- 
10 0- 
1 
Serum 11-8 in moderate patients-low dose FP 
IL8 pg/ml 
600- 
500- 
400- 
300- 
200- 
100- 
0- 
b+ b- 1+ 1- 4+ 4- 24+ 24- 
TIME HOURS 
serum IL-8 in moderate patients-PBO 
IL8 pg/ml 
600- 
500- 
400- 
300- 
200- 
100- 
knom\ý, 0- b+ b- 1+ 1- 4+ 4- 24+ 24- 
TIME HOURS 
Fig. 5.14 Effect of high and low dose inhaled FP and PBO on serum IL-8 levels. Time: 
b=baseline, 1,4,24 hrs whole blood incubation, += with IL-1P, -= without IL-1P. High dose 
FP reduced IL-8 levels at 1 hour compared with PBO (*p<0.05). n=7. 
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Fig. 5.15 Baseline expression of IL-8 in sputum supernatant in mild and moderate 
asthmatics. IL-8 levels were higher in moderate asthmatics compared to mild asthmatics. 
N=9 mild, and 6 moderate patients. 
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Fig. 5.16 Effect of high and low dose inhaled FP and PBO on IL-8 levels in sputum 
supernatant in mild asthmatics. No significant effect of FP was seen at either dose compared 
with PBO. N=9- 
169 
base 6 24 
base 6 24 
base 6 24 
IL8 pg/ml 
1500- 
1250- 
1000- 
750- 
500- 
250- 
0-- 
IL8 in sputum supernatant in 
moderate patients-high dose 
dose FP 
IL8 in sputum supernatant in 
IL8 pg/ml 
moderate patients-loe dose FP 
1500 
1250- 
1000- 
750- 
500- 
250 ] 
0 
IL8 pg/ml 
1500 
1250- 
1000- 
750- 
500- 
250- 
0-- 
IL8 in sputum supernatant in 
moderate patients-PBO 
Fig. 5.17 Effect of high and low dose inhaled FP and PBO on IL-8 levels in sputum 
supernatant in moderate asthmatics. No significant effect of FP was seen at either dose 
compared with PBO. N=7. 
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5.5 Discussion 
Previous studies have shown that regular use of ICS is effective in improving lung 
function and markers of airway inflammation in patients with mild asthma. However, 
although bronchial hyperreactivity was shown to decrease in several studies, many 
studies did not show an improvement in lung function (117,12 1). No effect of high or low 
dose FP was seen in mild asthmatics, and although a trend towards an increase in FEVI 
was seen in moderate asthmatics with both high and low dose FP at 8 hours, this was not 
significant when compared with PBO. There was a significant increase in FVC in 
moderate asthmatics at 24 hours with low dose FP only, but this was not significant when 
compared with PBO. That this occurred with a low dose of FP suggests that low dose FP 
can result in improvements in airway inflammation and lung function, and no additional 
benefit is gained by increasing the dose (118). There was no effect on bronchial 
hyperreactivity with either dose of FP in mild or moderate asthmatics. 
There was a trend for both high and low dose FP to reduce exhaled NO levels in 
mild asthmatics from baseline values, but at most time points, this was not statistically 
significant when compared with PBO. Exhaled NO was significantly reduced however at 
24 hours in mild asthmatics with high dose FP compared with PBO (p<0.05). In moderate 
asthmatics, both high and low dose FP significantly reduced NO levels at 4 hours only, 
compared with PBO. Although regular use of ICS has been shown in studies to reduce 
NO levels at reasonably high levels (for example, budesonide 800[tg bd) after a few 
weeks therapy, consistent reduction is not seen in this study after a single inhalation of 
low or high dose inhaled FP, suggesting that regular maintenance treatment is capable of 
inhibiting the induction of NO synthase in the respiratory tract, rather than a single dose. 
Low and high dose inhaled FP had no significant effect on eosinophil counts in 
mild or moderate patients. In mild asthmatics, high dose FP had no effect on neutrophil 
counts, but low dose FP resulted in a higher neutrophil counts after 3 hours compared to 
baseline values, but this was only significant compared to PBO at 8 hours. It is not clear 
why low dose, but not high dose FP had this effect on neutrophil counts. In the moderate 
group, a trend towards a higher neutrophil count was seen at 8 hours after 
high dose FP, 
although this was not statitistically significant when compared with PBO. The 
increase in 
neutrophil numbers seen in this study after a single dose of low or 
high dose inhaled FP is 
difficult to explain, unless in terms of rapid mobilisation of cells from the bone marrow 
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or dernargination of neutrophils, or response to an unknown antigen in the inhaler powder 
vehicle. 
This effect of inhaled FP in causing a peripheral blood neutrophilia is interesting 
in that Gizycki et al demonstrated that endobronchial biopsies in patients with mild to 
moderate COPD receiving high dose inhaled FP unexpectedly showed significantly more 
neutrophils than in the PBO group (220). Further, inhaled FP and budesonide have been 
shown to prolong human neutrophil survival by inhibiting apoptosis at clinically relevant 
drug concentrations (221). This effect of ICS to mobilise neutrophils into bronchial 
airways and to prolong their survival may be important in maintaining both beneficial and 
harmful effects of neutrophils in airway tissue through the continued release of 
inflammatory mediators. In contrast, Vagaggini et al (222) showed that in induced 
sputum, moderate doses of inhaled budesonide given for 4 weeks was able to reduce the 
increase in the percentage of sputum neutrophils and IL-8 concentrations in sputum 
supernatants in response to ozone exposure. 
Serum IL-8 levels were increased after whole blood incubation with IL- 10 in mild 
patients receiving PBO at 4 hours, and in moderate patients receiving PBO at I hour. 
Serum IL-8 levels in mild and moderate patients were otherwise not significantly 
increased after incubation of whole blood with IL- I P, 1 Ong/ml. Serum IL-8 levels in mild 
and moderate asthmatics in each treatment group were higher after 24 hour incubation, 
with or without IL- I P. No effect of high or low dose FP was seen on serum IL-8 levels in 
mild patients over 24 hours, compared with PBO. In moderate asthmatics, whole blood 
culture with IL- IP resulted in higher levels of IL-8 at 4 hours compared to levels without 
IL- IP incubation, in the group receiving high dose FP. In moderate asthmatics, high dose 
FP significantly reduced serum IL-8 levels (after incubation with IL-IP) at one hour 
compared with PBO. The number of mild patients for whom IL-8 results were available 
was 8, compared with 7 moderate patients. The curves for the diluted IL-8 standards were 
satisfactory in all IL-8 ELISA experiments, but no results were recorded for some 
patients, suggesting that the sample preparation or technique may have been suboptimal. 
Repeating the experiment may have given more reproducible results. 
The relative lack of effect of high and low dose FP on serum IL-8 levels may be 
due to the fact that a single dose of FP may be insufficient to significantly alter serum 
cytokine levels. However, it is difficult to determine if either dose is having an effect on 
serum IL-8 levels, as culture with IL- IP may have some bearing on the 
final IL-8 levels. 
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That ICS may not have any effect on circulating cytokines was shown in a study carried 
out in asthmatic children by Visser et al showed that no significant effect of prolonged 
treatment with high dose inhaled FP was seen on the release of IL-4, IL-5, IL-10 and 
IFN-y by Con A stimulated PBMCs (223). Also in that study, serum IL-4 and IL-5 levels 
were undetectable in the majority of children. In contrast, Morali et al were able to show 
that inhaled budesonide (800ýtg/day) given for 4 weeks in adult mild to moderate 
asthmatics significantly reduced serum IL-5 levels, suggesting that this may be one 
possible mechanism of the anti -inflammatory action of ICS (224). 
In sputum supernatant, IL-8 levels were significantly higher in the moderate 
group compared to mild asthmatics, but in addition, measuring IL-8 levels in a non 
asthmatic control group would have been interesting for comparison. There was no effect 
of high or low dose FP on sputum IL-8 levels in mild or moderate asthmatics over 24 
hours, compared with PBO. It has been shown however, that a prolonged course of ICS 
can reduce IL-8 and GM-CSF concentrations in sputum supernatant (123). In the current 
study, IL-5 levels were undetectable in sputum supernatant samples. The measurement of 
IL-5 in sputum in several studies has produced variable results, and one explanation is 
that there may be substances in the sputum that interfere with the recognition of IL-5 
epitopes by immunoassay, such as sputum proteases, or autoantibodies. The use of DTT 
for sputum homogenisation is known to cause a significant fall in the amount of sputum 
eosinophil peroxidase and MPO (225), but this is not thought to be the case with sputum 
IL-5 levels (226). Simpson et al (227) showed that the addition of a protease inhibitor to 
sputum processed with DTT significantly increased the amount of IL-5 recovery from 
sputum samples spiked with recombinant human IL-5. This has been confirmed by other 
workers (228), and thus suggests that a protease inhibitor should be added to processed 
sputum before regarding a sample as being negative for IL-5. 
Problems encountered with this study included recruitment of patients, as each 
subject had to be available for approximately one and a 
half days per week for 3 
consecutive weeks, which is not always convenient. 
The study protocol required that 12 
asthmatics in each group were recruited, but only 
9 moderate asthmatics were recruited. 
Increased patient numbers in each group would increase the power of the study, and a 
more prolonged course of inhaled FP (for example, twice 
daily for a week) may have 
resulted in a more marked change in the measured parameters. 
Wood et al (229) showed 
that an eight day course of inhaled budesonide was sufficient 
to demonstrate a systemic 
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effect in inhibiting the turnover of bone marrow derived eosinophil progenitors, although 
this inhibitory effect was overcome by inhalation of allergen. Although patients in the 
moderate group required a higher dose of ICS, and in some cases a long acting beta-2 
agonist to maintain symptom control, the baseline spirometry and NO values were not 
significantly different compared to milder asthmatics. Sputum slides were, in many cases, 
difficult to read as patients were unable to produce adequate sputum samples and 
therefore it was not possible to look at effects of FP on sputum eosinophil or neutrophil 
counts. Taking into account recent advances in sputum processing techniques, the 
addition of a protease inhibitor may provide different results with respect to IL-5 levels. 
A more useful study may have been to look at markers of neutrophil function after 
one week of inhaled high dose and low dose FP, as the present study was designed to 
look at the immediate effects of a single dose of inhaled FP. FACS analysis of neutrophil 
surface markers in blood samples would also be interesting to look at the effects of ICS 
on neutrophil activation markers. Using a longer course of inhaled FP may have detected 
any effect of inhaled FP on sputum supernatant IL-8 levels. The study protocol required 
that PC20 was measured at the initial screening visit, and thus the baseline levels Of PC20 
were the same in each group at the start of the study. It would have been better to 
measure PC20 in each group at time '0' to allow better comparison of treatment effect on 
PC20 at 6 and 24 hours against this value. Further, the trial was not designed to see if PC20 
was improved before 6 hours. However, further measurements of bronchial 
hyperresponsiveness within each 24 hour period would have been too demanding for 
patients. Repeat sputum analysis for IL-5 using the current knowledge of the effect of 
DTT on IL-5 recovery may provide positive results. 
The effect of ICS on neutrophil number and function in severe corticosteroid- 
dependent asthmatics would be difficult to investigate given the need for high dose 
inhaled steroids in this population, and also the possible confounding contribution of 
concomitant oral steroid therapy on peripheral neutrophil numbers. Further, ICS may not 
be beneficial in patients with severe asthma, especially those who who go on to develop 
relatively fixed airflow obstruction. Tsoumakidou et al (230) showed that patients with 
COPD and severe persistent asthma with fixed airflow limitation had similar numbers of 
neutrophils in their sputum, suggesting that a similar lack of response to ICS 
in severe 
asthmatics, as occurs in COPD, may be expected. 
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Chapter 6 
Role of anti-IgE therapy in poorly controlled moderate to severe allergic asthma 
6.1 Introduction 
In atopic asthmatics, exposure to specific allergen can result in increased airway 
responsiveness with subsequent exacerbation of asthma symptoms through IgE mediated 
pathways. It has also been shown that non atopic or 'intrinsic' asthmatics also produce 
IgE in their airways, suggesting that IgE may also play a role in these patients. IgE 
therapy represents a new therapeutic approach for the treatment of allergic disease, and 
has been shown in initial studies to reduce asthma symptom scores and improve quality 
of life, as well as reduce oral and ICS requirements and the need for rescue inhaled 
bronchodilators. They have also been shown to reduce the number of exacerbations and 
have been shown to be safe with no reports of any significant side effects. IgE therapy is 
therefore useful as a steroid sparing agent. IgE therapy can be given intravenously or by 
subcutaneous injection, although frequent i. v. injections may not be acceptable to some 
patients. The efficacy of a long term subcutaneous form of therapy is unknown. 
More recently, Gounni et al showed that peripheral blood and BAL neutrophils 
from asthmatics expressed the high affinity IgE receptor, FcF'Rl, which is the main 
receptor involved in binding IgE molecules to the surface of mediator cells. Further, 
activation of these FcFR1 receptors induced the release of IL-8 by neutrophils (169). 
These studies suggest that neutrophils may play a role in allergic inflammation through 
an IgE-dependent activation mechanism. In the context of severe allergic asthma, this is 
important as increased numbers of neutrophils have been demonstrated in sputum and 
bronchial biopsy samples in patients with severe corticosteroid-dependent asthma. 
6.1.1 Aim of study 
The aim of this study was to evaluate the efficacy and tolerability of subcutaneous 
administration of rhuMab-E25 in subjects with moderate persistent to severe persistent 
allergic asthma over period of I year. All previous studies had involved administering 
this therapy through intravenous injections. In addition, the effect of rhuMab-E25 on 
175 
surface activation molecules on cells thought to be important in the allergic inflammatory 
cascade was carried out. 
6.2 Methods and study protocols 
6.2.1 Protocol IA 04 
Protocol IA04 at the Brompton hospital was part of an international multicenter, 
randomized, open label, controlled study to evaluate efficacy, tolerability, and 
effectiveness of subcutaneous administration of rhuMab-E25 (Omalizumab) in subjects 
with moderate persistent to severe persistent allergic asthma over aI year period. The 
trial was sponsored by Novartis Pharmaceuticals Corporation. Patients were randomized 
to receive rhuMAb-E25 on top of their current asthma treatment (according to the best 
medical practice), compared to patients receiving their current asthma treatment alone. Its 
aim was to see if there was benefit of Omalizumab in a setting more representative of real 
life clinical practice. This was a multicentre study in 5 European countries: France (10 
centres), Spain (7 centres), Germany (9 centres), Switzerland (3 centres), and the United 
Kingdom (20 centres). Although the quality and access to healthcare may vary from one 
country to another, entry criteria to the IA04 study required all randomized patients to 
have had their asthma therapy optimized according to U. S. NHLBI treatment guidelines 
irrespective of country. 
Inclusion criteria were as follows: 
0 Males and females between 12 and 75 years of age 
Asthma for -2! 2 years 
1 emergency visit and I course of oral corticosteroids in the last year 
Positive skin test to common aero-allergens 
" Total serum IgE between 30-700 IU/ml 
" Reversibility of ý: 12% improvement in FEV I 
" Inhaled corticosteroid dose of at least 800[tg beclomethasone (BDP) equivalent for 
adults and 400ýtg BDP equivalent for children. 
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Exclusion criteria were as follows: 
Pregnant, nursing mothers or planning to become pregnant 
Previous treatment with E25 or known to be hypersensitive to any of its components 
or other drugs used in this trial 
Active lung disease other than asthma 
Elevated IgE levels for reasons other than atopy 
Smoking history ý! 10 pack years 
Clinically significant condition that may compromise the subject's safety 
Treatment with depot corticosteroids or investigational product within 30 days of 
starting the trial 
Ongoing desensitization immunotherapy 
Any factor that may limit the subjects ability to co-operate 
6.2.1.1 Methods 
Patients were recruited by advertisement and from outpatient clinics from the 
Royal Brompton Hospital. All patients gave written informed consent (or parents/legal 
guardians if subject < 18 years of age) and the study had approval from the Hospital's 
Ethics committee. All patients underwent a screening period in which all 
inclusion/exclusion criteria were met. 
Skin prick test was carried out as described in section 2.1.3. 
Total/free IgE was done at screening (Visit 1). 
Spirometry was carried out at every 3 monthly visits and at the end of the study, as 
described in section 2.1.4. 
Asthma reversibility testing was carried out at screening (Visit 1) as described in section 
2.1.5. The reversibilty of bronchoconstriction was demonstrated by an increase in FEVI 
of more than 12% from baseline, within 30 minutes after inhalation of up to 4 puffs 
(I 00ýtg/puff) or nebulization (2.5mg) of salbutamol. 
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Clinical symptom score was recorded at each scheduled physician visit during the trial 
core period using asthma and rhinoconjuntivitis symptom score questionnaire, developed 
and validated by Wasserfallen. A quality of life questionnaire was completed at each visit 
during the trial core period using the self-administered Mini Asthma Quality of Life 
Questionnaire was completed at each visit. Review of concomitant medication and 
adverse experiences was carried out at each scheduled visit. The dose of rhuMAb-E25 
was determined according to patient's body weight and total serum IgE level from a 
dosing table. 
Characteristics of patients who took part in this trial are given in Table 6.1. Details of the 
control patients and asthmatics who received anti-IgE therapy are given in appendix 4.2 
(page 258), and appendix 4.3 (page 259) respectively. 
6.2.2 Protocol 11 extension substudy 
II extension substudy was a separate open label study for patients who had 
previously completed the rhuMab E25 01 011 study. It was conducted in II of the 15 
countries which had previously participated in the rhuMab E25 01 Ol I trial. All patients 
received subcutaneous rhuMab E25 treatment every 2 or 4 weeks based on their baseline 
IgE level and current body weight for 2 years. Assessments included safety, spirometry, 
steroid use, assessment of asthma control and rescue utilization, and were carried out 
approximately every 3 months, with some additional assessments in the first month of the 
study and a6 and 12 week follow up following the last treatment. 
The primary objective was to assess safety and tolerability of long term 
subcutaneous rhuMab E25 treatment in a more natural clinical setting. The secondary 
objective of the study was to investigate the effects of long term rhuMab E25 treatment 
on bronchial inflammation in adult patients with severe asthma, by analysis of cell 
surface markers in blood samples over the course of the year. This was compared with a 
control asthmatic population who did not receive trial treatment. Blood was analyzed 
with flow cytometry for changes in cell profile and surface markers, including the low- 
affinity IgE receptor, and the Fas receptor, CD95. CD95 is a cell surface glycoprotein 
(MW 40-50 KDa) that was initially identified by 2 apoptosis inducing antibodies, anti- 
APO-1, and anti-FAS. It is expressed in a minority of resting T and B-cells and 
monocytes, and appears to be a cell surface apoptosis signalling molecule. It has been 
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postulated that CD95 plays a role in T-cell mediated cytotoxicity and possibly in the 
normal apoptotic process that occurs during T-cell and monocyte development. CCR3 is 
a chemokine receptor, and is a member of the G-protein coupled, seven-transmembrane 
receptor family. It is expressed on eosinophils, basophils, and monocyte derived dendritic 
cells, and acts as a receptor for several different chemokines including eotaxin and 
RANTES, which are involved in the allergic response and in stimulating migration of 
eosinophils. 
Inclusion criteria 
m Males and females between 12 and 75 years of age 
s Chronic severe asthma for ý! I year 
s Positive skin test to at least I common aeroallergen, or positive RAST test if 
borderline 
Total serum IgE between 30-700 IU/ml 
Reversibility of ý! 12% improvement in FEV I 
0 Inhaled corticosteroid dose of at least ý! 1000[tg inhaled FP or equivalent for adults 
and; ý! 500ýtg FP or equivalent for children. 
0 Use of maintenance oral corticosteroids allowed, up to a maximum dose of 20mg/day, 
and maximum of 5 years duration. 
0 No change in concomitant medication for 4 weeks prior to entry into the study. 
Exclusion criteria 
Pregnant, nursing mothers or planning to become pregnant 
Patients treated with an experimental or investigational drug within 30 days prior to 
starting the study. 
Patients with a history of noncompliance or who are considered potentially unreliable. 
In total, 10 patients were recruited into the II extension substudy and received 
rhuMAb-E25, whilst, a control population of adults with severe allergic asthma who 
did 
not participate in the original protocol 
01 11 study but who met the eligibility criteria 
were recruited from outpatient clinics at the 
Royal Brompton Hospital (n=5). The 
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characteristics of these patients are shown in appendix 4.4 (page 260). All patients gave 
written informed consent and the study received ethics approval from the Royal 
Brompton Hospital's Ethics committee. 
As previously mentioned, patients with severe allergic asthma who completed the 
original phase 3 trial of rhuMAb-E25 study protocol 01 11 were included in this study. 
The protocol 01 11 study looked at the safety and corticosteroid sparing effect of 
Omalizumab in 246 patients with severe allergic asthma requiring daily treatment with 
high dose ICS (FP > 1000ýtg/day) and in whom long acting beta agonists were allowed 
(275). This was a randomized, double blind, PBO controlled trial, and included a 16 week 
steroid stable phase with study medication added, followed by a 16 week steroid 
reduction phase. The percent reduction in ICS dose at the end of the treatment phase was 
significantly greater in Omalizumab treated patients compared to PBO patients 
(p=0.003). The proportion of Omalizumab patients who were able to reduce their FP dose 
to < 500ýtg/day was 60.3%, compared to 45.8% in the PBO group (p=0.026). The 
Omalizumab group also showed less rescue medication use, improved asthma symptoms, 
and asthma related quality of life compared to PBO. 
6.2.2.1 General Methods 
Spirometry, skin testing and reversibilty testing were carried out as described in section 
2.1. 
6.2.2.2 FACS analysis 
Indirect immunofluorescence staining for measurement of FcF-Rl receptors on basophils 
and monocytes, and direct immunofluorescence on lysed whole blood samples were 
carried out as described in 2.2.3.6,2.2.3.7, and 2.2.3.8. 
6.2.2.3 Sputum analysis 
Sputum from patients was processed at baseline, and at 6 months and 12 months, as 
described in section 2.2.1. 
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Table 6.1 Characteristics of patients in IA04 study. 
ý 
Male/female 
Age years (mean) 
Age (range) 
FEV I (L) (mean) 
RhuMAb-E25 group Control group 
54 
IM/4F IM/3F 
59.4 +/- 3.17 35.5 +/- 10.2 
52-68 years 18-65 years 
1.42+/- 0.17 2.0+/-0.57 
Results expressed as mean +/- SEM. 
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6.3 Results 
6.3.1 IA04 study 
6.3.1.1 Lungfunction 
There was a significant increase in FEV I in patients treated with rhuMAb-E25, at visits 3 
and 5 compared to visit 2 (fig. 6.1), but the FEV I readings were not significant when 
compared with the control group. No increase in FEVI was seen in the control group 
from visit I through to visit 7. 
6.3.1.2 Quality of life 
There was no significant effect on quality of life scores in the rhuMAb-E25 treated 
asthmatics, during the course of the treatment compared to the start of the trial. The 
asthmatics who received rhuMAb-E25 however, showed a significant improvement in 
quality of life scores at visit 6 compared with the control group (p=0.03, fig. 6.2). 
6.3.1.3 Clinical symptom score 
At the start of the trial (visit 2), clinical symptom scores were significantly higher in 
treatment group compared to the control group (p=0.03), suggesting that the patients in 
the treatment group were more symptomatic. Treatment with anti-IgE therapy resulted in 
lower symptom scores at visit 5 compared to the end of the trial (visit 7, p=<0.05, fig. 
6.3). There was no significant change in symptom scores in the control group, and scores 
in the rhuMAb-E25 treated group were not significantly different compared to 
corresponding scores in the control group, except at visit 2. 
6.3.1.4 Peripheral blood eosinophils and neutrophils 
No significant effect of anti-IgE therapy was seen on eosinophils or neutrophil counts 
during the trial, compared to the control group (fig. 6.4). 
6.3.1.5 Inhaled corticosteroid dose 
No significant decrease in the dose of ICS was seen over I year in rhuMAb-E25 treated 
patients compared with the control group (fig. 6-5), but there was a reduction in the 
number of courses of prednisolone required during the year in patients receiving 
rhuMAb-E25, and this approached significance (p=0.06, 
fig. 6.6). 
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6.3.2 Results - Protocol 11 extension 
6.3.2.1 Fce. RI expression on basophils and monocytes and whole blood analysis 
Anti-IgE therapy significantly reduced FcFRl expression on basophils and monocytes 
over a3 month period compared to baseline levels, but not when compared to control 
subjects (fig. 6.7). No effect was seen on CD23 (low affinity IgE receptor), on CD14+ 
monocytes or CD4+ T-helper cells. No significant difference was seen in CD95 or CCR3 
expression on monocytes and eosinophils respectively after anti-IgE therapy (fig. 6.8). 
6.3.2.2 Sputum counts 
No significant difference was seen in the sputum differential counts in patients receiving 
rhu-Mab E-25 over the course of treatment. 
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FEV1 in rhuMAB-E25 treated severe FEV1 (L) asthmatics 3.5- 
3.0- p<0.05 vs. V2 
2.5- 
2.0- 
1.5- 
1.0- 
0.5 
0.01 
FEV1 (L) 
3.5- 
3.0- 
2.5- 
2.0- 
1.5- 
1.0- 
0.5- 
0.0-- 
FEV1 in control severe 
asthmatics 
Fig. 6.1 FEV1 in rhuMAb-E25 treated severe allergic asthmatics (n=5) and controls. (n=4). 
VI=screening visit. V2=randomization. V6=end of study visit. V7=flnal follow up visit. No 
significant effect on FEV1 in the treatment group compared to controls. 
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vi V2 V3 V4 V5 V6 V7 
vi V2 V3 V4 V5 V6 V7 
Effect of rhuMAb-E25 on QOL in asthmatics QOL score 
100-1 
75 
50 
25 
V2 
QOL score QOL scores in control group 
100-1 
75 
50 
25 
01 
V2 
Fig. 6.2 Quality of life scores (Juniper-Mini asthma quality of life questionnaire) in 
asthmatics treated with rhuMAb-E25 (n=5) and in control subjects (n=4). Quality of life 
score was higher in the rhuMAb-E25 treated group at visit 6 compared with controls (0 p< 
0.03). 
186 
V3 V4 V5 V6 V7 
V3 V4 V5 V6 V7 
Effect of rhuMAb-E25 on clinical symptoms in asthmatics 
CSS score 60- 
50- 
p<0.05 vs. V7 
40- 
30- 
20- 
10- 
0 
V2 V3 V4 V5 V6 V7 
clinical symptoms in control group 
CSS score 
60- 
50- 
40- 
30- 
M, 
20- 
10- 
0 
V2 V3 V4 V5 V6 V7 
Fig. 6.3 Clinical symptom scores (Wasserfallen-combined clinical symptom score) in 
rhuMAb-E25 treated asthmatics (n=5) and control subjects (n=4). Clinical symptom scores 
were higher at visit 2 compared with the control group. (0 p =0.03). 
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Eosinophil count in 
rhuMAb-E25 treated 
xlO 9/L asthmatics 
1.00- 
0.75- 
0.50- 
0.25- 
0.00-19 
Neutrophil ýcounts 
in rhuMAb-E25 
xlO 9/L 
treated asthmatics 
7.5 -1 
5.0 
2.5 
0.0 
Eosinophil count in control 
AO 9/L group 
1.5-1 
1. 
0. 
0, 
Neutrophil counts in control 
AO 9/L group 
10.0- 
7.5- 
5.0- 
2.5- 
0.0 
Fig. 6.4 Peripheral blood eosinophil and neutrophil counts in rhuNL4, b treated asthmatics 
(n=5) and control subjects (n=4). Vl=screening visit. V6=end of study visit. No significant 
difference was seen in neutrophil or eosinphil counts in either group. 
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vi V6 vi V6 
vi V6 
vi V6 
Dose of ICS in rhuMAb-E25 treated asthmatics 
Dose of ICS 
[tg BDP 
equimalent 
2200 
2000 
1800 
1600 
1400 
1200 
1000 
800 
600 
400 
200 
0 
n=5 
Dose of ICS in control group 
Dose of ICS 
pg BDP 
equivalent 
2200 
2000 
1800 
1600 
1400 
1200 
1000 
800 
600 
400 
00 
0 
r-%-A 
Fig. 6.5 Dose of ICS, (BDP ýig/day or equivalent) in rhuMAb-E25 treated asthmatics and in 
control subjects. No significant reduction in dose of ICS was seen at the end of the trial in 
rhuMAb-E25 treated asthmatics comapered with control subjects. 
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vi V7 
vi V7 
Effect of rhuMAb-E25 on number of steroid courses/year 
Nlo. of steroid 
cour yr 
II n=9 
Number of steroid courses/year in control patients 
No. of steroid 
coursestyr 
"I 
pre post 
Fig. 6.6 Number of courses of prednisolone required per year, during the year prior to 
treatment and during treatment in rhuMAb-E25 treated asthmatics and in control subjects. 
Reduction in steroid courses approached significance in rhuMAb-E25 treated asthmatics, 
but this was not significant compared with the control group. 
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FceRl expression on basophils during E-25 therapy 
E 
Fc6RI expression on monocytes during E-25 theral 
125-1 n=7 
1 
E 
Visit I Visit 2 
FcseRl expression on basoph ils -control group 
250-1 n=5 
200 
150 
100 
50 
0 
FcsR1 expression on monocytes -control group 
125-1 n=5 
1 
'I- 
E 
Fig. 6.7 FcF. R1 expression on basophils and monocytes in rhuMAb-E25 treated asthmatics 
and in control subjects (n =5) after 3 month period. RhuMAb-E25 significantly reduced 
FcsRI expression on basophils and monocytes at visit 2 during treatment, compared with 
baseline. This was not significant compared with the control group. 
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Visit I Visit 2 
Visit I Visit 2 
Visit 1 Visit 2 
E 
E 
CD23 expression on CD14+ 
cells after rhuMAb-E25 n=10 
1 
CD23 expression on CD4+ cells 
follovving rhuMAb-E25 n=10 
I 
nr% 
1 
Ei 
CD95 expression on 
monocytes, during rhuMAb-E25 
therapy n=10 
CCR3 expression on 
eosinophils during 
rhuMAb-E25 therapy n=10 
E 
Fig. 6.8. Protocol 11 extension substudy. Expression of CD23, CD95, and CCR3 on 
monocytes (CD14+), lymphocytes (CD4+) and eosinophils (CD9+) in rhuMAb-E25 treated 
asthmatics over a3 month period. Total number of patients in Protocol 11 extension 
substudy =10. No effect of rhuMAb-E25 treatment on surface markers. 
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6.4 Discussion 
Despite recent advances in the understanding of the role of inflammation in 
asthma, and improved drug treatments, asthma morbidity and mortality continues to rise 
worldwide (23 1). Asthma is a multifactorial disease in which interaction between allergic 
factors and non-allergic triggers result in bronchial obstruction and inflammation. Most 
patients with asthma have atopy, with specific IgE antibodies to inhaled indoor and 
outdoor allergens (e. g. house dust mite allergen, cockroach allergen, pollen, and mould) 
which drive the inflammatory process in the airways. Although allergen avoidance is 
recommended in the management of allergic asthma, it is rarely completely effective. 
Immunotherapy directed against common allergens in patients with asthma is not 
typically used in the UK, but US studies have shown that this treatment is disappointing 
in such patients and carries a small risk of serious adverse effects. 
Corticosteroids are the mainstay of anti-inflammatory treatment for asthma and 
produce their effects on various cells by binding to intracellular glucocorticoid receptors, 
which in turn inhibit transcription factors that are normally activated by inflammation. 
Many patients can be maintained on a low dosage of ICS with minimal risk of adverse 
effects, but systemic effects can occur with longterm oral cortico steroids. These include 
hypothalamic-pituitary-adrenal axis suppression, osteoporosis, cataracts, hyperglycaernia, 
dermal thinning and growth retardation in children. 
Because of the central role it plays in atopic disease, inhibition of IgE with IgE 
antibodies represents a novel approach to improve IgE-mediated allergic reactions and to 
reduce the severity of asthma. RhuMAb-E25, a humanized murine monoclonal antibody 
directed to the FcFRI binding domain of human IgE, inhibits the binding of IgE to mast 
cells without provoking mast cell activation. 
In clinical studies, rhuMAb-E25 exhibited a prolonged pharmacological effect 
without inducing anaphylaxis, blunted the early and late-phase allergic response to 
inhaled allergen, reduced the symptoms of seasonal allergic rhinitis, reduced the 
symptoms of asthma (and improved some physiological measures of asthma) and 
reduced corticosteroid use. RhuMAb-E25 has been well tolerated in clinical trials to 
date. One of the limitations of rhuMAb-E25 is that it is a protein that must be given by 
injection. Initial studies with rhuMAb-E25 involved giving twice weekly i. v. injections. 
Results from the Protocol IA04 study, did not show a significant increase in FEV I 
in rhuMAb-E25 treated asthmatics during the course of the treatment compared to the 
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control group. There was no effect on quality of life scores in the treated group, although 
scores were significantly higher in the rhuMAb-E25 treated group at visit 6 compared 
with PBO (p=0.03). Clinical symptom scores were improved at visit 5 in the treatment 
group, but this was not significant when compared with PBO. There was no effect of 
rhu-MAb-E25 on the peripheral eosinophil or neutrophil counts, and although there was 
no significant reduction in the final dose of ICS at the end of the study in patients 
receiving anti-IgE therapy, the total number of courses of prednisolone required for 
treatment of asthma exacerbations fell from 17 (mean 3.4 courses per patient) over the 
course of the previous year to 7 ý(mean-1.4 courses per patient) over the year in patients 
receiving rhuMAb-E25 (p=0.06). Although not statistically significant, this compares to 
15 courses of prednisolone over the previous year in control patients (mean of 3.75 
courses per patient) and II courses (mean of 2.75 courses per patient) during the course 
of the study. The final dose of ICS may have been affected by the timing of any 
exacerbations which may have necessitated an increase in ICS dose in order to maintain 
symptom control. 
The study showed that rhuMAb could be given safely by subcutaneous in ections i 
over a one year period, and that the subcutaneous route of treatment was well tolerated 
with no significant adverse effects being reported. Only one patient reported mild 
influenza like symptoms after rhuMAb-E25 injections which persisted for 4 months 
although symptoms responded to paracetmol and were not severe enough to stop 
treatment. 
The main problem with the IA04 trial was the short recruitment time available 
before the commencement of the trial period. This meant that patient numbers in the 
active and control groups were low, and therefore the trial at this centre was not 
adequately powered to detect any significant changes in the parameters being measured. 
Apart from one patient, FEVI measurements in the control group were generally higher 
than in the treatment group, although there was not a statistically significant difference. 
Patients in the control group were also much younger than the rhuMAb-E25 treated 
asthmatics, and thus not well age matched. 
The IA04 study, also known as the ETOPA study, has since been published in 
2004 by Ayres et al (276). In total, 312 patients aged between 12 to 73 years, receiving 
400ýtg/day or more (if adolescent) or 800[tg/day (adults) inhaled BDP or equivalent were 
included. Although long acting beta agonists were not an entry criteria, 78% of patients 
were using them at baseline. Patients received best standard care with asthma medication 
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with or without Omalizumab (with appropriate dosing) every 4 weeks for 12 months. 
Results showed that the mean number of asthma deterioration related incidents was from 
9.76 with best standard care alone in 106 patients, to 4.92 in 206 patients who received 
Omalizumab. Patients who received omalizumab experienced 49.6% fewer asthma 
deterioration related related incidents per patient-year compared to best standard of care 
alone. The Omalizumab group showed a 61% reduction in clinically significant asthma 
exacerbation rate (p<0.001) than the best asthma treatment alone. 
Basophils are a constituent of the cellular infiltrate in bronchial tissue of atopic 
asthmatic patients and are further increased after allergen challenge. They are also a 
major constituent of the cellular infiltrate in the cutaneous late-phase reaction to 
allergens. Basophils can be identified as a single population of cells that stain positively 
for CD123 (anti-IL-Mcc which stains predominantly basophils and monocyte derived 
dendritic cells, and which plays an important role in haematopoietic progenitor cell 
growth and differentiation), and negatively for HLA-DR (which labels the dendritic cells 
and distinguishes them from basophils). Anti-CD14 labelled monocytes were detected by 
their increased fluorescence on the FLI channel. The experiments performed on blood 
samples in protocol 11 extension substudy showed that rhuMAb-E-25 significantly 
reduced FcFRI expression on basophils and monocytes after 3 months treatment 
compared to baseline, as a consequence of reducing serum IgE levels which can regulate 
the expression of high affinity IgE receptors. In contrast, no significant difference was 
seen at 3 months in the levels of FcF. RI receptor on basophils or monocytes in the control 
patients. The reduction in FcE; RI expression on basophils and monocytes was not 
significant compared to control subjects, and this is likely due to the fact that there were 
insufficient patients in the treatment group to reach significance. 
No significant difference was seen in the expression of the low affinity IgE 
receptor (CD23) on monocytes or CD4+ lymphocytes, or of CD95 on monocytes 
following anti-IgE therapy. Studies in mice have suggested that rhuMAb can affect cells 
other than mast cells and basophils, and may inhibit CD23 on other cells such as 
macrophages and T-cells (232). Pre-treatment of allergen challenged mice with anti-IgE 
treatment has been shown to reduce serum IgE levels and eosinophil infiltration into the 
lungs, and also reduce IL-4 and IL-5 production from Th2 lymphocytes. Coyle et al (232) 
showed that anti-IgE antibodies achieve this by inhibiting IgE-CD23 facilitated antigen 
presentation to T-cells. 
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Also no effect of anti-IgE therapy was seen on CCR3 expression on eosinophils, 
which can be identified by expression of surface CD9 molecules and high side scatter or 
granularity. Survival of eosinophils has been shown to be reduced by treatment of cells 
with anti-CCR3 antibody (233). The chemokine eotaxin, which is a highly specific 
chemoattractant for eosinophils, appears to be a principal ligand for CCR3. Thus 
although anti-IgE therapy can reduce sputum eosinophil numbers (163), it does not 
appear to reduce peripheral blood eosinophil numbers or the expression of CCR3 
receptors on eosinophils, suggesting an alternative mechanism of its anti -inflammatory 
action. 
Although rhuMAb-E25 is likely to be expensive, as are other antibody treatments 
such as anti-TNF-oc, such a treatment may be justified in patients with severe asthma who 
are only controlled on doses of oral corticosteroids that cause side effects (165). Patients 
with severe atopic disease, in addition to asthma may also benefit. 
The role of neutrophils in the allergic inflammatory cascade is now being realized. 
Gounni et al showed that peripheral blood and BAL neutrophils from asthmatics 
expressed FcF-R1, which is the main receptor involved in binding IgE molecules to the 
surface of mediator cells. Further, activation of these FcF'RI receptors induced the release 
of IL-8 by neutrophils (169). Further, Yamaoka et al showed that neutrophils can 
synthesize CD23 molecules following stimulation with GM-CSF, and this CD23 
expression might be of physiopathological relevance in IgE dependent activation during 
allergic processes (168). The presence of three forms of IgE receptor has been 
demonstrated on neutrophils, as well the observation that in vitro challenge of neutrophils 
with allergens to which the patients were sensitive, elicited a release of elastase by these 
cells, suggesting that an IgE dependent mechanism may promote elastase release by 
neutrophils at allergic sites (234). Taken together, these studies suggest that neutrophils 
may play a role in allergic inflammation through an IgE-dependent activation 
mechanism. In the context of severe allergic asthma, this is important as increased 
numbers of neutrophils have been demonstrated in sputum and bronchial biopsy samples 
in patients with severe corticosteroid-dependent asthma. 
It has been shown that corticosteroids may prolong the life of neutrophils by 
inhibiting their apoptosis and, in some instances, can lead to activation of neutrophil 
function, both of which can result in possible tissue damage through the inappropriate 
release of intracellular mediators and enzymes. Corticosteroid therapy could also, by 
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prolonging the life of neutrophils at the sites of inflammation, allow them to participate in 
IgE mediated allergic responses through their IgE receptors which would further drive the 
inflammatory cascade and lead to worsening symptoms in asthmatics. Anti-IgE therapy 
may thus prove to be a useful steroid sparing agent in these more severe asthmatics who 
show many troublesome side-effects of their current medication, and in whom an 
alternative safe and effective treatment is required. Further, the recognition that IgE 
mediated mechanisms may occur in asthma irrespective of the atopic status of the patient, 
suggests that despite the distinct clinical and biological features, there is a common 
immunopathological mechanism, suggesting a possible role for anti-IgE therapy in severe 
non-atopic asthmatics. 
The studies in this chaper could have been improved by including larger numbers 
of patients in each of the groups, to increase the power of the studies. The IA04 trial 
protocol only required measurement of serum total IgE levels at the initial screening visit, 
but it would have been interesting to measure IgE levels during the 3 monthly scheduled 
visits to look at the effect of Omalizumab on IgE levels. The reduced numbers of patients 
in the II extension substudy, in whom expression of FcsRI on basophils and monocytes 
was measured by FACS, was due to the fact that the staining antibody required was not 
available for use in all patients at the time of commencement of the study. FACS analysis 
was thus not possible in some of the early entrants into the IA04 study. It would have 
useful to look at the level of neutrophil surface molecule expression in peripheral blood 
using FACS during treatment with anti-IgE therapy in severe asthmatics, to see if this 
form of treatment has any effect on neutrophil activation markers. A study of anti-IgE 
therapy in non atopic severe asthmatics to see if there is any beneficial effect in 
improving symptom control, may result in an increase in the number of patients who can 
be treated with form of therapy, if benefits were shown. 
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Chapter 7 
Overall conclusion 
Eosinophils have long been thought to be the main cell causing bronchial mucosal 
injury in asthma, and it has been shown that eosinophil numbers and eosinophil mediator 
levels in blood, BAL and bronchial biopsies correlate with asthma severity. However, 
several studies suggest that airway eosinophilia is not a universal finding and that the 
neutrophil may be the more important effector cell in certain circumstances. Douwes et al 
(235) for example, showed that eosinophilic inflammation is seen in the airway lumen of 
only 50% of asthmatic subjects, whilst intense eosinophilic inflammation, as occurs in 
eosinophilic bronchitis, fails to induce asthma (236). Many asthma exacerbations show 
increased levels of neutrophils rather than eosinophils in the airways, and studies have 
shown that the use of specific anti-eosinophil cytokine agents such as anti-IL-5 and anti- 
IL-12 are poorly efficacious in-vivo (237-238). Frangova et al (239) showed increased 
neutrophils, eosinophils, and MPO in asthmatics versus controls, but found similar levels 
of neutrophils, eosinophils, and epithelial cells numbers and MPO in allergic versus non- 
allergic asthmatics, suggesting that airway recruitment and activation of neutrophils 
occurs in parallel with eosinophils and that airway neutrophils do not contribute 
significantly to epithelial cell injury or to airway hyperresponsiveness in the steady state, 
in mild asthma. 
The role of neutrophils in more severe asthmatics however, has been highlighted 
in a number of studies. Wenzel et al (240) showed that in severe disease, eosinophils and 
neutrophils are usually found together but that neutrophils may gradually replace 
eosinophils in proportion to the severity and/or duration of the disease. Further 
characterization of severe corticosteroid-dependent asthmatics showed two distict 
pathological subtypes based on the presence or absence of airway eosinophils. In both 
types however, neutrophil numbers were elevated. That neutrophils may have a role in 
the development of asthma was shown by Yasui et al (256), who showed a low incidence 
of asthma in a group of Japanese children with autoimmune neutropenia, with the 
development of asthma after the neutropenia reolved. Evidence of airway neutrophil 
activation leading to more severe disease was demonstrated by Little et al (241), who 
showed that the FEVI was inversely proportional to neutrophil numbers in sputum 
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samples, and that neutrophil numbers correlated well with markers of neutrophil 
degranulation which implies that these cells are also activated. Kikuchi et al (242) 
showed that, in severe persistent asthmatics treated with oral and high dose ICS, there 
was a correlation between the percentages of neutrophils and eosinphils in induced 
sputum, which may be responsible for the eventual manifestation of airway inflammation 
in severe asthma. 
Silvestri et al (257) showed that in severe asthmatics, elevated levels of the 
neutrophil chemoattractant TNFa, released in IgE mediated responses by mast cells and 
eosinophils, correlated with increased numbers of airway neutrophils. TNFa has been 
shown to contribute to bronchial hyperesponsiveness in asthma. Halasz et al (277) 
showed that increased levels of TNFa and its soluble receptors 55kDa (sTNF-Rl) and 
75kDa (sTNF-R2) in patients with hyperreactive airways. There was a positive 
correlation between cytokine levels and cytokine receptor levels and negative correlation 
between serum TNF(x and concentrations of sTNF-R2. and PC20 in hyperreactive patients. 
Inhaled TNFa induces airway neutrophilia and increases airway reactivity in normal 
subjects. Thomas et al (278) showed reduction in PC20 and thus increased bronchial 
hyperresponsiveness after inhaled recombinant human TNFU compared to PBO and an 
increase in sputum neutrophilia and eosinophilia at 24-48 hours versus the control group. 
The increase in airway responsiveness and sputum inflammatory cell influx suggests that 
TNFa may contribute to the airway inflammation in asthma. 
Patients with refractory asthma have been shown to have evidence of up 
regulation of TNFa. Berry et al (279) showed increased TNFa activity in PBMCs with 
increased expression of membrane bound TNFa, TNFa receptor 1, and TNFa converting 
enzyme by PBMCs in patients with refractory asthma compared to mild and moderate 
asthmatics and control subjects. Following on from this, the same authors conducted a 
PBO controlled, double blind, crossover pilot study lasting 10 weeks, aimed at looking at 
the effect of etanercept, a soluble TNF-a receptor antagonist in patients with refractory 
asthma, mild to moderate asthmatics and control subjects. Compared with PBO, 
treatment with etanercept was associated with an improvement in airway 
hyperresponsiveness (p==0.05), an increase in asthma related quality of life scores 
(P=: 0.02), and an increase in post bronchodilator FEV I (p=0.01). 
Rouhani et al (280) looked at the effect of treatment with etanercept on the early 
and late phase response to inhaled allergen challenge in 26 patients with mild to moderate 
asthma, who were receiving only P-2 agonists. Anti-TNFa therapy with etanercept did 
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not attenuate pulmonary eosinophilia, and was associated with an increase in IL-4 at 24 
hours following segmental allergen challenge. Treatment with etanercept was not 
associated with a change in airway hyperresponsiveness to methacholine, suggesting that 
this therapy may not be effective for preventing allergen mediated eosinophilic airway 
inflammation in mild to moderate asthmatics. In addition, one patient in the trial 
developed a transient hemiplegia, thought to be a potential toxicity of anti-TNFa therapy, 
and this resulted in suspension of the study. 
Morjaria et al recently conducted a recent 12 week study of the effect of 
etanercept in 39 patients with severe corticosteroid refractory asthma (281). Significant 
reductions in sputum macrophages and serum C-reactive protein levels were seen, along 
with an increase in serum TNFa and albumin levels following therapy. There was a small 
but significant difference in reduction of asthma control questionnaire scores between 
treatment and PBO. However, there was no significant difference in asthma related 
quality of life scores, lung function, PEFR, bronchial hyperresponsiveness, or 
exacerbation rates between the groups. There was an increase in minor adverse effects 
such as injection site pain and skin rashes with etanercept. Larger trials are thus needed to 
clarify the role of treatment with TNFa antagonists in patients with severe corticosteroid 
refractory asthma. 
Neutrophils have also been shown to be involved in the acute inflammatory 
reaction of the airways that occur after bronchoprovocation with allergens and sensitising 
agents during spontaneous asthma exacerbations, during nocturnal asthma, and in the 
dramatic bronchopulmonary inflammation associated with asthma death. Wark et al (243) 
showed that patients with proven virus induced exacerbation of asthma (by sputum 
immunofluorescence antigen detection, sputum viral culture, and sputum PCR for 
respiratory viruses) had evidence of increased sputum neutrophilia and increased levels of 
neutrophil elastase compared to patients with non infective asthma. One possible reason 
for this may be due to the increased expression of epithelial growth factor receptor 
(EGFR) levels. Expression of EGFR is increased in proportion to asthma disease severity 
and is a reflection of the extent of epithelial injury. Hamilton et al (244) showed that 
epithelial damage in bronchial biopsies of severe asthmatics showed increased levels of 
epithelial IL-8 and submucosal neutrophils and increased EGFR levels compared to 
milder disease. There was a strong correlation between EGFR levels and IL-8 
expression, suggesting that epithelial damage may contribute to neutrophilic 
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inflammation through the enhanced production of IL-8 via an EGFR dependent 
mechanism. 
Neutrophils contain several mediators which are capable of killing bacteria, but 
they also release enzymes and cytokines and oxygen radicals which play an important 
part in tissue damage, tissue remodelling and which are capable of activating other cells 
such as eosinophils resulting in degranulation and release of mediators which are 
potentially capable of causing further tissue damage. Studies on sputum, BAL and 
endobronchial biopsy specimens have shown that neutrophils and its chemoattractant, IL- 
8 and MPO, are significantly elevated in more severe asthmatics in the absence of 
infection. Little et al (241) showed that some patients with chronic asthma develop 
irreversible airflow obstruction and disease duration was shown to be a predisposing 
factor. Sputum MPO levels in patients was shown to be proportional to numbers of 
sputum neutrophils and inversely associated with FEVI suggesting that neutrophils may 
be involved in the pathophysiology of irreversible airflow obstruction in chronic asthma. 
Neutrophils can also release matrix-metalloproteinases (MMP) such as MMP-9 following 
stimulation with IL-8 and GM-CSF (245), and have been shown to express MMP-9 in 
bronchial biopsies from asthmatics (246). MMP-9 can lead to airway wall remodelling 
which may be an important factor in the development of severe asthma. 
The consistency of the finding of airway neutrophilia in more severe chronic 
asthmatics cannot be solely explained by the effects of smoking and concomitant acute 
infection. One possible explanation for the airway neutrophilia in this subgroup of 
asthmatics is that these patients may have had chronic airway infection with viruses or 
atypical bacteria such as mycoplasma or Chlamydia. There is serological evidence for 
infection with Chlamydia pneumonia in asthma, and evidence linking infection with more 
severe disease (258). In addition, Kraft et al (259) showed evidence of airway infection 
with mycoplasma pneumonia in asthmatics using PCR techniques. However, treatment 
with macrolide antibiotics failed to show sustained improvement in pulmonary function 
in asthmatics with serological evidence of Chlamydia pneumoniae infection (260). 
Another possible mechanism in the development of airway neutrophilia in chronic severe 
asthma is that airway epithelial cells are chronically activated and hypersecrete neutrophil 
chemoattractants including IL-8 in response to environmental pollutants such as diesel 
exhaust particles (261). This suggests that lower airway epithelial cells may have an 
intrinsic functional abnormality that is important in the pathogenesis of asthma. 
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Linden et al (247) showed that IL-17 may be responsible for mobilising 
neutrophils into airways of patients in acute severe asthma exacerbations. IL-17 is 
produced by T-lymphocytes of the memory (CD45 RO+) subset, and causes human 
bronchial epithelial cells in vitro to produce and release IL-8 and IL-6 which can lead to 
neutrophil recruitment and activation in the airways. Further, Hellings et al (248) looked 
at the IL- 17 expression in the airways of ovalbumin sensitized mice following inhalation 
of nebulised ovalbumin. Increased levels of IL-17 mRNA expression were seen in the 
inflamed lung tissue, and this was associated with a prominent bronchial neutrophilic 
influx. As neutrophils may be important in airway remodelling in chronic severe asthma, 
targeting IL- 17 may be a useful therapeutic strategy in human asthma. 
The regular use of ICS improves lung function, bronchial hyperreactivity and 
markers of airway inflammation in sputum and exhaled NO in asthma. Some studies 
also show a decrease in sputum cytokine levels, which can influence recruitment of 
inflammatory cells into airways. Further, use of high dose ICS have been shown to be 
effective in treating acute asthma exacerbations and regular high dose inhaled FP, has 
been shown to be better than oral prednisolone at improving PC20 to methacholine whilst 
producing similar trends in FEVI, and reduction in sputum eosinophils and ECP as 
prednisolone (249). However, in a study by Green et al (130), a distinct subgroup of 
patients with mild to moderate asthma showed a predominantly neutrophilic airway 
inflammation in their sputum and responded less well to ICS in terms of improvements 
in symptoms, FEV I, or PC20. The presence of increased neutrophils in asthmatic airways 
may thus account for less improvement following ICS therapy in such patients. 
Gauvreau et al (250) showed that ICS attenuated allergen induced airways inflammation 
but were less effective at inhibiting allergen induced sputum eosinophils after challenge 
in asthmatics that had increased levels of sputum neutrophils at baseline. This suggests 
that ICS are less effective in attenuating allergen induced airway inflammation in 
subjects with increased levels of neutrophils and that the heterogeneity of airway 
inflammation in some asthmatics may influence response to steroid treatment. 
The beneficial effects of ICS on airway inflammation may also be attenuated by 
continued smoking in asthmatics. Compared to never smokers, smokers with asthma have 
been shown to have worse median total asthma control scores using the Juniper asthma 
control questionnaire, and this was independent of the FEV1 (282). Further, in a study of 
104 uncontrolled asthmatics, of who 33 were ex-smokers, asthma was more severe in 
former smokers both before and after treatment (283). Severe asthma and cigarette 
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smoking were associated with difficulty in asthma control. Quality of life (as measured 
by the St George Hospital respiratory questionnaire) was improved in non-smokers but 
not in former smokers, suggesting that smoking has a persistent negative impact on the 
response to treatment in patients with uncontrolled asthma, even after smoking cessation. 
This highlights the importance of smoking cessation as an important part of the treatment 
of asthmatics. 
Tomlinson et al (284), showed that compared with non smokers, smokers with 
mild persistent asthma are insensitive to the therapeutic effect of low dose ICS therapy 
given for 12 weeks. In addition, morning peak expiratory flow values were shown to be 
significantly lower after treatment with FP (1000ýtg/day) in asthmatics who smoked, 
compared to non-smoking asthmatics, suggesting that smoking impairs the efficacy of 
short term ICS therapy in mild asthma (285). This has important implications in mild 
asthmatics who smoke. 
The use of induced sputum and bronchoscopy studies has supported the idea of a 
'non-eosinophilic' asthmatic phenotype. Simpson et al (262) confirmed the heterogeneity 
of airway inflammation pattern seen in astmatics. In their study, 41% had predominantly 
eosinophilic inflammation in induced sputum, whilst 28% had predominantly sputum 
neutrophilia. Eight percent had both eosinophils and neutrophils in their sputum, whilst 
31% demonstrated a 'pauci-immune' phenotype with neither eosinophils nor neutrophils 
in airway secretions. The eosinophil phenotype had increased levels of MMP-9, whilst 
those with predominantly neutrophilic inflammation had increased levels of neutrophil 
elastase. Whether the distinct inflammatory phenotypes occur as a result of different 
aetiological pathways is unclear, although recent studies suggest that the innate immune 
system is more activated in neutrophilic asthma, with increased expression of Toll like 
receptors (TLR), TLR2 and TLR4 and CD14 in induced sputum (263) in these patients. 
Both innate and adaptive mechanisms are important in the initiation and maintenance of 
asthma. The hygiene hypothesis suggests that respiratory infections should protect 
individuals from allergic disease, but epidemiological data in asthma is contradictory. It 
is thought that Toll receptors, which are present on dendtritic cells and mast cells, may 
control Thl and Th2 cell differentiation, with signalling through TLRs leading to 
decreased Th2 allergic inflammatory response through induction of Thl responses. 
There are several definitions of severe asthma in the literature. The term 
6refractory' asthma was coined by the American Thoracic Society in 2000 (264), to 
describe those asthmatics whose asthma proved troublesome and difficult to control. It is 
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an umbrella term and includes, among other patients, those with fatal or near fatal 
asthma, corticosteroid dependent or resistant asthmatics, brittle asthmatics and those with 
fixed irreversible asthma. Diagnosis depends on the presence of one or both major criteria 
and 2 minor criteria and requires the exclusion of other conditions and exacerbating 
factors, and demonstration of good compliance with therapy. Refractory asthma may 
represent a different inflammatory process than mild asthma, with more neutroPhilic 
inflammation which is poorly responsive to cortico steroids, or else, the poor response to 
therapy can be explained by airway remodelling, which differs in amount, type, and 
distribution of airway smooth muscle proliferation and fibrosis, in the more severe patient 
group. Evidence suggests, for example, an increased proportion of cells that stain positive 
for TGFP, a cytokine with fibrogenic properties, are found in the airway submucosa, in 
patients with refractory asthma. Possible molecular mechanisms that have been put 
forward to explain the more severe asthmatic phenotype includes down regulation of the 
binding affinity of glucocorticoid receptors, or up regulation of the less active 
glucocorticoid-beta receptor which prevents transcription. In addition, there may be 
reduced ability of corticosteroids to interfere with nuclear transcription factor binding, 
and failure to suppress c-jun-N-terminal phosphorylation. 
The European Network for Understanding the Mechanism of severe asthma 
(ENFUMOSA) study also showed increased sputum neutrophilia in patients with severe 
asthma compared to those with well controlled asthma (265), with no difference in the 
number of other inflammatory cells, and this was independent of regular use of 
corticosteroids. Patients with severe asthma were also more likely to be female and non 
atopic. More recently, the severe asthma research program (SARP) showed that risk 
factors for severe asthma included a low initial FEVI, a history of pneumonia, and less 
atopic disease (266). Interestingly, Nguen et al (267) suggested that ICS alone do not 
contribute to elevated neutrophil numbers in asthmatics, whereas oral corticosteroids 
appeared to do so. It is unclear whether corticosteroid use results in, or is the reason for, 
the increase in airway neutrophilia. 
The use of anti-IgE treatment represents a novel treatment for patients with 
allergic asthma and has been shown to be useful in patients with mild and severe asthma. 
The fact that it can be administered by subcutaneous injection twice weekly and is 
relatively free of side effects, means it will be of benefit in severe corticosteroid- 
dependent asthmatics in whom other treatments, including the use of corticosteroids, fail 
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to provide symptom control. Neutrophils from asthmatics express the FCCR 1, whereas 
neutrophils from non-asthmatics do not. Activation of these FCFRl receptors leads to 
release of IL-8, which is a potent neutrophil chemoattractant and activator. The fact that 
neutrophils have been shown to express high and low affinity receptors for IgE 
antibodies, suggest that they may play a role in allergic inflammation through an IgE 
dependant activation mechanism. Monteserin et al (251) showed that neutrophils 
challenged in vitro with allergens to which atopic asthmatics were known to be sensitive, 
resulted in increased release of MPO. This appears to be an allergen specific response in 
that no degranulation occurred in response to allergens to which patients were not known 
to be sensitive. Allergen exposure did not result in MPO release from neutrophils in 
healthy donors. Therefore, an IgE dependant mechanism may be important in promoting 
MPO release by neutrophils at allergic sites. 
To date, seven large phase 3 trials of Omalizumab (Xolair Novartis 
Pharmaceuticals S. A. S. Huningue, France), a humanized monoclonal antibody that 
targets IgE, have been completed in adults and adolescents with allergic asthma. These 
studies consist of 5 double-blind, PBO-controlled studies and 2 randomized open-label 
standard therapy controlled studies. Omalizumab was given as add-on therapy to at least 
ICS in all studies and in some patients, to long acting beta agonists. Ninety three percent 
of the enrolled patients met the Global Initiative for Asthma (GINA) 2002 step 4 criteria 
for severe persistent asthma. Of these studies, the INNOVATE study included 419 
patients aged between 12-75 years with allergic asthma. Patients treated with 
Omalizumab in addition to their existing therapy had a 26.2% lower rate of clinically 
significant asthma exacerbations. In addition, emergency room visits were reduced by 
44% and hospital visits reduced by 51% (268). 
Omalizumab was launched in the UK in 2005, and has been approved in 53 
countries world wide. The National Institute for Health and Clinical excellence (NICE) 
recommended omalizumab for severe persistent allergic asthma in August 2007 as add-on 
therapy for patients with clinically confirmed severe persistent IgE mediated asthma. 
Specifically, patients should have experienced either 2 or more severe exacerbations of 
asthma requiring hospital admissions within the previous year, at least one of which 
required hospital admission and a further 2 which required treatment or monitoring in 
excess of the patient's usual regimen, in an emergency department. Patients must have a 
positive skin or blood test for a perennial aero-allergen, an FEVI of less than 80%, as 
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well as frequent day time symptoms and/or night time awakenings, and FEV I less than 
60% and PEF variability of more than 30%. 
Studies in the United States have looked at using anti-IgE therapy in patients with 
allergic bronchopulmonary aspergillosis (ABPA) who have IgE levels outside the 
recommended dosing limits. It is likely however, that a large component of non-specific 
IgE is present within the total IgE, and routine treatment with anti-IgE therapy at present 
cannot be recommended for patients outside the approved dosing range (the upper limit 
being 700 IU/ml). There are reports however, of Omalizumab being used as a 
corticosteroid sparing agent in cystic fibrosis patients with ABPA, with a reduction in 
respiratory symptoms and improved lung function (269). 
At present, a study looking at the benefit of anti-IgE treatment after an acute 
exacerbation of asthma requiring hospitalisation is being conducted at the Royal 
Brompton Hospital, to look at its effect on the improvement in lung function and use of 
anti-asthma medication. It would be useful to look at activation markers such as CD IIb, 
CD62L, CD18, CD35 and CD23 and FcsRl on neutrophils before and during treatment 
with anti-IgE treatment to look at the effect of this form of treatment on neutrophil 
activation and receptor levels. Indeed, in a study involving anti-IgE antibodies, 
Monteserin et al (252) challenged blood lymphocytes in vitro from normal patients and 
adult allergic asthmatics some of whom had received immunotherapy. CD62L was shown 
to be reduced in a dose dependant manner with anti-IgE antibody, more so in non- 
immunotherapy patients than in the normal or immunotherapy groups, suggesting that 
CD62L can be modulated by an IgE dependant mechanism and that it can be affected by 
immunotherapy. Further, Monteserin et al (253) also showed that asthmatics showed a 
greater fMLP induced MPO release from neutrophils compared to healthy controls. MPO 
release was reduced in asthmatics receiving immunotherapy, suggesting that MPO release 
is modified in vitro by neutrophils from allergic asthmatic patients. The effect of 
treatment with anti-IgE treatment on MPO release or IL-8 release in cultured whole blood 
would also be useful to study. 
This thesis adds to the hypothesis that neutrophils may be activated in the 
circulation of severe asthmatics. This may be a result of the chronic steroid therapy that 
is used to treat these patients, suggesting that steroids may be having an adverse effect in 
these patients by prolonging neutrophil survival and allowing them to release tissue 
damaging mediators. Alternative pharmacological therapy can, in theory, target various 
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stages in neutrophil recruitment, transmigration, and interaction to prevent tissue injury. 
Possible mechanisms of action include inhibiting the release or accumulation of 
proinflammatory mediators, altering neutrophils or endothelial cell activation, and 
attenuating adhesion molecule expression on neutrophils, endothelium and target cells 
such as myocytes or airway epithelial cells. Martin et al (254) for example, showed that 
neutrophils have a short half life in the asthmatic airways using BAL fluid levels (<8 
hours) suggesting a high state of flux of neutrophils in the airway wall. Stratergies 
designed to block influx may be efficacious. Cadwallader et al (255) have recently 
shown that the enzyme phosphoinositide 3-kinase is important in controlling neutrophil 
migration, activation and survival, and the discovery of neutrophil specific isoforms 
makes selective therapeutic targeting a possibility. 
Other potential new targets for treatment include antagonists of neutrophil 
chemoattractants including GM-CSF and IL-8, and blockade of neutrophil products such 
as neutrophil elastase. LTB4 antagonists may be particularly important as LTB4 has a 
central role in enhancing neutrophil survival in response to cytokines and corticosteroids. 
LTB4 antagonists may promote neutrophil apoptosis in the airway, leading to resolution 
and repair. The finding of 'non-eosinophilic' asthma in induced sputum samples may 
provide a case for the regular use of this technique in identifying asthma subtypes, but 
although relatively safe, sputum induction can produce respiratory symptoms in some 
patients. The finding of increased levels of urinary LTE4 and LTB4 in severe asthmatics, 
suggests that 5-lipoxygenase inhibitors, such as zileuton, may be efficacious in neutrophil 
predominant asthma, as it inhibits LTB4 along with the cysteinyl leukotrienes. This 
suggests that in future, targeted therapy against both eosinophils and neutrophils may be 
the best form of treatment in severe steroid-dependent asthmatics. 
Current available therapy, in the form of long acting beta-2 agonists, has been 
shown to have some anti-neutrophil activity. Salmeterol given at a dose of 50ýtg twice 
daily, significantly reduced neutrophil numbers in bronchial biopsy samples, and the 
concentrations of MPO compared to PBO. Compared to FP, salmeterol also reduced 
neutrophil number and human neutrophil lipocalin level in BAL fluid (270). Further, 
Maneechotesuwan et al (271) showed that treatment with fon-noterol significantly 
reduced neutrophil numbers and sputum IL-8 levels compared to PBO. There was a 
significant correlation between reduction in sputum IL-8 levels and the number of 
neutrophils, indicating that formoterol may attenuate neutrophil airway inflammation by 
inhibiting IL-8 production. 
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Macrolides have also been shown to reduce neutrophilic inflammation. A study 
by Simpson et al (272) showed that a group of patients with severe refractory asthma 
treated with oral clarithromycin (500mg bd) for 8 weeks, had reduced sputum 
concentrations of IL-8 and neutrophil numbers, and showed improved quality of life 
scores compared with PBO. These reductions were most marked in those with refractory 
non-eosinophilic asthma. Johnston et al (273) studied the effect of Telithromycin in 278 
asthmatics within 24 hours of an acute asthma exacerbation, versus PBO. Although a 
reduction in asthma symptoms was demonstrated, no effect of on PEF was demonstrated. 
In-vitro studies have shown that theophylline at therapeutic concentrations can restore the 
the reduced HDAC activity that is induced by oxidative stress, and can return steroid 
responsiveness to normal. Low dose theophylline can therefore lead to increased HDAC 
activity, thus reducing the inflammatory potential of effector cells in COPD and severe 
asthma (274). New classes of drug that activate HDACs might be identified in future. 
In conclusion, asthma can no longer be considered a chronic eosinophilic airway 
disorder triggered by various allergens and stimuli. Mounting evidence suggests it is 
characterized by heterogenous airway inflammation, with neutrophils predominating in 
certain asthma phenotypes, and after certain trigger factors. The increase in neutrophil 
numbers is associated with evidence of neutrophil activation and mediator release, and 
correlates with asthma disease severity. Patients with severe asthma demonstrate different 
pathology on biopsy of their airways compared to milder asthmatics, and a number of 
molecular mechanisms have been put forward to explain the state of relative 
corticosteroid resistance in this group. Both biopsy studies and large observational studies 
point to the relative increase in airway neutrophil numbers as a possible explanation for 
the more severe asthma phenotype. Whether severe asthmatics represent a small number 
of patients mild disease who are unresponsive to corticosteroids, or whether it is a 
separate entity characterized predominantly by airway neutrophilia is unclear. It is also 
unclear whether the airway neutrophilia is a result of corticosteroid useage, or whether 
the persistent symptoms in severe corticosteroid dependent asthmatics are the result of 
ongoing neutrophilic inflammation which is unresponsive to corticosteroid therapy. Some 
evidence does suggest however, that sputum neutrophilia can be seen in mild steroid 
niave asthmatics. 
This thesis shows that, in addition to the airways, neutrophils may also be 
activated in the peripheral circulation of patients with severe asthma. The use of 
corticosteroids is associated with unacceptable side effects in a number of corticosteroid- 
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dependent asthmatics, and may in fact lead to further airway and tissue damage through 
the promotion of neutrophil survival and mediator release as a result of reduced 
neutrophil apoptosis. The development of alternative forms of therapy to target either 
eosinophilic or neutrophilic inflammation, or perhaps both, seems an attractive way in 
treating this condition. Although several current therapies have been shown to have anti- 
neutrophil effect as outlined above, the use of these therapies is not the answer in more 
severe asthmatics as many patients are already on these treatments and demonstrate 
ongoing symptoms. A theoretical disadvantage of targeting neutrophils however is that a 
state of neutropenia may be induced with the risk of developing infections as a result. 
Anti-IgE therapy is an exciting new development in the field of asthma, and is associated 
with considerable clinical benefit and significantly less adverse effects than other 
immunosuppressant drugs that have been used in the treatment of severe asthmatics. 
However, it is likely that only a small proportion of severe asthmatics will benefit from 
this form of therapy as less than 50% of severe asthmatics are atopic, and in this atopic 
group, issues regarding body weight (increased through the use of oral corticosteroids), 
cost of treatment, and IgE levels above the recommended dosing range means that in 
practice, only between 10- 15% of these patients are likely to benefit. New pharmaceutical 
developments are thus urgently required in the field of non-eosinophilic asthma, and this 
may provide a significant break through in the management of severe asthmatics. 
The shortcomings of the experiments in this Thesis are presented in the 
discussions at the end of each chapter. A major problem was the lack of patient 
recruitment into various studies such as the IA04 and II extension substudy (chapter 6), 
which were due to commence shortly after the research period started. There was thus 
insufficient time to recruit patients into these trials and to become familiar with FACS 
analysis techniques for the 11 extension substudy. Unfortunately, it was not possible to 
get any help with the experiments at the time, and I had to attend a course on FACS 
analysis in Oxford to become familiar with FACS analysis techniques. The protocol for 
the fluticasone study (chapter 5) was difficult to recruit to, as it meant that patients had to 
be available for one and a half days per week for three consecutive weeks, which is 
demanding for patients. Recruiting subjects well in advance would help to increase 
numbers and the power of the studies. It would have been beneficial to consult a 
statistician from the outset. The lack of a non asthmatic control group taking prednisolone 
(chapter 3) meant that it is difficult to analyse fully the effect of prednisolone on cell 
surface activation markers. Trial designs could also have been improved to give more 
209 
meaningful results. For example, bronchial hyperreactivity could have been measured at 
the start of the fluticasone study, so that comparisons with later time points could have 
been carried out. In addition, the trial design for the IA04 study did not allow the routine 
measurement of serum IgE levels at each scheduled 3 monthly hospital visit. The control 
population in some of the studies were not well matched in terms of age, sex, and severity 
of disease and this may have had some effect on the results, and again highlights the 
importance of timely and careful patient selection. Most of the mild and severe patients 
who took prednisolone in chapter 3 were compliant with treatment as can be judged by 
the prednisolone and cortisol levels. However this may not necessarily have been the case 
for asthmatics who took prednisolone in the HDAC study (chapter 4), as not all 
prednisolone levels were available to ensure patient compliance with therapy. Finally, the 
IL-8 ELISA experiements in blood and sputum failed to Produce results in some patients 
and thus repeating these experiments would be useful to demonstrate reproducibility and 
accuracy of results. 
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Appendix I- List of equipment/reagents 
Spirometer: Dry Bellows vitalograph spirometer (Vitalograph Business Park, Maids 
Moreton, Buckinghamshire, MK18 TSW). 
Methacholine: Stockport Pharmaceuticals, (Pharmacy department, Stepping Hill hospital, 
Poplar Grove, Stockport). 
Allergens for skin prick testing: Soluprick SQ, (Alk abello Ltd. Hungerford, Berkshire 
RG 17 OYT). 
Sputum induction: Ultra-Neb 2000 Ultrasonic nebuliser (De Vilbiss Co, Heston, UK). 
Nitric oxide chemiluminescence analyzer (ModelLR2000; Logan Research Ltd, 
Rochester, UK, ME2 4NP). 
FACScan flow cytometer, with Maclntosh G4 FACStation and CellQuest software. 
((Becton Dickinson, 21 Between Towns road, Oxford, Oxfordshire OX4 MY, UK). 
CaliBrite Beads (no. 349502, unlabelled, FITC, PE, 25 tests, BectonDickinson, 21 
Between Towns road, Oxford, Oxfordshire OX4 MY, UK). 
Solutions/reagents 
Hank's balanced salt solution (HBSS, H6648, Sigma Aldridge, Irvine, UK) 
Dithiothreitol (DTT) (Sigma chemicals, Fancy road, Poole, Dorset, UK). 
RPMI 1640 (no. 21875-091, I Ox5OOml, Gibco, Invitrogen, UK) 
Ficoll-Hypaque (no. 17-14440-03, Amersham Biosciences, UK) 
Dulbecco's Phosphate-buffered saline (no. 14190-185,20x I 00ml, Gibco, Invitrogen, UK) 
3% Dextran T-500 (Pharmacia Biotech, Uppsala, Sweden) 
Bovine serum albumin (A2153-50g, Sigma Aldridge, Fancy road, Poole, UK) 
Sodium azide (no. 58032-100g, Sigma Aldridge, Poole, UK) 
Erythrolyse (BUF04A, 20 ml of I Ox concentration, Serotec Ltd, Oxford, UK) 
Paraformaldehyde (no. 16005- 1 KG-R, Sigma Chemical Co, Poole, UK) 
DMSO, dimethyl sulfoxide (D1435,500ml, Sigma Aldridge, Poole, UK) 
PAF, platelet activating factor, (p7568,1mg, Sigma Aldridge, Poole, UK) 
PMA, phorbol myristate acetate, (P8139,5mg, Sigma Aldridge, Poole, UK) 
HEPES solution (H4034, Sigma Aldridge, Poole, UK) 
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fMLP, N-formyl-methyl-leucyl-phenylalanine (F3506,10mg, Sigma Aldridge, Poole, 
UK) 
Dexamethsone (D8893, I mg, Sigma Aldrich, Poole, UK) 
Lipopolysaccharide, LPS (L7770, I mg, Sigma Aldrich, Poole, UK) 
IL- I beta (no. 19401,5 ýtg/vial, Sigma Aldrich, Poole, UK) 
GMCSF (RDI-303, lmg, R&D systems, Oxon, UK) 
Cytopinslides (Shandon, Runcom, Cheshire, UK) 
Round bottom glass tubes (no. 352085,1000/case, BD Falcon, Marathon Ltd, UK) 
Monoclonal antibodies 
Rabbit anti-human FcsRI antibody (no. 06-725, Upstate biotechnology, Lake Placid, 
USA) 
FITC conjugated swine anti-rabbit secondary antibody (F020502,2mls, Dako, Via Real 
Carpinteria, Denmark) 
CD123 PE (no. 33335B, mouse IgGl, K, 0.2mg, Pharmingen International, Europe, 
Heidelberg, Germany). 
RPE-Cy5 conjugated HLA-DR (MCA1721C, mouse igG2b, 100 tests/0.5ml, Serotec Ltd, 
22 Bankside Station Approach, Kidlington, Oxford, OX5 I JE, UK) 
PE conjugated CD14 PE (MCA596PE, IgG2a, 100 tests/0.1ml, Serotec Ltd, Oxford, UK) 
FITC conjugated CD95 (MCA 1539F, IgG, Iml/0.1 mg, (Serotec Ltd, Oxford, UK) 
FITC conjugated CD23 (MCA 1316F, IgG, 0.1 mg/I ml, Serotec Ltd, Oxford, UK). 
PE conjugated CD9 (MCA469PE, IgG2b, 100 tests/ml, Serotec Ltd, Oxford, UK). 
PE conjugated CD14 (MCA596PE, IgG2a, 100 tests/ml, Serotec Ltd, Oxford, UK). 
PE conjugated CD4 (MCA1267PE, IgGl, 100 tests/ml -Serotec Ltd, Oxford, UK). 
FITC conjugated rat anti-human CCR3 (FAB 155F, 50[tg/ml)- R&D systems Europe, 
Oxon, UK. 
PE conjugated CD 16 (MCAI 193PE, IgGl, 100 tests/ml, Serotec Ltd, Oxford, UK). 
FITC conjugated CD 62L (MCA1076F, IgG2b, 100 tests/ml, Serotec Ltd, Oxford, UK). 
FITC conjugated CD I lb (MCA551F, IgGl, 100 tests/ml, Serotec Ltd, Oxford, UK). 
FITC conjugated CD 18 (MCA5, IgG2b, 100 tests/ml, Serotec Ltd, Oxford, UK). 
FITC conjugated CD 35 (MCA554F, IgGl, 100 tests/ml, Serotec Ltd, Oxford, UK). 
RPE-Cy5 conjugated igG2b negative control, (MCA691C, 0.5ml/100 tests, Serotec Ltd, 
Oxford, UK). 
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PE conjugated IgGl negative control (MCA928PE, IgGl, 100 tests/ml, Serotec Ltd, 
Oxford, UK). 
FITC conjugated IgG2b negative control, (MCA691F, IgG2b, 100 tests/ml, Serotec Ltd, 
Oxford, UK). 
PE conjugated IgG2a negative control (MCA929PE, IgG2a, 100 tests/ml, Serotec Ltd, 
Oxford, UK). 
FITC conjugated IgGI negative control, (MCA928F, IgGl, 100 tests/ml, Serotec Ltd, 
Oxford, UK). 
FITC conjugated IgG2a negative control, (IC006F, IgG2a, 25ýt/ml, R&D systems Europe, 
Barton Lane, Abingdon, Oxon, OX14 3YS, UK). 
N-benzyloxycarbonyl-Ala-Ala)2-rhodamine 110 (R-6504,5mg, Molecular probes, 
Upsaala, Sweden) 
Dihydrorhodamine 123 (D-632,10mg, Molecular Probes, Upsaala, Sweden), 
ELISA 
Human IL-8 Duoset ELISA (no. DY208, R&D systems, Oxon, UK). 
MPO ELISA kit (no. 475918, Calbiochem, San Diego, USA). 
Human IL-5 Duoset ELISA (no. D5000, R&D systems, Oxon, UK). 
HDAC 
HDAC fluorometric cellular activity assay kit, (AK-503, I kit, BIOMOL International 
Inc., Plymouth Meeting, PA, USA). 
Grgph-pad Prism 
Version 4.0, Graphpad software, Inc. La Jolla, CA 92037 USA. 
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Appendix 3-Data for chgpter 5 
Data for Fig. 5.1 (page 152). FEV I (L) in mild -patients taking high dose FP 
0 1 2 3 4 6 8 24hours 
bb 2.30 2.53 2.46 2.74 2.76 2.91 2.87 2.76 
zc 2.94 2.85 2.92 2.98 2.93 2.93 2.83 2.83 
hl 3.65 3.50 3.61 3.56 3.72 3.75 3.62 3.78 
A 2.82 2.80 2.68 2.73 2.75 2.80 2.96 2.94 
jn 2.94 2.85 2.80 2.96 3.00 3.15 3.20 3.05 
cdb 2.43 2.35 2.50 2.34 2.34 2.42 2.67 2.60 
ss 3.13 3.12 2.95 2.95 2.85 2.68 3.20 3.28 
Imcr 2.90 2.66 2.76 2.67 2.83 2.93 3.11 3.06 
ip 3.35 3.25 3.36 3.32 3.42 3.22 3.36 3.22 
bp 2.75 2.63 2.58 2.68 2.64 2.73 2.80 2.75 
gi 2.85 2.76 2.70 2.73 2.82 2.72 2.76 2.71 
sg 3.08 3.00 3.00 3.08 3.02 3.00 3.05 3.00 
FEV I (L) in mild patients taking low dose FP 
0 1 2 3 4 6 8 24hours 
bb 2.72 2.67 2.82 2.90 2.99 2.94 2.91 2.50 
zc 2.68 2.78 2.65 2.76 2.67 2.67 2.81 2.62 
hl 3.71 3.55 3.65 3.47 3.75 3.65 3.90 3.93 
VI 2.76 2.79 2.77 2.80 2.78 2.87 2.92 2.85 
jn 2.92 2.85 2.77 2.99 2.76 2.77 2.84 3.08 
cdb 2.32 2.21 2.37 2.23 2.24 2.35 2.45 2.51 
ss 3.35 3.07 3.07 3.05 3.27 2.82 3.07 3.25 
Imcr 2.85 2.93 2.98 2.95 3.03 2.83 3.10 3.10 
ip 3.15 3.34 3.25 3.35 3.15 3.05 3.55 3.58 
bp 2.77 2.57 2.52 2.35 2.30 2.37 2.51 2.68 
gi 2.78 2.75 2.74 2.75 2.80 2.52 2.56 2.72 
sg 3.04 3.00 3.03 3.00 2.98 2.92 3.15 3.10 
FEV I (L) in mild patients taking PBO 
0 1 2 3 4 6 8 24hours 
bb 2.43 2.74 2.70 3.12 3.02 3.01 2.92 2.63 
zc 2.86 2.79 2.46 2.38 2.95 2.90 2.80 2.98 
hl 3.85 3.66 3.60 3.45 3.71 3.56 3.30 3.72 
A 2.62 2.72 2.82 2.66 2.85 2.83 2.95 2.78 
jn 2.67 2.78 2.95 2.66 2.58 2.57 2.97 2.91 
cdb 2.49 2.41 2.38 2.56 2.29 2.31 2.00 2.43 
ss 3.25 3.10 2.93 2.93 2.43 2.61 2.89 2.99 
Imcr 3.08 2.91 3.01 2.95 2.88 3.00 3.12 3.05 
ip 3.55 3.30 3.23 3.45 3.43 3.35 3.68 3.48 
bp 2.70 2.58 2.70 2.61 2.55 2.77 2.95 2.67 
gi 2.78 2.76 2.70 2.64 2.75 2.75 2.25 2.65 
sg 2.95 2.96 2.95 2.97 3.00 3.02 2.92 3.01 
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Data for Figure 5.2 (page 153). FVC (L) in mild joatients-high dose FP 
0 24 hours 
bb 3.83 3.83 
zc 3.39 3.38 
hl 4.69 4.90 
VI 3.50 3.57 
jn 4.00 4.16 
cdb - 2.63 
ss 4.71 4.84 
Imcr 3.25 3.60 
ip 4.40 4.39 
bp 3.17 3.05 
gi 3.00 2.90 
sg 3.80 3.80 
FVC (L) in mild -patients taking low dose FP 
0 24 hours 
bb 3.83 3.83 
zc 3.39 3.38 
hl 4.69 4.90 
VI 3.50 3.57 
jn 4.00 4.16 
cdb - 2.63 
ss 4.71 4.84 
Imcr 3.25 3.60 
ip 4.40 4.39 
bp 3.17 3.05 
gi 3.00 2.90 
sg 3.80 3.80 
FVC (L) in mild patients taking PBO 
0 24 hours 
bb 3.67 3.86 
zc 3.55 3.49 
hl 4.78 4.64 
A 3.46 3.55 
jn 3.95 3.86 
cdb 2.55 2.46 
ss 4.82 4.68 
Imcr 3.60 3.70 
ip 4.59 4.60 
bp 3.10 3.10 
gi 2.95 2.80 
sg 3.65 3.80 
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Data for Figure 5.3 (page 154). FEVI (L) in moderate patients taking high dose'PT) II 
0 1 2 3 4 6 8 24 hours 
rf 3.35 3.20 3.25 3.22 3.41 3.40 3.63 3.42 
gb 2.90 2.73 2.70 2.65 2.71 2.62 2.80 2.76 
rp 1.65 1.60 1.85 1.70 1.74 1.81 1.77 1.55 
ep 3.38 3.56 3.65 3.50 3.75 3.52 3.72 3.55 
gc 4.57 4.50 4.52 4.45 4.48 4.33 4.45 4.44 
ii 1.38 1.48 1.38 1.50 1.47 1.45 1.55 1.47 
LM 3.53 3.35 3.23 3.20 3.40 3.39 3.45 3.75 
nd 3.65 3.65 3.81 3.95 3.85 3.90 4.30 4.12 
ca 2.21 2.31 2.19 2.45 2.26 2.20 2.65 2.30 
FEV IQ in moderate patients taking low dose FP 
patient 0 1 2 3 4 6 8 24 hours 
rf 3.15 3.10 3.36 3.35 3.20 3.20 3.35 3.40 
gb 3.73 2.70 2.80 2.79 2.51 2.00 2.64 2.87 
rp 1.41 1.73 1.63 1.62 1.60 1.56 1.80 1.56 
ep 3.30 3.62 3.49 3.55 3.50 3.42 3.70 3.45 
gc 4.38 4.56 4.51 4.55 4.55 4.45 4.55 4.60 
ii 1.35 L38 1.60 1.71 1.54 1.35 1.63 1.32 
LM 3.55 3.25 3.43 3.39 3.33 3.35 3.56 3.41 
nd 3.70 3.90 3.85 4.00 3.93 3.85 4.13 3.72 
ca 2.10 1.88 1.83 1.66 1.96 2.08 2.60 2.42 
FEV IQ in moderate patients taking PBO 
patient 0 1 2 3 4 6 8 24 hours 
rf 3.26 3.40 3.30 3.37 3.50 3.38 3.40 3.33 
gb 2.85 2.65 2.72 2.85 2.61 2.74 2.75 2.75 
rp 1.46 1.69 1.54 1.53 1.50 1.40 1.75 1.36 
ep 3.65 3.65 3.54 3.73 3.70 3.75 3.65 3.60 
gc 4.51 4.40 4.35 4.45 4.37 4.45 4.40 4.50 
ii 1.36 1.41 1.75 1.77 1.75 1.55 1.68 1.41 
LM 3.48 3.60 3.48 3.55 3.35 3.41 3.47 3.68 
nd 4.00 3.85 3.88 3.99 3.91 3.67 3.95 3.86 
ca 3.46 3.48 2.28 2.35 2.51 2.65 2.37 2.29 
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Data for Figure 5.4 (page 155). FVC (L) in moderate i)atients taking high dose FP 
0 24 hours 
rf 4.70 4.80 
gb 3.45 3.15 
rp 2.20 2.10 
ep 4.85 4.75 
gc 5.65 5.67 
ii 2.55 2.62 
LM 4.26 4.55 
nd 5.55 5.93 
ca 3.23 3.33 
FVC (L) in moderate patients taking low dose EP 
0 24 hours 
rf 4.62 4.87 
gb 3.00 3.40 
rp 1.99 2.13 
ep 4.68 4.80 
gc 5.54 5.72 
ii 2.46 2.45 
LM 4.25 4.20 
nd 5.60 5.63 
ca 3.16 3.59 
FVC (L) in moderate patients taking PBO 
24 hours 
rf 4.75 4.80 
gb 3.30 3.25 
rp 2.06 2.01 
ep 4.85 4.75 
gc 5.62 5.56 
ii 2.58 2.58 
LM 4.20 - 
nd 5.74 5.73 
ca 3.61 3.29 
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Data for fig 5.5. PC20 m /mI)jn mild atients., takin high dose FP. 
Patient BASE 6 hours 24 hours 
bb 0.53 2.53 0.50 
zc 2.31 2.50 12.67 
hl 0.37 1.80 1.20 
VI 0.55 1.20 0.94 
jn - 2.90 1.79 
cdb 0.67 13.12 21.09 
ss 1.08 - - 
Imcr 2.19 2.30 0.24 
ip 0.70 13.60 4.16 
bp 2.72 4.80 4.61 
gj 0.84 8.00 4.76 
sg 2.52 1.84 0.61 
PC70 in mild patients, taking low dose FP. 
Patient BASE 6 hours 24 hours 
bb 0.53 1.940 1.17 
zc 2.31 7.900 1.28 
hl 0.40 1.290 0.73 
A 0.60 3.300 1.71 
jn - 9.100 1.37 
cdb 0.70 4.700 11.51 
ss 1.08 0.810 2.10 
Imcr 2.19 1.980 0.68 
ip 0.70 2.950 2.56 
bp 2.80 4.980 1.61 
gj 0.84 0.250 1.63 
sg 2.52 0.810 1.36 
PCL 0 
Patient BASE 6 hours 24 hours 
bb 0.53 2.24 0.53 
ze 2.31 3.07 7.85 
hl 0.37 0.54 0.59 
A 0.55 0.34 0.40 
jn - 3.64 4.98 
cdb 0.67 16.00 8.00 
ss 1.08 0.50 2.79 
Imcr 2.19 2.00 1.47 
ip 0.70 0.98 0.72 
bp 2.72 7.13 5.79 
gj 0.84 37.70 36.49 
sg 2.52 0.25 0.686 
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Data for fig 5.6. (page L57) 
-PC20 
(Mg/Ml) in moderate patients, taking high dose FP. 
Patient BASE 6 hours 24 hours 
rf 2.140 2.350 1.660 
gb 2.790 4.000 24.800 
ep 2.350 0.870 9.290 
ii 1.150 2.030 2.750 
LM 0.160 13.100 39.000 
nd 0.730 0.230 0.850 
PC20 in moderate patients, taking low dose FP. 
Patient BASE 6 hours 24 hours 
rf 2.1400 0.670 0.710 
gb 2.7900 52.100 15.500 
ep 2.3500 7.600 5.740 
gc 1.0900 - 0.710 
LM 0.1600 3.480 0.070 
nd 0.7300 0.500 2.320 
PC? o in moderate patients, taking PBO. 
Patient BASE 6 hours 24 hours 
rf 2.14000 0.830 0.830 
gb 2.79000 - 2.220 
ep 2.35000 9.590 15.270 
gc 1.09000 1.140 2.230 
LM 0.16000 46.100 1.590 
nd 0.73000 0.500 0.500 
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Data for fig. 5.7 Opage 160). NO levels (-ppb) in mild patients taking high dose FP. 
0 1 2 3 4 6 8 24 hours 
bb 32.45 33.95 44.35 40.50 28.25 33.70 36.90 43.70 
zc 26.75 26.45 27.30 22.75 27.65 23.80 21.55 19.75 
hl 43.75 45.85 48.45 41.10 48.15 45.50 39.90 34.60 
VI 28.20 30.20 25.65 22.95 16.15 18.40 25.10 26.40 
jn 59.65 70.05 70.30 49.90 58.05 59.20 53.30 38.40 
cdb 11.10 10.75 10.60 8.60 8.800 8.50 8.50 7.65 
ss 51.00 33.85 36.70 29.30 27.65 27.35 24.00 32.25 
Imcr 17.75 17.05 16.85 19.40 20.45 21.60 27.35 16.20 
ip 26.30 33.10 33.00 29.60 29.90 28.80 21.80 20.90 
bp 2.55 7.75 7.45 6.00 6.00 7.90 5.80 4.50 
gi 6.00 7.95 8.05 8.20 8.20 9.50 7.20 9.15 
sg 21.55 23.55 21.35 23.15 18.80 15.95 20.70 14.70 
NO levels in mild patients taking low dose inhaled FP. 
0 1 2 3 4 6 8 24 hours 
bb 24.70 24.20 26.10 24.30 27.550 22.30 21.250 24.10 
zc 17.40 22.35 0.00 18.75 17.300 18.35 17.950 17.65 
hl 45.90 36.60 44.80 44.00 41.800 48.45 42.300 39.95 
VI 21.60 19.10 18.70 21.70 16.500 13.95 16.350 16.80 
jn 7.85 7.35 7.75 9.15 6.900 8.45 8.500 11.80 
cdb 7.70 5.80 6.20 7.10 6.850 7.75 7.600 6.60 
ss 33.30 22.00 20.30 20.85 17.900 16.95 17.650 19.05 
Imcr 21.60 19.50 21.60 23.85 19.650 21.65 22.750 20.80 
ip 23.30 28.00 23.80 24.35 23.100 31.15 21.750 23.75 
bp 3.20 8.10 8.95 11.75 9.450 11.10 6.600 4.85 
gi 8.10 6.50 6.60 6.25 5.450 6.65 4.250 6.60 
sg 63.55 62.30 74.80 54.00 57.450 60.70 66.700 44.70 
NO levels in mild patients taking PBO. 
0 1 2 3 4 6 8 24 hours 
bb 67.20 56.350 51.80 40.0 60.050 51.60 39.60 48.30 
zc 25.05 24.550 22.90 23.7 24.800 19.05 19.60 24.55 
hl 42.65 44.700 42.70 37.55 33.750 41.40 29.15 42.60 
A 19.95 18.700 16.75 18.7 16.150 21.95 16.85 19.00 
jn 30.75 29.650 35.70 33.15 25.850 31.50 29.45 27.65 
cdb 29.80 8.500 8.90 9.75 8.800 7.90 6.50 11.85 
ss 31.10 35.550 32.50 34.2 30.500 32.85 31.35 59.20 
Imcr 23.40 25.600 22.95 24.65 28.550 25.75 23.60 22.65 
ip 18.75 18.750 20.60 18.8 19.800 19.60 15.80 12.80 
bp 7.95 11.450 8.20 9.4 7.550 9.85 5.70 6.40 
gi 4.30 7.150 5.90 7.55 6.200 10.35 5.55 6.95 
sg 51.75 49.200 57.50 46.15 49.700 46.40 35.90 63.50 
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Data for fig. 5.8 (page 161). NO (ippb) levels in moderate -patients taking high dose FP. 
0 1 2 3 4 6 8 24 hours 
rf 72.150 75.30 69.80 66.30 75.350 62.30 57.70 93.50 
gb 15.400 13.35 15.30 14.00 14.500 16.55 12.65 11.50 
rp 8.100 13.50 14.40 11.00 8.500 10.80 10.45 9.20 
ep 28.500 29.80 32.60 28.20 30.700 27.90 24.60 16.80 
gc 69.500 92.10 88.70 91.50 90.400 101.20 80.30 130.10 
ii 11.650 18.05 19.05 6.00 6.050 5.55 6.40 6.25 
LM 13.000 11.05 12.05 12.85 8.900 10.25 8.75 15.30 
nd 44.950 40.60 38.85 37.85 43.600 42.10 41.10 30.30 
ca 16.700 13.00 11.10 7.10 8.700 8.60 8.40 14.10 
NO (ppb) in moderate patients taking low dose FP. 
0 1 2 3 4 6 8 24 hours 
rf 177.40 96.60 98.50 87.20 83.70 82.20 80.50 114.10 
gb 5.30 8.10 10.10 12.35 12.20 12.20 7.55 5.45 
rp 13.95 14.45 15.20 11.90 10.25 11.10 12.90 11.50 
ep 14.90 16.30 18.00 20.50 16.70 15.70 13.40 16.90 
gc 51.10 55.40 60.10 64.40 65.90 55.60 69.60 57.30 
ii 6.15 5.20 5.10 7.65 6.55 4.10 5.50 6.45 
LM 12.30 15.80 13.00 11.35 9.75 11.50 11.00 11.75 
nd 32.80 30.70 36.95 31.00 42.70 39.20 30.20 31.60 
ca 7.60 8.70 7.70 8.00 6.60 9.60 10.70 9.10 
NO levels (ppb) in moderate patients taking-PBO. 
0 1 2 3 4 6 8 24 hours 
rf 116.950 115.90 131.0 127.90 175.40 137.50 116.0 178.60 
gb 15.000 13.60 12.15 13.40 12.20 14.70 10.1 13.30 
rp 10.750 12.90 10.7 11.10 9.50 9.70 8.4 10.35 
ep 23.700 20.60 19.2 19.20 19.50 19.40 18.6 14.20 
gc 46.400 46.20 45.7 52.50 56.10 51.90 45.1 41.50 
ii 9.300 8.80 8.75 6.25 7.70 7.30 6.35 8.45 
LM 11.500 18.85 14.35 16.25 11.00 10.80 8.4 11.95 
nd 53.500 57.60 58.4 57.70 48.90 60.80 53.9 81.00 
ca 13.10 8.13 7.90 12.1 12.9 8.7 14.2 17.5 
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Data for fig. 5.9 (Dage 162). Eosino-phil counts (x I 09/L) in mild asthmatics taking hig 
dose FP. 
0 1 2 3 4 6 8 24 hours 
bb 0.50 0.50 0.50 0.50 0.40 0.40 0.40 0.30 
zc 0.50 0.40 0.40 0.40 0.40 0.30 0.40 0.30 
hl 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.00 
VI 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.30 
jn 0.30 0.40 0.40 0.30 0.30 0.30 0.30 0.30 
cdb 0.10 0.20 0.20 0.10 0.10 0.20 0.20 0.20 
ss 0.00 0.00 0.20 0.10 0.20 0.20 0.20 0.20 
Imcr 0.30 0.30 0.30 0.30 0.30 0.30 0.40 0.30 
ip 0.40 0.40 0.40 0.40 0.40 0.50 0.40 0.40 
bp 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 
gi 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 
sg 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.00 
Eosinophil counts (x I 09/L) in mild asthmatics taking, low dose FP. 
0 1 2 3 4 6 8 24 hours 
bb 0.50 0.40 0.40 0.40 0.30 0.50 0.40 0.60 
zc 0.30 0.30 0.30 0.30 0.30 0.30 0.40 0.30 
hl 0.20 0.10 0.10 0.10 0.10 0.20 0.20 0.10 
VI 0.30 0.20 0.20 0.20 0.20 0.20 0.20 0.20 
jn 0.20 0.30 0.30 0.30 0.20 0.30 0.30 0.30 
cdb 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.00 
ss 0.30 0.30 0.20 0.20 0.20 0.30 0.30 0.20 
Imcr 0.30 0.10 0.20 0.20 0.20 0.10 0.10 0.10 
ip 0.40 0.50 0.50 0.50 0.30 0.50 0.50 0.40 
bp 0.10 0.10 0.00 0.10 0.10 0.10 0.00 0.10 
gi 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 
sg 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 
Eosinophil counts (x I 09/L) in mild asthmatics taking PBO. 
0 1 2 3 4 6 8 24 hours 
bb 0.30 0.20 0.20 0.20 0.10 0.10 0.10 0.40 
zc 0.40 0.30 0.30 0.20 0.30 0.30 0.30 0.30 
hl 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.00 
A 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.10 
jn 0.30 0.30 0.30 0.30 0.40 0.40 0.30 0.30 
cdb 0.20 0.10 0.20 0.10 0.00 0.20 0.20 0.10 
ss 0.30 0.20 0.20 0.30 0.20 0.20 0.30 0.30 
Imcr 0.30 0.30 0.20 0.30 0.30 0.30 0.30 0.30 
ip 0.40 0.40 0.40 0.40 0.40 0.50 0.50 0.40 
bp 0.10 0.10 0.10 0.10 0.10 0.00 0.00 0.10 
gi 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 
sg 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 
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Data for fig. 5.10 (page 163). Eosino-phil counts (x I 09/L) in moderate asthmatics taking 
high dose FP. 
0 1 2 3 4 6 8 24 hours 
rf 1.10 1.10 1.0 1.0 1.0 1.0 1.0 0.90 
gb 0.20 0.20 0.2 0.1 0.2 0.2 0.2 0.20 
rp 0.20 0.30 0.2 0.2 0.2 0.2 0.2 0.20 
ep 0.30 0.20 0.2 0.2 0.1 0.1 0.1 0.30 
gc 0.70 0.70 0.7 0.8 0.8 0.9 0.8 0.80 
ii 0.10 0.10 0.1 0.1 0.1 0.1 0.1 0.10 
LM 0.20 0.30 0.2 0.2 0.1 0.2 0.2 0.30 
nd 0.30 0.20 0.1 0.2 0.2 0.2 0.2 0.30 
ca 0.10 0.2 0.3 0.2 0.4 0.2 0.3 0.10 
Eosinophil counts (x I 09/L) in moderate asthmatics taking low dose FP. 
0 1 2 3 4 6 8 24 hours 
rf 0.800 0.800 0.80 0.80 0.80 0.80 0.80 0.80 
gb 0.100 0.200 0.20 0.20 0.20 0.10 0.10 0.10 
rp 0.300 0.300 0.30 0.30 0.30 0.30 0.40 0.20 
ep 0.200 0.200 0.10 0.10 0.10 0.10 0.20 0.20 
gc 0.600 0.500 0.60 0.70 0.60 0.70 0.80 0.70 
ii 0.100 0.100 0.10 0.10 0.10 0.10 0.10 0.10 
LM 0.300 0.300 0.30 0.30 0.30 0.30 0.40 0.30 
nd 0.200 0.200 0.20 0.10 0.20 0.20 0.20 0.30 
Eosino-phil counts (x 1 09/L) in moderate asthmatics taking PBO. 
0 1 2 3 4 6 8 24 hours 
rf 0.90 0.90 0.80 1.0 1.0 1.10 1.10 1.10 
gb 0.20 0.10 0.10 0.2 0.2 0.20 0.20 0.20 
rp 0.40 0.40 0.30 0.3 0.3 0.30 0.40 0.30 
ep 0.20 0.20 0.20 0.2 0.2 0.20 0.20 0.20 
gc 0.60 0.60 0.70 0.7 0.7 0.70 0.70 0.60 
ii 0.20 0.20 0.10 0.1 0.1 0.10 0.10 0.20 
LM 0.20 0.30 0.30 0.2 0.3 0.40 0.40 0.20 
nd 0.00 0.00 0.00 0.0 0.0 0.00 0.00 0.00 
ca 0.20 0.20 0.20 0.1 0.2 0.20 0.30 0.30 
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Data for fig. 5.12 (page 165). Neutro-phil counts (x109/L) in moderate asthmatics taking 
high dose FP. 
0 1 2 3 4 6 8 24 hours 
rf 4.10 4.10 4.90 4.80 5.10 6.10 6.50 3.80 
gb 4.30 4.10 4.40 4.20 5.00 4.20 4.40 4.20 
rp 3.70 4.20 3.70 3.70 3.80 4.30 4.50 4.20 
ep 5.40 5.60 7.10 7.10 6.10 7.70 7.30 4.80 
gc 4.60 5.70 5.90 6.40 6.00 6.40 6.30 4.40 
ii 3.20 3.90 3.70 3.80 3.70 3.50 3.90 3.00 
LM 3.40 4.10 3.70 3.70 3.30 3.30 4.10 4.20 
nd 2.80 3.10 2.70 3.10 3.10 3.40 2.80 3.60 
ca 7.20 7.40 7.20 7.00 6.00 4.80 4.10 2.70 
Neutrophil counts (xl09/L) in moderate asthmatics taking low dose FP. 
0 1 2 3 4 6 8 24 hours 
rf 5.0 5.70 5.0 5.20 6.0 6.50 6.30 4.10 
gb 4.1 5.20 5.2 5.20 5.3 6.30 5.70 4.50 
rp 3.5 2.90 3.3 3.50 3.7 3.80 3.90 3.30 
ep 2.4 2.70 3.0 3.30 3.8 4.70 4.80 2.50 
gc 4.6 4.60 5.7 5.90 5.4 5.80 5.20 4.70 
ii 3.0 3.50 3.5 3.60 3.5 3.60 3.30 3.30 
LM 3.6 3.30 3.7 3.30 3.3 4.10 4.20 3.50 
nd 2.7 3.20 3.8 3.20 3.2 3.10 2.70 2.50 
ca 2.5 2.70 2.3 2.30 0.0 0.00 0.00 2.30 
Neutrophil counts (x 1 09/L) in moderate asthmatics taking PBO. 
0 1 2 3 4 6 8 24 hours 
rf 4.20 4.80 4.60 4.5 4.60 5.30 7.10 4.3 
gb 4.40 4.40 4.10 5.0 5.50 5.50 5.70 4.0 
rp 3.60 3.40 3.30 3.1 3.30 4.30 4.40 3.0 
ep 3.20 3.70 4.40 4.7 4.70 5.30 4.80 4.8 
gc 5.60 4.80 5.60 4.9 5.30 5.60 5.60 4.1 
ii 2.30 3.60 2.10 1.9 1.90 3.80 2.00 2.9 
LM 3.50 3.90 3.30 4.0 3.70 3.90 3.90 3.4 
nd 2.90 3.10 3.30 3.0 3.00 3.00 2.80 2.5 
ca 2.90 0.00 3.10 2.6 2.90 2.50 2.90 2.9 
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Data for Fig 153 (nage 166). Serum IL-8 levels (-og/ml) in mild ast 
dose FP. 
b+ b- 1+ 1- 4+ 4- 24+ 24-hours 
bb 69.3 46.1 32.6 52.8 112.8 35.6 221.1.0 179.8 
zc 24.5 27.3 35.4 26.4 18.8 34.9 187.6 177.6 
hi 132.6 210.8 124.5 153.0 92.3 135.4 153.0 190.9 
VI 0.0 0.0 1.8 0.0 103.8 18.5 0.0 0.0 
jn 145.4 161.6 210.0 170.1 70.4 69.6 271.4 211.9 
cdb 24.1 18.2 6.3 20.2 31.2 14.3 132.5 1892 
Imcr 49.2 25.2 34.9 41.1 18.6 21.7 11.3 31.7 
bp 145.4 161.6 210.0 170.1 70.4 69.6 271.4 211.9 
gi 196.9 542.9 249.6 140.3 151.3 124.0 534.1 620.6 
sg 160.8 236.7 202.6 223.8 0.0 0.0 155.1 123.7 
Serum IL-8 levels (pg/ml) in mild asthmatics taking low dose FP. 
b+ b- 1+ 1- 4+ 4- 24+ 24-hours 
bb 0.0 0.0 97.0 88.8 153.3 43.1 55.8 43.8 
zc 55.8 77.1 56.7 112.7 31.1 35,8 0.0 0.0 
hl 116.9 119.8 116.5 135.9 195.2 152.0 146.8 111.4 
A 0.0 0.0 28.1 7.1 295.0 14.6 69.4 67.7 
jn 283.2 281.7 104.7 172.7 69.3 34.2 185.3 205.2 
cdb 421.6 426.0 394.6 442.8 411.7 342.9 0.0 0.0 
Imcr 110.2 113.8 34.7 26.8 32.7 35.4 0.0 0.0 
gi 175.6 179.0 159.3 165.0 152.1 152.5 446.5 380.9 
sg 122.5 66.7 254.2 130.5 201.8 210.1 253.4 118.7 
Serum IL-8 levels (pg/ml) in mild asthmatics taking PBO. 
b+ b- 1+ 1- 4+ 4- 24+ 24-hours 
bb 18.3 63.3 0.0 0.0 44.6 66.3 28.8 1.1 
hl 190.0 238.0 220.0 178.8 184.0 168.3 239.5 293.5 
VI 54.3 33.9 65.2 42.0 382.0 52.9 107.0 93.2 
jn 212.5 243.7 179.5 215.2 103.2 73.3 133.0 217.0 
cdb 64.0 5.0 3.5 58.7 15.5 6.7 40.8 30.7 
Imcr 30.8 49.0 48.4 41.8 30.9 35.4 34.0 19.1 
gi 56.4 89.5 73.3 95.8 41.5 100.0 163.3 179.2 
sg 300.1 259.8 191.2 213.9 213.9 169.2 471.2 332.3 
b=baseline 
(+) =cultured with IL- 1 =without IL- I 
252 
Dat 
dose FP. 
b+ b- 1+ 1- 4+ 4- 24+ 24-hours 
rf 325.6 199.8 181.3 226.1 276.5 129.5 899.5 617.3 
gb 342.8 168.3 322.1 17.8 62.3 44.7 238.5 21.3 
rp 32.9 25.9 0.00 0.00 3.8 0.00 33.8 62.4 
ep 71.9 8.0 93.0 0.00 33.4 0.00 0.00 55.0 
gc 686.5 257.3 429.9 160.2 670.9 23.5 730.8 246.5 
ii 0.00 0.00 15.7 35.1 36.4 29.1 35.1 16.3 
Serum IL-8 levels (pg/ml) in mild asthmatics taking low dose FP. 
b+ b- 1+ 1- 4+ 4- 24+ 24-hours 
rf 552.2 460.3 419.1 374.6 396.6 371.7 0.00 0.00 
gb 221.6 157.8 180.8 148.6 129.6 70.7 370.4 256.2 
LM 0.00 0.00 32.3 44.5 16.1 10.9 86.3 83.7 
rp 5.3 2.9 28.6 25.7 16.1 21.5 0.00 0.00 
ep 1054.5 740.4 1028.7 949.0 1009.0 962.2 650.5 175.2 
gc 590.0 253.7 502.5 87.1 286.1 78.1 694.3 477.9 
nd 48.5 16.8 34.0 13.2 47.9 5.8 0.00 0.00 
ii 27.8 21.1 -2.0 16.3 34.8 10.6 107.9 66.3 
Serum IL-8 levels (pg/ml) in mild asthmatics taking PBO. 
b+ b- 1+ 1- 4+ 4- 24+ 24-hours 
rf 341.0 309.3 196.2 171.8 275.7 321.2 612.7 538.9 
gb 70.1 47.5 154.5 144.9 145.1 203.4 134.4 36.0 
LM 33.1 33.4 6.5 20.5 7.2 0.9 10.2 29.7 
rp 0.00 3.6 43.4 47.2 14.7 49.4 43.7 54. 
ep 147.0 48.7 417.9 114. 197.4 60.7 286.7 201.6 
gc 1263.1 813.0 1178.0 699.1 991.6 624.1 1233.7 810.6 
nd 5.0 0.00 4.1 0.00 4.7 5.3 34.43 54.2 
ii 94.6 166.1 220.5 257.1 7.4 31.3 22.7 25.6 
Data for Fig. 5.15. Baseline IL-8 (pg/ml) levels in sputum supematant in mild and 
moderate asthmatics. 
Mild (n=9) Moderate (n=6) 
285.30 1372.53 
139.40 313.25 
201.34 1342.74 
74.24 247.13 
417.91 790.59 
211.76 1429.03 
65.44 
574.30 
683.30 
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Data for Fig 5.16, (page 169). IL-8 levels (pg/Ml) in sputum suvematant, in mild 
asthmatics taking high dose FP. 
base 6 hours 24 hours 
Imc 285.3 92.6 173.3 
sg 139.4 58.1 99.9 
jn 201.3 - 66.4 
ze 12.3 - 74.7 
cduB 74.2 - 309.1 
VI 417.9 718.8 410.2 
bp 211.7 414.9 419.1 
gj 65.4 183.3 225.3 
ip 574.3 968.2 387.7 
ss 683.3 377.6 686.2 
IL-8 levets (-Pg/ml) in sputum supernatant, in mild asthmatics taking low dose FP. 
base 6 hours 24 hours 
Imc 285.3 82.5 236.6 
sg 139.4 88.9 122.8 
jn 201.3 144.9 - 
zc 12.3 24.0. - 
cduB 74.2 260.5 - 
VI 417.9 334.3 946.3 
bp 211.7 423.8 917.8 
gi 65.4 275.1 329.0 
ip 574.3 307.1 386.5 
ss 683.3 407.2 586.7 
IL-8 levels (pg/ml) in s-putum supematant, in mild asthmatics taking PBO. 
base 6 hours 24 hours 
Imc 285.3 72.8 70.1 
sg 139.4 225.2 223.3 
jn 201.3 - - 
zc 12.3 50.8 1.7 
hl - - 84. 
cduB 74.2 - 395.4 
VI 417.9 491.3 411.9 
bp 211.7 611.0 489.0 
gi 65.4 217.6 257.3 
ip 574.3 310.6 727.1 
ss 683.3 387.7 392.4 
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Individual data for Fig 5.17, ýpage 170). IL-8 levels (t)p, /ml) in sputum supematant, in 
moderate asthmatics taking high dose FP. 
base 6 hours 24 hours 
rf 1372.5 1002.7 1808.1 
gb 313.2 - 104.6 
rp 1342.7 687.6 1268.1 
ep 386.5 683.3 407.2 
gc 247.1 - 219.6 
LM 790.5 790.5 410.2 
nd 1429.0 1372.5 1377.6 
ca - 763.3 650.3 
IL-8 levels (pg/ml) in sputum sLipernatant, in moderate asthmatics taking low dose FP. 
base 6 hours 24 hours 
Tf 1372.5 1404.3 1458.8 
gb 313.2 343.3 126.0 
rp 1342.7 643.7 1311.7 
ep 386.5 214.5 359.6 
gc 247.1 - - 
ii - 912.3 597.9 
LM 790.5 643.7 1311.7 
nd 1429.0 1418.7 989.3 
ca - 773.6 720.1 
IL-8 levels-(pg/ml) in sputum sppematant, in moderate asthmatics taking PBO. 
base 6 hours 24 hours 
rf 1372.5 - 
gb 313.2 99.4 
rp 1342.7 890.7 1117.8 
ep 386.5 586.7 387.7 
gc 247.1 - 71.6 
LM 790.5 945.9 727.0 
nd 1429.0 1420.8 1284.1 
ca - 1308.8 1268.7 
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Appendix 4.1 - Data for chapter-6 
Data for Fig 6.1 (p. 18 5). Effect of rhuMab E2 5 on FEV I Qjn asthmatics. (V=visit 
numberj 
vi V2 V3 V4 V5 V6 V7 
cmd 2.03 1.80 2.85 2.66 2.89 2.75 2.13 
os 1.41 1.20 1.45 1.32 1.22 1.50 1.55 
sein 1.17 1.75 1.25 1.72 1.41 1.59 1.62 
wh 1.01 0.85 1.26 1.05 1.25 1.37 1.33 
ma 1.51 1.65 1.52 1.60 1.38 1.59 1.65 
FEV I (L) in control group. 
vi V2 V3 V4 V5 V6 V7 
jae 0.60 0.71 0.61 0.63 0.45 0.60 0.60 
vc 1.67 2.33 1.45 1.85 2.01 2.03 1.85 
cc 3.23 3.37 3.15 3.45 3.34 3.26 3.34 
mb 2.62 2.62 3.15 3.48 2.80 2.75 3.45 
Data for Fig 6.2. (P. 186). Effect of rhuMab E25 on QOL scores in asthmatics. (V=visit 
number) 
V2 V3 V4 V5 V6 V7 
cmd 53.0 93.0 96.0 99.0 81.0 57.0 
os 34.0 75.0 63.0 66.0 67.0 76.0 
sein 52.0 67.0 73.0 77.0 65.0 70.0 
wh 44.0 63.0 66.0 72.0 63.0 49.0 
ma 60.0 64.0 95.0 27.0 71.0 77.0 
QOL scores in control group. 
V2 V3 V4 V5 V6 V7 
jae 58.0 53.0 40.0 36.0 35.0 34.0 
vc 25.0 49.0 59.0 39.0 33.0 38.0 
cc 56.0 74.0 67.0 63.0 68.0 76.0 
mb 57.0 59.0 87.0 66.0 58.0 94.0 
Data for Fig 6.3. (p. 187). Effect of rhuMab E25 on clinical symptom scores in asthmatics. 
(V=visit number) 
V2 V3 V4 V5 V6 V7 
cmd 46.0 9.0 7.0 2.0 26.0 47.0 
os 59.0 49.0 61.0 55.0 44.0 49.0 
sein 32.0 19.0 23.0 22.0 26.0 26.0 
wh 54.0 16.0 21.0 28.0 39.0 30.0 
ma 53.0 40.0 14.0 35.0 52.0 26.0 
Clinical symptom scores in control group. 
V2 V3 V4 V5 V6 V7 
jae 40.00 37.00 28.00 40.00 42.00 38.00 
vc 0.00 22.00 16.00 21.00 34.00 22.00 
cc 24.00 24.00 25.00 27.00 31.00 18.00 
mb 32.00 13.00 24.00 25.00 35.00 15.00 
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Data for Fig 6.5 (p. 189). Effect of rhuMab E25 on dose of ICS (BDP equivalent jig/day) 
in asthmatics. (V=visit number) 
vi V7 
cmd 1600 800 
os 2000 2000 
sein 2000 2000 
wh 2000 2000 
ma 800 400 
Dose of inhaled corticosteroid (BDP equivalent Ljg/day) in control group. 
vi V7 
jae 1600 2000 
vc 2000 2000 
cc 2400 1000 
mb 400 800 
Data for Fig 6.6 (p. 190). Effect of rhuMab E25 on number of corticosteroid courses 
year in asthmatics. 
ma 
os 
cmd 
wh 
sein 
Pre-trial period 
2 
3 
3 
5 
4 
post-trial period 
1 
2 
1 
0 
3 
Number of oral corticosteroid courses per year in control group. 
jae 
vc 
cc 
mb 
Pre-trial period 
2.0 
3.0 
7.0 
5.0 
post-trial period 
2.0 
2.0 
5.0 
2.0 
Data for Fig 6.7 (page 191) 
FCERI expression on basophils during E25 therapy (3 months) 
visit I Visit 2 
Patient mean mfi SEM mean mfi SEM 
vt 195.150 11-05 29.850 3.55 
si 129.450 20.25 4.440 0.94 
bh 182.800 18.60 24.350 2.65 
99 49.450 10-95 39.750 6.04 
jh 59.350 4.35 25.700 0.30 
ms 95.600 12.00 13.850 2.95 
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FCCRI expression oil nionocytes during E25 therapy Q months 
Visit I Visit 2 
Patient mean mfi SEM mean mfi SEM 
vt 47.80 9.40 11.50 1.90 
Si 55.40 0.30 4.96 4.74 
bh 35.93 0.765 20.58 1.61 
99 90.00 2.50 78.05 3.14 
jh 197.90 11.50 125.60 1.09 
ms 195.90 12.80 0.20 0.10 
P9 33.40 1.40 0.30 0.30 
FCF, Rl expression on basophils-control patients 
Visit I Visit 2 
Patient mean mfi SEM mean mfi SEM 
at 145.05 3.65 61.95 17.15 
Ic 435.95 22.34 423.90 66.89 
pk 5.15 2.45 8.45 0.15 
ca 142.15 3.04 150.35 17.65 
eh 166.05 29.65 3.650 1.960 
FCCRI expression on monocyles-control patients 
Visit I Visit 2 
Patient mean mfi SEM mean mfi SEM 
at 78.95 3.95 76.60 19.20 
IC 43.45 1.64 76.45 43.75 
pk 59.85 4.95 34.20 1.29 
ca 104.80 3.20 101.90 33.70 
eh 22.70 1.40 25.60 1.80 
mfi-mean fluorescence intensity 
SEM-standard error of the mean 
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